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Herbal dietary supplements (HDS) are widely used in complementary, 
alternative, and integrative medicine, but data on attitudes, behavior, safety, and 
efficacy are lacking.  Using mixed methods, we administered an online survey to 
>1,000 breast cancer survivors to investigate HDS practices and perceptions and 
performed in vitro studies assessing the efficacy and toxicity of actein, a bioactive 
component of the HDS black cohosh (Actaea racemosa).  Among cancer survivors, 
curcumin, flaxseed, and green tea were reported as the most frequently used HDS.  
Many subjects increased HDS intake after diagnosis and sought web-based 
information on HDS.  In human breast cancer (MCF-7) and liver (HepG2/C3A) cell 
lines, actein had anti-proliferative and anti-estrogenic effects and did not exhibit 
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1.1 Cancer and CAM 
Cancer, a disease characterized by uncontrolled cell growth and division, is 
the second most common cause of death in the United States and responsible for one-
fourth of all deaths.  In 2009, an estimated 1,479,350 new cancer cases were 
diagnosed in the United States (American Cancer Society, 2009).  Of these, 192,370 
were breast cancer cases diagnosed in females.  Tragically, 40,170 women died from 
breast cancer in 2009.  Cancer not only has a devastating emotional impact on its 
victims and their families, but also has a significant economic impact.  The National 
Institutes of Health (NIH) estimated that about $228.1 billion were spent on cancer-
related costs in 2008 (American Cancer Society, 2009).  Certain risk factors such as 
family history, race, and other demographic factors may increase the likelihood of 
cancer diagnosis and affect the outcome, but in general, cancer can affect anyone 
regardless of age, lifestyle, gender, or ethnicity. 
Radiation and chemotherapy, common conventional cancer treatments, often 
kill or damage healthy cells in addition to cancerous cells.  These treatments also 
produce many side effects, including hair loss, vomiting, nausea, fever, 
immunodeficiency, and fatigue (Smith & Toonen, 2007).  Even if a patient’s cancer 
can be overcome through treatment, his/her quality of life is usually significantly 
decreased.  Activities once taken for granted - eating, taking a walk outside, or 




The drawbacks of conventional treatments cause many cancer patients to seek 
complementary and alternative therapies.  Complementary and alternative medicine 
(CAM) is becoming increasingly popular, especially among those with life-
threatening illnesses such as cancer (Boon, Olatunde, & Zick, 2007; D. M. Eisenberg 
et al., 1998).  According to the NIH National Center for CAM (NCCAM), CAM is “a 
group of diverse medical and health care systems, practices, and products that are not 
generally considered part of conventional medicine” (National Center for 
Complementary and Alternative Medicine, 2010).  CAM can include a variety of 
therapies, from prayer and meditation to food, vitamins, and herbal supplements.  
Specifically, alternative medicine is used in place of conventional treatments, while 
complementary medicine is used in conjunction with conventional treatments.  When 
complementary medicine use is based on scientific evidence and overseen by a 
physician or practitioner, it is often known as Integrative Medicine (IM) (National 
Center for Complementary and Alternative Medicine, 2010).  Increasing the use of 
IM is a goal of CAM researchers since physicians need adequate and accurate 
information to fully advise their patients on incorporating non-standard treatments 
into their regimes.  
 
1.2 Need for Reliable Information 
A study conducted in 2004 found that over half of the cancer patients 
surveyed began to use one or more CAM modalities following cancer diagnosis 
(Vapiwala, Mick, Hampshire, Metz, & Denittis, 2006).  However, many patients do 




patients said that their healthcare providers were their primary source of information 
about CAM (Vapiwala, et al., 2006). 
Physicians are often wary of recommending CAM for several reasons. First, 
most forms of CAM have not been clinically proven safe and effective, leaving 
physicians without the information necessary to make recommendations.  Second, 
many health care providers have received little education and training in this area 
(Tovey & Broom, 2007).  Some cancer patients choose not to discuss CAM use with 
health care providers, either because they believe discussing CAM is unimportant or 
because they expect that the health professional will disapprove.  Instead, patients 
often turn to friends, family, the Internet, or vitamin/herbal store employees to learn 
more about CAM, despite the fact that these may not be reliable sources of 
information (Vapiwala, et al., 2006). 
Failure to discuss CAM use with a physician, as well as a lack of reliable 
information regarding CAM, could be extremely harmful to the patient.  When CAM 
is used, unexpected interactions may occur between CAM and conventional 
treatments, resulting in unpleasant or even dangerous side effects.  For example, St. 
John’s Wort is an herbal dietary supplement that can decrease the effectiveness of 
some cancer treatments, such as the drug irinotecan, by increasing the rate at which 
anticancer drugs are metabolized (Lumpkin & Alpert, 2000).  Symptoms of harmful 
interactions may not be recognized, especially if the healthcare provider is unaware of 
the patient’s CAM use, resulting in adverse physiological effects.  Additionally, since 
metabolism varies among individuals, use of a form of CAM that may be effective for 




Despite the general lack of reliable information available regarding many 
CAM therapies, the use of CAM is widespread.  In particular, herbal dietary 
supplements (HDS) are used by many breast cancer survivors.  Although various 
definitions of HDS exist, we defined HDS as “a product that contains a plant or a 
plant part that is used for medicinal or therapeutic properties.”  Such products “are 
meant to be taken by mouth as fresh or dried products or in tablet, capsule, powder, 
softgel, gelcap, or liquid form” (See Appendix A).  For our study, we chose to focus 
on one particular HDS, black cohosh, because reliable and conclusive information 
about this particular supplement is lacking and the literature is contradictory. 
 
1.3 Choosing Black Cohosh 
Black cohosh (Actaea racemosa) is a perennial herb in the buttercup family 
that is also known as black baneberry, black bugbane, and black snakeroot.  It is 
native to the central and eastern United States and Canada and considered endangered 
in Illinois and Massachusetts (United States Department of Agriculture, 2010). 
Black cohosh is used for many reasons, and there are various ways that it is 
ingested.  The stems and roots of black cohosh can be used to make a tea infusion.  
Alternatively, black cohosh can be taken in the form of capsules, pills containing 
solid extracts, or liquid extracts known as tinctures (National Center for 
Complementary and Alternative Medicine, 2010).  Historically, black cohosh was 
used by Native Americans for arthritis, rheumatism, and female conditions such as 
menstrual irregularity, painful menstruation, and pain after childbirth (Foster, 2009).  




menopause.  The German Commission E Monographs authorize the labeling of black 
cohosh for premenstrual discomfort, absence of menstruation, and menopausal 
symptoms (Blumenthal, 1998).  
We selected black cohosh for further study because it is commonly used by 
women specifically for menopausal symptoms, which breast cancer survivors 
frequently experience (Burstein & Winer, 2000).  Also, breast cancer survivors have 
reported using black cohosh to alleviate side effects from chemotherapy and other 
conventional cancer therapies (Jacobson et al., 2001). 
Furthermore, some black cohosh extracts contain bioactive compounds that 
are a potential cause for concern.  The chemical structure of black cohosh extracts 
includes several components identified as triterpene glycosides, compounds similar in 
structure to estrogens (Farnsworth, et al., 2008).  Estrogens are a family of female 
hormones, the most prevalent ones being estradiol and estrone.  Only tissues that 
express estrogen receptors (ERs), proteins inside cells that bind to the estrogen 
molecule, are responsive to estrogenic ligands.  Compounds that are similar in 
structure to estrogen can also bind to these estrogen receptors, and are considered 
estrogenic.  There are two main types of ERs: ERα, found mostly in the uterus, 
breast, ovaries, and hypothalamus, and ERβ, found mostly in other tissues including 
lungs, heart, brain, bone, and kidney.  Upon binding estrogen or estrogenic 
compounds, the estrogen receptors activate a series of events as shown in Figure 1.  
One of the events triggered by the binding of estrogenic ligands to ERα is the 
transcription of genes whose products promote cell growth and division (National 





Figure 1.  Estrogen-receptor pathway in a cell.  
Estradiol or an estrogenic compound binds to the estrogen receptor expressed in a cell. The estrogen-
receptor complex initiates a series of events in the cell. This results in certain genes being expressed 
and transcribed into mRNA. The mRNA strands are then translated into proteins involved in cell 
growth and division (National Cancer Institute, 2005). 
 
Normally, the ERα pathway is important for preparing a female for sexual 
reproduction, but it can also increase the risk for breast cancer since it promotes cell 
proliferation in the breast.  Random mutations in the DNA of breast cells could be 
amplified by increased cell proliferation, since each time a cell divides, DNA is 
duplicated and could incorporate defects with each successive duplication.  Some 
spontaneous mutations may be harmless, but others could alter a critical gene in a 
way that leads to the development of cancer. 
Breast cancer tumors are classified as estrogen-receptor positive or estrogen-
receptor negative based on whether they express estrogen receptors.  The growth of 
estrogen receptor-positive breast cancer tumors is promoted by estrogen or estrogenic 




Therefore, the structural similarity between some compounds in black cohosh 
extracts and estrogens is cause for concern, because black cohosh extracts could 
possibly promote the growth of estrogen-receptor positive tumor cells by activating 
estrogen-related pathways.  This concern is especially important for women who are 
also taking other supplements or medications that affect hormonal pathways, 
including the highly prescribed chemotherapy drugs tamoxifen and raloxifene. 
Several research groups have investigated whether or not various black 
cohosh extracts, and specific compounds contained in the extracts, are estrogenic.  
However, variations in methodology and compounds tested have resulted in a 
somewhat contradictory body of evidence, as described in the following chapter 
(Boon, et al., 2007; Shen, et al., 2002).  These extracts and compounds have been 
shown to have both proliferative (growth and division-inducing, i.e., cancer-
promoting) and antiproliferative effects in various systems, which will also be 
discussed in the literature review.  Furthermore, several reports of liver damage and 
liver failure have been associated with black cohosh use, necessitating investigation 
of the herb’s safety and possible liver toxicity (Mahady, et al., 2008).  
Because of the prevalent use of black cohosh among female breast cancer 
survivors and the controversy surrounding its safety and breast cancer-related effects, 
we selected black cohosh as an herbal dietary supplement that warrants further study.  
 
1.4 Study Objectives 
Our research objectives were to investigate the use and perceptions of HDS, 




the efficacy and safety of black cohosh on human breast cancer cells and human liver 
cells, respectively.  Specifically, we proposed the following questions to guide our 
research:  
Which HDS do female breast cancer survivors use most often, and in what 
combinations?  What are their reasons for using these HDS?  Do they use black 
cohosh directly to treat cancer?  How effective do they consider these HDS in cancer 
prevention, cancer treatment, or in alleviating the side effects of conventional cancer 
therapy?  What types of resources do breast cancer survivors consult to obtain 
information about HDS, and how reliable do they feel these resources are?  How do 
the sources of information consulted affect HDS use?  Are breast cancer survivors 
concerned about the safety and labeling of HDS?  Are there correlations between the 
use and perceptions of HDS?  What are the biological effects of black cohosh in 
vitro?  Is black cohosh safe according to in vitro studies?  Are female breast cancer 
survivors’ uses and perceptions of HDS in alignment with in vitro data on the efficacy 
and safety of black cohosh? 
 
1.5 Study Design 
In order to accomplish our objective, we utilized a mixed methods approach 
that combined survey and laboratory research.  The survey portion of our research 
was designed to study the use and perceptions of HDS by female breast cancer 
survivors.  The survey provided evidence regarding types of supplements used, 
patterns of use, reasons for use, perceived efficacy of supplements, sources of HDS 




safety and labeling.  By analyzing the survey results, we gained knowledge of the 
general beliefs and practices of breast cancer survivors regarding HDS. 
In the laboratory portion of our research, we studied the biological effects and 
safety of black cohosh.  In one aspect of our laboratory research, we investigated the 
effects of actein, a bioactive compound from black cohosh, on human breast cancer 
cell proliferation (cell growth).  High levels of cell proliferation and particularly 
estradiol-induced cell proliferation, cell growth as a result of the steroid estradiol, are 
characteristics of breast cancer that promote tumor growth and metastasis, and 
decreased cell proliferation would be beneficial.  In the second aspect of our 
laboratory research, we assessed the safety of actein by determining its potential 
hepatotoxicity through various assays on human liver cells. 
Based on the findings of our survey and laboratory research, we examined the 
degree to which breast cancer survivors’ uses and perceptions of HDS, including 
black cohosh, were in alignment with the demonstrated biological effects of this 
particular HDS as shown in our study and in the literature.  
 
1.6 Expected Results 
Since the HDS we focused on in our survey were chosen based on their 
reported use in the literature, we expected that they would be widely used by many 
participants.  We anticipated that more popular and better known HDS would be used 
more frequently and considered more reliable.  We also expected that the reasons for 
using HDS would vary widely among our sample subjects.  We predicted that 




may not be considered scientifically reputable or reliable. Lastly, we hypothesized 
that more highly educated, higher-income women would be more likely to use HDS 
than other demographic groups as was the case in published studies (see Literature 
Review).  
Based on previous studies, actein was expected to inhibit breast cancer cell 
proliferation and estradiol-induced cell proliferation.  We expected that actein, along 
with tamoxifen and raloxifene, two anti-cancer drugs currently used in conventional 
treatment, would have a synergistic inhibitory effect.  This means that the 
combination of actein and chemotherapeutic drugs would inhibit cell proliferation 
more than simply combining the effects of actein and either drug in isolation.   
Regarding the safety of black cohosh as a dietary supplement, we 
hypothesized that black cohosh is a safe supplement, because there are no previous 
reports that conclusively linked taking black cohosh supplements regularly to liver 
damage or other significant side effects.  Specifically we predicted that actein, at 
normal physiological concentrations, would not be toxic to liver cells in vitro because 




2. Literature Review 
 
2.1 Breast Cancer and Integrative Medicine 
2.1.1 Brief Overview of Breast Cancer and Treatments 
Other than skin cancers, breast cancer is the most commonly diagnosed cancer 
among women (American Cancer Society, 2009).  In 2000, women in the United 
States had a 12.6% lifetime risk of developing breast cancer and a 3.6% risk of death 
from breast cancer (Burstein & Winer, 2000).  According to the American Cancer 
Society, there were an estimated 192,370 new cases of breast cancer in women in 
2009 (American Cancer Society, 2009).  Despite this high annual incidence, the 
American Cancer Society reported that there had actually been a 2.2% decrease in 
female breast cancer rates every year between 1999 and 2005 (American Cancer 
Society, 2009).  Furthermore, from the 1960s to 2009, the five-year survival rate for 
female breast cancer patients improved from 63% to 89% (American Cancer Society, 
2009).  As of 2005, there were an estimated 2,477,850 female breast cancer survivors 
alive (American Cancer Society, 2009).  Despite the advances that have been made in 
the fight against breast cancer, many patients are still affected by this disease each 
year.  As a result, more research is needed on the etiology of breast cancer and its 
treatment.   
Chemotherapy is used to treat many different types of cancers, including 
breast cancer.  Since cancer is characterized by unregulated cell division, most 




body.  Unfortunately, this also targets healthy cells throughout the body that grow and 
divide rapidly, including cells in the lining of the mouth and intestines, bone marrow, 
and hair follicles.  Radiation therapy, which uses radiation to kill cancer cells in a 
specific area of the body, can also damage nearby healthy cells (American Cancer 
Society, 2010).  Resulting side effects from radiation often include hair loss, nausea, 
vomiting, fever, immunodeficiency, and fatigue (Smith & Toonen, 2007).  Even when 
a patient’s cancerous tumors can be destroyed through treatment, the patient’s quality 
of life is decreased by the side effects of this treatment.  Therefore, many patients 
seek complementary and alternative treatments in order to alleviate these side effects, 
increase immune system function, augment overall health, and sometimes even to 
replace conventional therapy (Balneaves, Weeks, & Seely, 2008). 
In addition to the side effects associated with general chemotherapy and 
radiation therapy, breast cancer patients frequently experience amenorrhea, premature 
menopause, and menopausal symptoms such as hot flashes (Burstein & Winer, 2000).  
They also may experience changes in the urogenital epithelium due to endocrine-
targeted therapies and the action of chemotherapy on the ovaries (Burstein & Winer, 
2000; Ganz, 2005).  Hormone replacement therapy with estrogen alone or together 
with progestin has been found to be effective in relieving menopausal symptoms 
(National Institutes of Health, 2005).  However, estrogen stimulates the growth and 
development of some types of breast cancer, and there is some evidence that hormone 
use is related to breast cancer recurrence and mortality (Deniz et al., 2007).  




order to reduce side effects of breast cancer treatment and menopause (Antoine, 
Liebens, Carly, Pastijn, & Rozenberg, 2007). 
 
2.1.2 Prevalence of CAM Use 
CAM is becoming increasingly popular among the general population, 
especially among those with life-threatening illnesses such as cancer (Eisenberg, et 
al., 1998; Vapiwala, et al., 2006).  The 1999 National Health Interview Survey 
(NHIS) found that 29% of adults in the United States used at least one CAM modality 
(Ni, Simile, & Hardy, 2002).  The 2002 National Health Interview Survey (NHIS) 
found that 75% of adults in the United States had used CAM and that 18.9% of all 
people surveyed used natural products (Davis et al., 2008; D.M. Eisenberg, Davis, & 
S.L., 2004).  Barnes, et al., analyzed the CAM supplement usage data from the NHIS 
in 2002 and again in 2007 to measure CAM trends among adults and children in the 
United States.  The results in both years were similar, but the use of CAM (excluding 
prayer) increased from 36% in 2002 to 40% in 2007 (Barnes, Powell-Griner, 
McFann, & Nahin, 2002).  
Frequent use of CAM was also specifically reported among cancer patients.  
Of outpatients in a large cancer center in the southern United States, 69% reported 
using some form of CAM (Richardson, Sanders, Palmer, Greisinger, & Singletary, 
2000).  A study conducted in 2004 found that over half of the cancer patients 
surveyed began to use one or more CAM modalities following cancer diagnosis 
(Vapiwala, et al., 2006).  More often than not, cancer patients used a combination of 




2007).  Studies of cancer survivors suggest that those who had used at least one CAM 
modality were more likely to have survived cancer for extended periods of time, 
received chemotherapy or radiation therapy, been patients in clinical trials, been 
women, and had relatively high household incomes (Goldstein et al., 2005; Lerner & 
Kennedy, 1992; Sparber, 2000; Vapiwala, et al., 2006). 
CAM use is widespread among breast cancer survivors as well.  In a survey of 
San Francisco Bay area breast cancer patients including four different ethnic groups, 
50% reported using some form of CAM (Lee, Lin, Wrensch, Adler, & Eisenberg, 
2000).  Breast cancer patients reported increased use of complementary treatments 
after cancer diagnosis and studies suggest that CAM use is greater among breast 
cancer patients who are younger, have higher levels of education or income, have a 
history of chemotherapy, and have attended a support group (Adler, 1999; H. Boon et 
al., 2000; Lengacher et al., 2006; Matthews, Sellergren, Huo, List, & Fleming, 2007).  
One common type of CAM used by breast cancer patients is dietary 
supplements, such as HDS or vitamins and minerals.  A 2002 study showed that 73% 
of patients with advanced-stage breast cancer used some form of CAM, with HDS 
being the most common modality (Shen, et al., 2002).  In a study comparing 2005 
survey data to 1998 data, breast cancer patients reported using a variety of 
complementary treatments, most commonly an herbal supplement or high-dosage 
vitamin.  The use of these therapies significantly increased from 66.7% in 1998 to 
81.9% in  2005, with 41% of breast cancer patients reporting that they used CAM in 




survivors at a large oncology center, 69% used CAM and 39% specifically used herbs 
or medicinal herbal teas (Matthews, et al., 2007).  
The NHIS examined reasons for use of CAM and prevalence of CAM use 
among certain demographic groups.  Of the 149,271 participants who reported using 
CAM, 657 reported using CAM modalities for menopause.  Although a small portion 
of the total survey respondents, there are a number of individuals who use CAM 
specifically to treat menopause symptoms.  Furthermore, the 2002 study found CAM 
use more likely among higher-educated women, and a majority of CAM users were 
likely to try CAM because they believed it would be helpful when combined with 
conventional medical treatments (Barnes, Powell-Griner, McFann, & Nahin, 2002).  
In both 2002 and 2007, CAM use was positively correlated with the number of 
medical conditions or visits to doctors, suggesting that those with illnesses were more 
likely to use CAM (Barnes, Bloom, & Nahin, 2008). 
However, all of the estimates on the prevalence of CAM use are cast in doubt 
when the inconsistencies in the definition of CAM are considered.  A 2006 study of 
334 breast cancer patients arrived at two disparate estimates of CAM usage: a 
“conservative” figure (19.5%) and a “liberal” figure (79.9%).  The intent of this study 
was to expose the differences in CAM definitions among researchers (Balneaves, 
Bottorff, Hislop, & Herman, 2006).  Eisenberg, et al., recommended differentiating 
between the “alternative” and the “complementary” portions of CAM in order to 
more precisely discriminate survey results (Eisenberg, et al., 2004).  Our study 
attempts to differentiate the two terms by asking survey participants whether they 




conventional treatments while using CAM are considered to have used 
complementary medicine.  Those who solely used non-conventional treatments are 
considered to have used alternative medicine.  More research is necessary to 
determine the specific complementary and alternative therapies that women are using 
and their reasons for use, within the confines of a discrete definition of CAM.  Our 
study specifically investigates one type of CAM, HDS, under narrowly defined 
criteria.    
 
2.1.3 Perceptions of Integrative Medicine: Information and Communication 
A female breast cancer survivor’s choice to use or not use complementary or 
alternative therapies is affected by many factors, including her physician’s knowledge 
about and attitude towards CAM modalities, her sources of information, and her 
personal opinions and background.  The prevalence of CAM use among cancer 
patients underscores the need for further research on how patients decide to use such 
therapies, how they communicate with their healthcare providers about the therapies, 
and how safe and effective these therapies are. 
The lack of clear distinctions between CAM and non-CAM therapies and the 
definitions of CAM modalities make reproducible testing on safety and efficacy 
difficult (Adams & Jewell, 2007).  Much of the existing knowledge about CAM is 
based on cultural beliefs, rather than on scientific evidence, indicating the need for 
further studies (Adams & Jewell, 2007).  Additionally, individual genetic and 
behavioral differences make the safety and efficacy of CAM patient-specific, which 




The lack of adequate research funds and barriers in recruiting patients for studies 
further impede conducting rigorous, peer-reviewed investigations.  This overall lack 
of available scientific data hinders physicians from suggesting CAM therapies to 
patients (Adams & Jewell, 2007). 
Physicians are often wary of recommending many CAM modalities, including 
HDS, due to their perception of limited empirical evidence of the safety and efficacy 
of CAM (Tovey & Broom, 2007).  One survey investigated how confident health care 
professionals were about their knowledge of HDS, and how well healthcare 
professionals communicated with their patients regarding HDS.  The authors found 
that healthcare professionals need more training about HDS, in order to establish 
consistent communication about HDS with patients (Kemper, Gardiner, Gobble, & 
Woods, 2006).  A survey of internists at Mayo Clinic in Rochester, MN found that 
76% had never referred a patient to a CAM practitioner, yet 57% thought 
incorporating CAM would positively affect patient satisfaction (Wahner-Roedler, et 
al., 2006).  A 2004 European study found that oncology professionals were less 
skeptical about the use of CAM when it was used in conjunction with conventional 
therapy, as opposed to it being used solely as an alternative therapy (Richardson, 
Mâsse, Nanny, & Sanders, 2004).  A major concern among many physicians is that 
using alternative medicine during the earlier stages of cancer is unwise at a time when 
conventional therapy could be more effective in eradicating the tumor.  Delaying the 
use of conventional medical treatment could have irreparable consequences and result 




 Despite the risks of CAM, including HDS, and the lack of information 
available about safety and drug interactions, many people do not discuss their use of 
CAM with their healthcare providers.  In a survey of people over the age of 50 in the 
United States, only 31% of CAM users said that they had discussed CAM with their 
physician.  Also, 22% reported that friends or family were their primary source of 
information about CAM, while only 12% said that their physician was their primary 
source (American Assocation of Retired Persons, 2007).  In a survey of cancer 
patients and physicians, 61% of patients reported that they did not discuss CAM use 
with their physician, most frequently because the doctor did not ask about CAM use.  
Additionally, only 52% of the physicians said that they had referred patients to 
sources of information on CAM (Roberts, et al., 2005).  Clearly, more efforts need to 
be made to encourage patient-physician communication and to adequately educate 
both patients and physicians about CAM, including HDS.  While our survey does not 
specifically explore patient-physician communication, it does include several 
questions intended to gauge the influence of physicians on their patients’ decisions to 
use HDS, and the extent that female breast cancer survivors turn to their physicians 
for information regarding HDS. 
 
2.2 Breast Cancer and HDS 
2.2.1 Definition of HDS 
Our study addressed the need for more detailed information about breast 
cancer survivors’ use of HDS.  CAM, including herbal supplements, is commonly 




the purposes of our study, we used the NCCAM definition of HDS: a product 
containing a plant or plant part used for medicinal or therapeutic properties, taken by 
mouth as fresh or dried product or in tablet, capsule, powder, softgel, gelcap, or liquid 
form (National Center for Complementary and Alternative Medicine, 2010). 
 
2.2.2 Patterns of HDS Use 
In order of retail sales, the top-selling herbal supplements in 2002 were: 
garlic, ginkgo, echinacea, soy, saw palmetto, ginseng, St. John’s wort, black cohosh, 
cranberry, valerian, milk thistle, evening primrose, kava kava, bilberry, grape seed, 
yohimbe, green tea, ginger, Pycnogenol®, and aloe vera (Blumenthal, 2003).  
According to the 2002 NHIS, the most commonly used non-vitamin, non-mineral 
natural products in the U.S. in order of prevalence are: echinacea, ginseng, ginkgo 
biloba, garlic supplements, glucosamine, St. John’s wort, peppermint, fish oils/omega 
fatty acids, ginger supplements, soy supplements, ragweed/chamomile, bee pollen or 
royal jelly, kava kava, valerian, and saw palmetto (Barnes, Powell-Griner, McFann, 
& Nahin, 2002).  Among individuals diagnosed with breast cancer, the most 
commonly used HDS include green tea, flax seeds/flaxseed oil, soy 
supplements/isoflavone extracts, and mistletoe (Boon, et al., 2007; Fasching, et al., 
2007). 
Supplements frequently used to relieve menopausal symptoms include soy 
supplements/isoflavone extracts, red clover supplements/isoflavone extracts, and 
black cohosh (Nelson, et al., 2006).  Chamomile, dong quai root, wild yam cream, 




vitex agnus castus oil have also been studied for their estrogenic or menopause-
related effects (Geller, Studee, & Chandra, 2005; Srivastava & Gupta, 2007).  Other 
HDS with potential anti-cancer effects include curcumin from turmeric; resveratrol 
from red grapes, peanuts and berries; diallyl sulfide and S-allyl cysteine from onions; 
allicin from garlic; lycopene from tomato; capsaicin from red chili; diosgenin from 
fenugreek; 6-gingerol from ginger; ellagic acid from pomegranate and other plants; 
ursolic acid from apple, pears, prunes; silymarin from milk thistle; anethol from 
anise, camphor, and fennel; and eugenol from cloves (Aggarwal & Shishodia, 2006).   
 
2.2.3 Concerns about the Safety of HDS 
There was and remains a very real concern about the safety of taking an HDS.  
A study published in Breast Cancer Research notes that many breast cancer patients 
look to HDS as a way to evade the painful and damaging symptoms of most standard 
cancer treatments, despite the fact that there are only a very limited number of 
scientific trials to establish the safety and efficacy of these supplements (Cassidy, 
2003).  This author further pointed out that serious health risks can occur when 
patients take HDS, as these supplements can have harmful interactions with the 
patient’s regimen of standard treatments.  The supplement itself may be harmful at a 
high dose, and patients often do not tell their doctors that they are taking supplements.  
This study recommends additional scientific trials to establish a greater knowledge 
base about the safety and efficacy of HDS, as well as to address improving  
communication between doctors and patients with respect to HDS and their possible 




 There are few studies which compare the uses of HDS between women with 
female-specific cancer to those in other diagnostic groups. This is an important issue 
to address because of potential interactions between HDS and conventional 
treatments used for female-specific cancers (Eschiti, 2007).  
 
2.3 Breast Cancer and Black Cohosh 
2.3.1 Prevalence and Patterns of Black Cohosh Use 
The patterns and prevalence of black cohosh use are not well documented.  
While some studies report usage rates of 10% among women, other studies with 
larger sample sizes report a figure of 2% (Kam, Dennehy, & Tsourounis, 2002; Kelly, 
et al., 2005).  The Canadian black cohosh monograph indicates that the typical black 
cohosh dose is 40-200 mg of dried root or rhizome per day (Health Canada, 2007; 
Mahady, et al., 2008).  According to a survey of 1296 women aged 45-65 in Sydney, 
Australia, black cohosh is used primarily by perimenopausal women to relieve hot 
flashes and is considered to be one of the most effective herbal supplements (van der 
Sluijs, Bensoussan, Liyanage, & Shah, 2007). 
In another survey of 100 self-identified peri- and post-menopausal women at a 
women’s health conference, 48 reported using herbal supplements to treat their 
symptoms (32 used herbal supplements alone while 16 used herbal supplements in 
combination with hormone replacement therapy).  Black cohosh was the third most 
commonly-used supplement, taken by 10% of the participants (Kam, et al., 2002).  A 
much larger survey of 3,853 postmenopausal women over 50 years of age 




independent of age, race, and education (Kelly, et al., 2005).  There is a dearth of 
demographic data regarding people who use specific dietary supplements such as 
black cohosh, since most studies report total HDS use.  Moreover, there is very little 
literature addressing factors that influence people’s decisions to use specific 
supplements, including black cohosh. 
 
2.3.2 Efficacy of Black Cohosh: Previous Studies 
Black cohosh is a good candidate for further investigation because the 
literature on the efficacy of black cohosh is controversial and inconclusive.  Black 
cohosh, although widely used as a menopausal remedy among breast cancer survivors 
and women without breast cancer, has not been shown to have significant effects on 
menopause-related symptoms in clinical trials (Antoine, et al., 2007; Kronenberg & 
Fugh-Berman, 2002).  Additionally, some clinical studies have not been able to 
confirm that black cohosh has any protective role in cancer prevention (Walji, Boon, 
Guns, Oneschuk, & Younus, 2007).  
Nonetheless, in vitro experiments have been able to show that several black 
cohosh extracts and compounds are cytotoxic and reduce proliferation of human 
breast cancer cells (Al-Akoum, Dodin, & Akoum, 2007; Einbond, Shimizu et al., 
2008; Einbond et al., 2004; Einbond, Su, Wu, Friedman, Wang, Jiang et al., 2007; 
Einbond, Su, Wu, Friedman, Wang, Ramirez et al., 2007; Einbond, Wen-Cai et al., 
2008; Gaube, Wolfl, Pusch, Kroll, & Hamburger, 2007; Hostanska, Nisslein, 
Freudenstein, Reichling, & Saller, 2004a, 2004b).  Interpreting results from extracts 




are made of many active compounds and thus, it is hard to distinguish between the 
effects of different active compounds.  As a result, studies have been done to 
determine the active compounds in black cohosh. 
In a 2004 study investigating black cohosh’s active ingredients, black cohosh 
rhizomes were extracted with methanol/water and three fractions of hexane, ethyl 
acetate, or water were created by solvent-solvent partitioning.  The fraction 
displaying highest potency in inhibition of breast cancer cell proliferation was further 
analyzed and a triterpene glycoside called actein (Figure 2) was found to be the most 
potent compound.  Actein not only inhibited MCF-7 breast cancer cell proliferation, 
but also caused cell cycle arrest in G1, the stage in which cells typically grow the 
most (Einbond, et al., 2004).  Since then, actein has become one of the most studied 
active ingredients in black cohosh.  
 
 
Figure 2.  Chemical structure of actein.  
Actein is one of several compounds that have been isolated from Actaea racemosa rhizomes and 
extracts.  The structure was determined by spectroscopic methods (Mercier & Balansard, 1935; 
Watanabe, Mimaki, Sakagami, & Sashida, 2002). 
 
Whether black cohosh contains phytoestrogens or has estrogen-like effects is 
controversial.  When a compound is estrogenic, it behaves like estrogen and can 
increase cell proliferation in cells with estrogen receptors; that is, an estrogenic 
compound can induce estrogen-responsive breast cancer growth.  Although previous 




extract, estrogenic effects were reported in in vivo, ex vivo, and in vitro assays (Bolle, 
Mastrangelo, Perrone, & Evandri, 2007; Liu, Yu, Huo, Lu, & Chen, 2001).  For 
instance, according to a study done by Liu, et al., when black cohosh extracts were 
tested on MCF-7 human breast cancer cells, estrogen receptor levels increased and 
the doubling time of MCF-7 cells decreased.  If the doubling time decreases, then the 
cells are able to grow faster.  These results suggest that the black cohosh extract used 
was estrogenic, mimicking the behavior of estrogen and increasing breast cancer cell 
proliferation. 
Other studies have concluded that black cohosh does not have estrogenic 
effects in vitro or in vivo (Davis, et al., 2008; Lupu, et al., 2003; Ruhlen, et al., 2007). 
For instance, Davis’ study using a MMTV-neu mouse tumor model, which is used to 
study the pathways of mammary tumor development, found that black cohosh did not 
lead to an increase in estradiol levels and did not promote tumor formation, 
suggesting that black cohosh does not have estrogenic impacts on mammary cells 
(Davis, et al., 2008).  Possible explanations for contradictions in reported estrogenic 
effects are the use of different models, parts of the plant or extracts, sources of the 
plant material, or doses or concentrations used.  Overall, the efficacy of black cohosh 
in treating menopausal symptoms and affecting breast cancer cell proliferation is 
inconclusive.  While studies have generally shown black cohosh to be anti-
proliferative, these studies have not been able to conclusively determine whether 





2.3.3 Black Cohosh and SERMs 
Since most breast cancer patients take conventional anti-cancer drugs, 
investigating any effect black cohosh may have on the actions of these anti-cancer 
drugs is important.  Some typical anti-cancer drugs are selective estrogen receptor 
modulators (SERMs), which are frequently prescribed to patients with estrogen 
receptor positive (ER+) breast cancer in order to reduce estrogen-induced 
proliferation of the cancerous breast tissue.  SERMs will bind to estrogen receptors in 
specific tissues and will act as agonists or antagonists.  An agonist will mimic the 
response of bound estrogen; an antagonist will block or inhibit the response (Fabian 
& Kimler, 2005; Lewis & Jordan, 2005).  Since ER+ breast cancer cells have ERα 
proteins that bind estrogen and stimulate cell growth, ERα antagonists can prevent 
ER+ breast cancer growth (Fabian & Kimler, 2005).  
Two typical SERMs used to treat breast cancer are tamoxifen and raloxifene.  
Both tamoxifen and raloxifene predominately act as ER antagonists in breast tissue.  
Tamoxifen has long been established as an effective treatment for prevention and for 
early and late stages of breast cancer, having now been used for over three decades 
(Cuzick, et al., 2003; Fabian & Kimler, 2005).  However, tamoxifen has also been 
shown to increase the rate of endometrial cancer, since it acts differently on ERβ than 
on ERα, and resistance to the drug can develop in some patients (Fisher et al., 1998; 
Vogel et al., 2006).  More recently, raloxifene, a second generation SERM, has been 
developed, and shown to be as effective in preventing and treating breast cancer as 




risk of invasive breast cancer in postmenopausal women with osteoporosis 
(Cummings, et al., 1999). 
For ER+ breast cancer patients or survivors, understanding the interactions 
between black cohosh and SERMs is crucial.  Investigations that focus on potential 
interactions when black cohosh is used in combination with SERMs should consider 
four possible outcomes: a synergistic effect, an additive effect, an antagonistic effect, 
or no effect.  In other words, black cohosh may work together with SERMs to reduce 
cancer cell growth to an extent greater than the sum of their two effects, black cohosh 
may work together with SERMS to reduce cancer cell growth to an extent equal to 
the sum of their effects, it may work against SERMs and reduce the amount that 
SERMs inhibit breast cancer cell proliferation, or it may not have any effect on 
SERM function.  Al-Akoum found a synergistic effect in vitro for tamoxifen and 
black cohosh on inhibition of proliferation of ER+ MCF-7 breast cancer cells at 
increasing concentrations of tamoxifen (Al-Akoum, et al., 2007).  Similarly, Einbond 
found a synergistic effect between actein and different classes of chemotherapy 
agents on the inhibition of estrogen receptor negative (ER-) MDA-MB-453 human 
breast cancer cell proliferation (Einbond et al., 2006).  
 
2.3.4 Hepatotoxicity of Black Cohosh 
While determining the efficacy of black cohosh in treating breast cancer is 
important, so too is assessing its safety.  Previous investigators have examined the 
effect of black cohosh on liver function as an indicator of how safe it is to consume, 




substances from the body (Gurley, et al., 2006; Lude, et al., 2007).  Exposure of the 
liver to certain herbs, drugs, chemicals or metabolic by-products that adversely affect 
liver function results in hepatotoxicity. 
In addition to controversy regarding its estrogenic effects, black cohosh’s 
hepatotoxic effects are also debated.  Previous in vitro and in vivo hepatotoxicity 
assays of black cohosh have provided some evidence that black cohosh may have 
adverse effects in the liver.  One study using a 60% ethanolic black cohosh extract 
found that at media concentrations ≥75 µg/mL, cytotoxicity in HepG2 liver cells 
becomes apparent; at ≥10 µg/mL mitochondrial β-oxidation is impaired; at ≥100 
µg/mL mitochondrial membrane potential is decreased; and at ≥300 µg/mL oxidative 
phosphorylation is impaired (Lude, et al., 2007).  However, these HepG2 cells were 
treated when less than 100% confluent, and thus the results may not be applicable to 
the adult liver, since confluent cells better mimic the conditions of an actual liver 
(Flynn & Ferguson, 2008; Lude, et al., 2007).  Confluence refers to cells that have 
formed a complete monolayer over the culture surface.  In this study, steatosis was 
also observed in rat livers after rats were given more than 500 µg/kg body weight of 
black cohosh extract (Lude, et al., 2007).  Another study found that a black cohosh 
extract containing 6 triterpene glycosides had an IC50 value (half maximal inhibitory 
concentration, i.e., the concentration necessary for 50% inhibition) of 0.027 mg/mL 
for inhibition of CYP3A4, though the isolated compounds were not as effective in 
inhibiting CYP3A4 (Tsukamoto, Aburatani, & Ohta, 2005).  CYP3A4 is a 




extracts inhibit the activity of this enzyme, as suggested by the study, then the 
extracts may change the way the liver is able to process other drugs. 
There have also been several case reports of human liver malfunction 
attributed to black cohosh use.  In two case reports, the patients were admitted to a 
hospital and found to have normal levels of albumin and bilirubin, but hepatotoxicity 
was indicated by increased levels of gamma glutamyl transpeptidase which returned 
to normal after the patient discontinued use of black cohosh (Joy, Joy, & Duane, 
2008).  In another case report, a woman stopped taking her daily Remifemin® tablet 
(a black cohosh alternative to hormone replacement therapy) after experiencing 
darkened urine on day six, and was later admitted to a hospital for lethargy, jaundice, 
and incoherence.  After undergoing a liver transplant, her liver was found to have 
significant hepatic necrosis and weighed only 398 g, whereas a normal female liver 
weighs 1400 g (National Institutes of Health, 2004).  In 2007, one woman began to 
experience irregular liver function test results two weeks after taking black cohosh 
root supplements.  After two months, she was hospitalized and found to have 
hepatitis, fibrosis, and low liver cell recovery, but after a liver transplant her 
symptoms vanished and have since not reoccurred (Dunbar & Solga, 2007). 
While there have been various case reports suggesting that black cohosh is 
toxic to the liver, confounding factors in these case studies limits the ability to draw 
definitive conclusions.  Some of the study design problems seen in case studies 
reporting black cohosh as a probable cause of liver failure or hepatitis include use of 
multiple HDS, concurrent alcohol consumption, and/or a lack of data on the type of 




updated diagnostic algorithm from the Council for International Organizations of 
Medical Sciences showed that out of 42 case reports of severe hepatotoxicity in 
menopausal women using black cohosh, none were caused by this HDS (Teschke & 
Schwarzenboeck, 2009). 
In 2004, NIH held a “Workshop on the Safety of Black Cohosh in Clinical 
Studies,” in which experts reviewed 51 adverse event reports from the FDA, World 
Health Organization (WHO), Australian Adverse Drug Reactions Advisory 
Committee, German Federal Institute for Drugs and Medical Devices, and Committee 
on Safety of Medicines in the U.K.  The workshop consensus was that although there 
was no decisive evidence of adverse hepatic effects, continued monitoring was 
warranted (National Institutes of Health, 2004).  In 2007, a follow-up workshop was 
held by the Office of Dietary Supplements of NIH.  This second workshop generated 
five recommendations: 1) increase adherence to nomenclature guidelines among 
healthcare professionals when reporting adverse events associated with herbal 
medicines, 2) increase communication between regulatory and monitoring agencies 
regarding adverse event report-related data and analyses, 3) encourage research in 
monitoring herbal product related-adverse event reports, 4) conduct research on 
clinical benefit and safety of black cohosh, its chemistry, and the mechanism of 
action of black cohosh extracts and their chemical constituents, and 5) monitor liver 
function before, during, and after any clinical trials of black cohosh products (Betz, et 
al., 2009). 
In addition to hepatotoxicity, the potential interaction of black cohosh with 




cohosh on liver function.  P-glycoprotein is responsible for pumping foreign 
substances out of a cell.  If a substance is present that changes the activity of p-
glycoprotein, that substance can change the length of time that other substances, 
including conventional drugs, remain in cells and in the body.  In one study where 
eight subjects took 40 mg of black cohosh supplement for 14 days, their p-
glycoprotein activities measured before and after this period were not found to be 
significantly different, showing that black cohosh does not affect levels of this liver 
function-related protein in humans (Gurley, et al., 2006). 
Another concern with respect to black cohosh and liver function is the 
possible under reporting of any hepatotoxicity after its use.  The Dietary Supplements 
Information Expert Committee (DSI-EC) of the US Pharmacopeial Convention found 
that poison control centers collect more adverse event reports (AER) than FDA 
MedWatch, the main organization that handles AER, and that there is insufficient 
national and international communication about these reports and coordination in 
detecting health risks (Gardiner et al., 2008).  Thus, side effects of black cohosh may 
not be adequately reported.  Concerns about under reporting adverse effects 
associated with dietary supplements led the DSI-EC to recommend additional 
research on the safety of HDS (Gardiner, et al., 2008).  The US Pharmacopeia’s DSI-
EC recently decided that black cohosh products should be labeled with the following: 
“Discontinue use and consult a healthcare practitioner if you have a liver disorder or 
develop symptoms of liver trouble, such as abdominal pain, dark urine, or jaundice” 
(Mahady, et al., 2008).  In summary, there is conflicting and inconclusive information 




effects in the liver from potential interactions between black cohosh and conventional 






3.1 Survey: HDS Uses and Perceptions 
3.1.1 Questionnaire Design 
The questionnaire consisted of mostly forced-choice questions that addressed 
participants’ attitudes and behaviors with respect to HDS (See Appendix A).  
Initially, subjects were asked what their current stage of breast cancer was, whether 
they had ever received conventional cancer treatments, whether they had received 
conventional cancer treatments within the past 12 months, and whether they had ever 
used an HDS.   
Those who reported ever using an HDS were then asked whether black 
cohosh, chamomile, curcumin, evening primrose, flaxseed, green tea, ginger, ginseng, 
kava kava, milk thistle, red clover, saw palmetto, soy, St. John’s wort, and valerian 
were used for medicinal or other purposes.  They were also asked whether each 
supplement was used before and/or after their cancer diagnosis.  Open-ended 
questions regarding general reasons for using each supplement, as well as side effects 
of conventional cancer treatment that were treated with each supplement, were 
included.  Subjects were then asked to rate the effectiveness at treating side effects of 
conventional therapy for each HDS they used.  There were also opportunities for 
additional comments. 
Participants were next asked which sources of information were influential in 




considered their sources of information.  Possible sources of information included 
websites found through internet databases and search engines, government websites, 
information provided by companies or company websites, breast cancer support 
groups or other cancer related non-profit organizations, cancer related health 
organizations, popular magazines or newspapers, academic journals, friends, family 
members, physicians and other health care providers, and practitioners specializing in 
CAM.  These categories were determined at the discretion of the Gemstone team 
members and not based directly on the literature.  Finally, subjects were asked to rate 
how concerned they were regarding safety and labeling of supplements. 
 The exact number of questions completed depended on whether or not 
subjects reported using HDS, and how many they used.  Participants were asked from 
7 to 71 questions; for each supplement a participant had used, further questions were 
asked regarding the specifics of its use.  The survey also included demographic 
questions—including race, religion, income, education level, and age—for describing 
the sample and for analysis purposes.  The survey was approved by the University of 
Maryland Institutional Review Board (IRB) to ensure that our survey met ethical 
standards with respect to research on human subjects.  An online version of the 
survey with programmed skip patterns was created using the website 
SurveyMonkey.com. 
 
3.1.2 Pilot Testing 
The survey was pilot tested through a variety of informal channels before 




University of Maryland GEMS100 and GEMS202 students during the academic 
school year 2008-2009.  Pilot test procedures for this sample involved administering a 
paper version of the survey, asking participants to fill out a feedback form (See 
Appendix B), and conducting a cognitive interview with the participants. 
The second pilot test sample included staff and patients at the Georgetown 
Lombardi Cancer Center (Washington, DC).  Pilot test procedures for this sample 
involved administering the survey in an interview format.  Afterwards, the survey 
questions were discussed and feedback was received.  In some cases, participants 
were asked to participate in mock scenarios to more adequately test the survey’s skip-
pattern features.  All pilot test participants were volunteers, and the completed 
surveys were destroyed. 
 
3.1.3 Subject Recruitment 
All subjects were recruited via an advertisement on the breast cancer support 
website BreastCancer.net or via an e-mail blast from Love/Avon Army of Women.  
BreastCancer.net is an online support group and educational site that provides 
information to breast cancer patients.  Love/Avon Army of Women is a partnership 
between the Dr. Susan Love Research Foundation and the Avon Foundation for 
women.  This non-profit agency works to eradicate breast cancer and to improve the 
quality of women’s health through research, education, and advocacy. 
For subjects recruited through BreastCancer.net, potential subjects who 
viewed the advertisement clicked on the link and were directed to the team website 




link to complete our online survey on SurveyMonkey.com.  For subjects recruited 
from Love/Avon Army of Women, registered volunteers of Love/Avon Army of 
Women received an e-mail blast that contained the direct link to our survey.  In order 
to proceed with the survey, subjects had to agree that they met the criterion of being 
breast cancer survivors over the age of 18, and also had to complete the consent form. 
 
3.1.4 Questionnaire Completion 
Considering only the subjects who met the criterion of being a female cancer 
survivor over the age of 18, 1106 subjects began the questionnaire and 1072 subjects 
completed the entire questionnaire.  Of the 1106 subjects, approximately 98 subjects 
were recruited from BreastCancer.net and 1008 subjects were recruited from 
Love/Avon Army of Women.  The exact number of subjects from each sample 
population could not be determined, but the number was estimated based on the date 
that each survey was taken.  The survey was first advertised on BreastCancer.net, and 
the Love/Avon Army of Women e-mail blast was not sent out until later in the data 
collection process.  Thus, the surveys completed on earlier dates were from 
BreastCancer.net and those completed later on were from Love/Avon Army of 
Women.  All surveys took participants about 20 minutes to complete and were 





3.1.5 Statistical Analysis 
Raw data from the survey were downloaded directly into a Microsoft Excel 
spreadsheet and fixed-answer questions were pre-coded by SurveyMonkey.com as 
part of the services provided.  Open-ended questions were coded by hand by members 
of the IMAC team.  Data analyses were performed using both Excel and Statistical 
Analysis Software (SAS) System for Windows v.9.1 (SAS Institute, Cary, NC).  
Microsoft Excel was used to determine basic descriptive data and SAS was used to 
complete statistical tests, including basic descriptive statistics, chi-square tests, 
analysis of variance, and correspondence analysis.  All p-values were < 0.05 unless 
noted. 
Basic descriptive statistics, including mean, median, mode, and standard 
deviation, were used to analyze the number of supplements used by each subject. 
A Chi-square goodness of fit test was used to determine which HDS were 
used most and least frequently, which HDS were used more to treat conventional 
cancer therapy symptoms, which sources of information subjects were more likely to 
consult, and which information sources were considered more reliable. 
A Chi-square test of association was used to determine whether each specific 
HDS was used more for medicinal or other purposes, whether and how HDS use in 
general changed before and after cancer diagnosis, whether and how use of each 
specific HDS changed before and after cancer diagnosis, whether there was a 
difference between perceived efficacies of supplements, whether or not sources of 




with use of specific HDS, and whether there was an association between age (pre vs. 
post menopause) and starting or stopping black cohosh use. 
A one-way ANOVA was used to determine whether HDS in general were 
used more for medicinal or other purposes.  A multi-way ANOVA test was used to 
determine whether there was an association between the sources consulted and the 
number of HDS used. 
Correspondence analysis was used to determine which supplements were 
perceived as more effective, and whether certain HDS were taken together.  Cluster 
analysis was used to determine whether specific demographic clusters were more 
likely to use HDS in general.  Lastly, logistic regression was used to determine 
whether specific demographic clusters were more likely to use certain HDS. 
 
3.2 In vitro Study: Effects of Actein on Breast Cancer Cell Proliferation 
3.2.1 Materials 
Actein was purchased from Planta Analytica (Danbury, CT; lot number PA 
VI-13.A); purity was over 95% by high performance liquid chromatography (HPLC).  
Tamoxifen, raloxifene hydrochloride, trichloroacetic acid (TCA), sulforhodamine B 
(SRB), 17β−estradiol, and dimethylsulfoxide (DMSO) were purchased from Sigma-
Aldrich (St. Louis, MO).  Fetal bovine serum (FBS), charcoal stripped FBS (CSS), 
0.25% trypsin-EDTA, phosphate-buffered saline (PBS), and RPMI-1640 medium 
were obtained from Invitrogen (Carlsbad, CA).  Solutions of tamoxifen, raloxifene, 




was diluted to a final concentration of 1 nM in medium.  Tamoxifen and raloxifene 
were diluted in RPMI-1640 medium to final concentrations of 0.1, 1, 5, and 10 µM.  
Actein was diluted to test concentrations of 0.1, 1, 5, 10, and 25 µM.  
 
3.2.2 MCF-7 Cell Culture 
ER+ human breast cancer MCF-7 cells were obtained from the ATCC 
(Rockville, MD) and were cultured in RPMI-1640 medium with phenol red and 2 
mM L-glutamine, 5% FBS, and antibiotics (100 units/mL penicillin and 100 µg/mL 
streptomycin, BioSource International, Camarillo, CA).  The cells were cultured as 
monolayers at 37ºC and 5% CO2.  Cells were split every 7 days in a 1:5 ratio, and 
experiments were performed with cells from passages 7-17.  For some experiments, 
medium was replaced with RPMI-1640 medium without phenol red with 2 mM L-
glutamine, 5% CSS, and antibiotics one week prior to the experiment to remove 
exogenous estrogens. 
 
3.2.3 SRB Assay for Cell Proliferation  
MCF-7 cells were seeded (2.5 × 104 cells/well) in 24-well Costar plates 
(Corning, NY).  Following a 24-hour incubation, medium was replaced with DMSO 
control or test compounds dissolved in DMSO.  Treatment medium was replaced 
every 24 hours for 96 to 120 hours.  Cell growth was analyzed using the SRB assay 
described by Skehan, et. al, and Rubinstein, et. al (1990; 1990).  Treated cells were 




were then washed 5 times with water and left to air dry.  The fixed cells were stained 
for 20 minutes with 0.4% SRB in 1% acetic acid, and then washed five times with 1% 
acetic acid and left to air dry.  Bound dye was solubilized with 10 mM unbuffered 
Tris base at pH 10.5 for 5 minutes on a gyratory shaker.  Aliquots were transferred to 
a 96-well microtiter plate, and absorbance was read by a plate reader at 490 nm.  If 
necessary, dilutions were performed on all samples to ensure that readings were 
below 1.8 optical density (OD) units.  For cell proliferation assays, data were 
expressed as mean ± SEM.  Control and treated cells were compared using one-way 
ANOVA. 
 
3.2.4 Gene Expression Analysis 
MCF-7 cells were seeded (2.5 × 105 cells/well) in 6-well Costar plates 
(Corning, NY).  Following a 24-hour incubation, medium was replaced with DMSO 
control or test compounds dissolved in DMSO.  Treatment medium was replaced 
every 24 hours for 48 hours.  Treated cells were washed with PBS, and total RNA 
was isolated and quantified with Trizol (Invitrogen) and spectrophotometric analysis 
according to the manufacturer's instructions.  To synthesize cDNA, 1 µg of total RNA 
was reverse-transcribed with the AffinityScript Multiple Temperature cDNA 
Synthesis Kit as described in the provided First-Strand cDNA Synthesis Protocol 
(Stratagene, La Jolla, CA).  cDNA was diluted to a total volume of 200 µL in DEPC-
treated water. 
mRNA levels of genes of interest were determined by real-time PCR (RT-




phosphate dehydrogenase (GAPDH); vascular endothelial growth factor A (VEGFA); 
trefoil factor 1 (TFF1); cytochrome P450, family 1, subfamily A, polypeptide 1 
(CYP1A1); and cyclin-dependent kinase inhibitor 1A (p21, Cip1, CDKN1A) were 
obtained as TaqMan Gene Expression Assays (Applied Biosystems; Foster City, CA).  
Each 20 µL of PCR reaction mix contained 4.3 µL cDNA, 10 µL TaqMan Fast 
Universal Master Mix (2x, Applied Biosystems), and 1 µL TaqMan Gene Expression 
Assay mixture.  RT-PCR was performed with an ABI-PRISM 7000 Sequence 
Detector (Applied Biosystems).  PCR conditions were 50°C for 2 minutes, 
denaturation at 95°C for 10 minutes, followed by 46 cycles at 95°C for 15 seconds 
each, and 60°C for 1 minute.  Each sample was assayed in triplicate in a 96-well 
optical plate.  Ratios between experimental and control target gene expression were 
calculated after normalization of expression values to the housekeeping gene 
GAPDH.   
 
3.2.5 Statistical Analysis 
All treatment experiments were repeated at least twice.  Cell proliferation 
experiments were performed in quadruplicate and gene expression assays in triplicate.  
For cell proliferation and gene expression assays, data were expressed as mean ± 
SEM.  Control and treated cells were compared using one-way ANOVA followed by 
a multiple comparison post-test.  Probability values less than or equal to 0.05 were 





3.3 In vitro Study: Hepatotoxicity of Actein in Liver Cells 
3.3.1 Materials 
Actein was obtained from Planta Analytica (Danbury, CT; lot number PA VI-
13.A); purity was over 95% by HPLC.  Tamoxifen and raloxifene hydrochloride were 
purchased from Sigma-Aldrich (St. Louis, MO).  HepG2/C3A cells were obtained 
from ATCC (Manassas, VA) and media components were obtained from Invitrogen 
(Grand Island, NY), except for CSS which was received from Atlanta Biologicals 
(Lawrenceville, GA).  Reagents for the endpoint assays were obtained from Sigma-
Aldrich (St. Louis, MO), with the exception of the assay reagents for the albumin 
assay, which were obtained from Bethyl Laboratories (Montgomery, TX). 
A BMG PolarStar™ Plate Reading Spectrofluorometer was used for all 
endpoint assays except for the albumin assay, for which an ELISA plate reader was 
used.  For the test compounds, solutions of 0, 0.76, 1.55, 3.10, 6.25, 12.50, 25.00, 
50.00, and 100.00 µM of actein, raloxifene, and tamoxifen in culture media and 
<0.5% DMSO were used to determine concentrations where significant levels of 
hepatotoxicity occurred.  For the combination studies, test compound solutions of 90 
µM tamoxifen with 0, 10, 30, and 100 µM actein, 50 µM raloxifene with 0, 10, 30, 
and 100 µM actein, 30 µM actein with 0, 3, 10, and 30 µM raloxifene, and 30 µM 





3.3.2 HepG2/C3A Cell Culture 
Cyropreserved HepG2/C3A cells were thawed and plated on the inner 60 
wells of 96-well plates in a culture medium consisting of 2 mM GlutaMAX™, 1% 
ITS, 1% MEM-NEAA, 10 mM HEPES, 10% CDS-FBS, 10 nM triiodothyronine, 20 
nM dexamethasone, 1 mg/mL albumin, 9.4 µg/mL linoleic acid, 9.4 µg/mL oleic acid, 
2 nM testosterone, 2 nM progesterone, and 0.4 nM estradiol in phenol-red free 
DMEM, to an average density of 2.0 × 105 viable cells/mL.  The cells were incubated 
at 37°C and 5% CO2.  Culture medium was changed every 48-72 hours until cells 
reached confluence on culture day 10.   
 
3.3.3 DCFDA Assay for Oxidative Stress 
On day 10, cells were treated with the non-fluorescent dye 
dihydrodichlorofluorescein diacetate (DCFDA) for 30 minutes at 37°C and 0% CO2, 
and then treated with the test compound.  After a 45-48 hour incubation at 37°C and 
5% CO2, the fluorescent product dichlorofluorescein (DCF), which resulted from any 
oxidation of DCFDA by reactive oxygen species (ROS), was measured as pmol of 
DCF formed/45-48 hrs/µg DNA with the spectrofluorometer (Yerushalmi, Dahl, 
Devereaux, Gumpricht, & Sokol, 2001).  
 
3.3.4 EROD Assay for Cytochrome P450IA1 Activity 
After completion of the DCFDA Assay, on day 12 cells were washed with 




The amount of fluorescent resorufin product of CYP1A1 dealkylation of EROD was 
measured every 3 minutes for 1 hour to determine the pmol of resorufin 
formed/min/µg DNA (Donato, Gomez-Lechon, & Castell, 1993; Lubinski, Flint, & 
Durham, 1994).  After this assay, cells were washed with HBSS and stored at -80°C 
until assayed for double-stranded DNA. 
 
3.3.5 Nile Red Assay for Steatosis 
On day 10 the test compounds were added, and the plate was incubated at 
37°C in 5% CO2 for 45-48 hours.  50 µL of media were removed from each well and 
stored at -80°C on a separate 96-well plate to be saved for the albumin assay.  Cells 
were washed with HBSS, incubated with Nile Red for 15 minutes at 37°C and 5% 
CO2, and the fluorescence of Nile Red in the phospholipid and neutral lipid areas of 
the cells was determined in fluorescence units/µg DNA (McMillian, et al., 2001).  
After this assay, cells were washed with HBSS and stored at -80°C until assayed for 
double-stranded DNA. 
 
3.3.6 Total Double-Stranded DNA Assay for Cell Death 
The plates were thawed at room temperature, refrozen at -80°C with dH2O, 
thawed at room temperature, treated with non-fluorescent Hoeschst 33258 (H33258), 
protected from exposure to light and incubated at room temperature for 30 minutes.  
The fluorescence of H33258 bound to double-stranded DNA was measured in µg/0.1 





3.3.7 Quantification of Albumin Secretion to Measure Cell Viability 
The plates with the 50 µL of media per well were thawed so that 5 µL from 
each well could be used to determine ng of albumin/well via the Bethyl Laboratories 
human albumin ELISA method. 
 
3.3.8 R123 Assay for Mitochondrial Membrane Depolarization 
On day 10 the test compounds were added to the cells and incubated for 2.5 
hours at 37°C in 5% CO2.  Rhodamine 123 was added and incubated with the cells for 
30 minutes at 37°C in 5% CO2.  Cells were washed with HBSS and incubated with 
the test compound for 45-48 hours at 37°C and 5% CO2.  The fluorescence of 
rhodamine 123 was read on day 12 to determine pmol of rhodamine retained/45-48 
hours (Rat, Korwin-Zmijowska, Warnet, & Adolphe, 1994).  After this assay, cells 
were washed with HBSS and stored at -80°C until assayed for double-stranded DNA. 
 
3.3.9 Statistical Analysis 
The data were tested for normal distribution using the Shapiro-Wilk Test.  
One-way ANOVA, followed by the Fisher LSD post-test was used to analyze the 
effects of actein, tamoxifen, and raloxifene on the HepG2/C3A cells as measured by 
the endpoint assays.  Two-way ANOVA was used for the interaction studies.  






4.1 HDS Uses and Perceptions 
4.1.1 Demography of Sample 
Of the subjects that completed the demographic portion of the survey, the 
majority were ≥51 years of age (Table 1).  Only about one-third of the participants 
were between the ages of 25 and 51, and only one participant was under the age of 
25.  The vast majority (94%) of participants reported themselves as white/Caucasian.  
Regarding their religious beliefs, approximately two-thirds were of Christian religion. 
The average participant reported having both a high level of education 
completed and a high household income.  Approximately two-thirds of participants 
reported an annual household income of at least $60,000, and nearly 40% of all 
participants reported an annual household income of over $100,000.  Regarding their 
highest education completed, approximately 30% had completed a Bachelor’s degree 
and 40% had completed an advanced or professional degree.   
Over half of the survey participants reported that their cancer was currently in 
remission.  Of participants whose cancer was not in remission, the majority reported 
that their cancer was in one of the less advanced stages, including Stage 0, Stage 1, 
Stage 2A, and Stage 2B.  The vast majority of participants (1077, 97.6%) had been 
treated with conventional cancer treatments, and approximately one third (354, 
32.1%) had been treated with conventional cancer treatments within the last 12 





Table 1.  Demographic variables and HDS use among breast cancer survivors. 
Total Used HDS Did Not Use HDS Characteristic n % of totala n % of groupb n % of groupb 
Age       
18-25 1 0.1% 1 100.0 0 0.0% 
36-50 301 28.0% 268 89.0 33 11.0% 
51-65 301 55.9% 531 88.4 70 11.6% 
65+ 142 13.2% 120 84.5 22 15.5% 
Race       
White 1011 94.0% 882 87.2% 129 12.8% 
Black 19 1.8% 16 100.0% 0 0.0% 
Asian 16 1.5% 17 89.5% 2 10.5% 
Hispanic 6 0.6% 5 83.3% 1 16.7% 
Other 23 2.1% 22 95.7% 1 4.3% 
Educationc       
Grade 2 0.2% 1 50.0% 1 50.0% 
High 63 5.9% 42 66.7% 21 33.3% 
Some College 181 16.8% 161 89.0% 20 11.0% 
Associate’s 88 8.2% 80 90.9% 8 9.1% 
Bachelors 312 29.0% 283 90.7% 29 9.3% 
Advanced 416 38.7% 364 87.5% 52 12.5% 
Other 13 1.2% 11 84.6% 2 15.4% 
Incomed       
<$20,000 39 3.6% 35 89.7% 4 10.3% 
$20,000-39,999 105 9.8% 89 84.8% 16 15.2% 
$40,000-59,999 116 10.8% 97 83.6% 19 16.4% 
$60,000-99,999 303 28.2% 268 88.4% 35 11.6% 
>$100,000 408 38.0% 364 89.2% 44 10.8% 
Don’t Knowe 104 9.7% 89 85.6% 15 14.4% 
Religion       
Christian 714 66.6% 625 87.5% 89 12.5% 
Jewish 102 9.5% 84 82.4% 18 17.6% 
Muslim 1 0.1% 1 100.0% 0 0.0% 
Hindu 1 0.1% 1 100.0% 0 0.0% 
Buddhist 12 1.1% 12 100.0% 0 0.0% 
Deist/Agnostic 40 3.7% 32 80.0% 8 20.0% 
Atheist 26 2.4% 20 76.9% 6 23.1% 
None 111 10.4% 101 91.0% 10 9.0% 
Other 65 6.1% 63 96.9% 2 3.1% 
Cancer Stage       
Remission 555 50.3% 499 89.9% 56 10.1% 
Stage 0 107 9.7% 82 76.6% 25 23.4% 
Stage 2 A 78 7.1% 68 87.2% 10 12.8% 
Stage 2 B 65 5.9% 60 92.3% 5 7.7% 
Stage 3 A 24 2.2% 20 83.3% 4 16.7% 
Stage 3 B 18 1.6% 17 94.4% 1 5.6% 
Stage 3 C 6 0.5% 4 66.7% 2 33.3% 
Stage IV 31 2.8% 30 96.8% 1 3.2% 
Other/Don’t Knowe 56 5.1% 45 80.4% 11 19.6% 
apercentage of all subjects that reported themselves as a member of each demographic group.   
bpercentage within each demographic group that used or did not use HDS, respectively.   
chighest level of education attained by the subject.   
dtotal household income for the past year.   




We performed a cluster analysis to group subjects with similar characteristics 
into categories.  Cluster analysis confirmed the homogeneity of the sample—that is, 
mostly older, high income, and highly educated participants.  Age, income, and 
education were used to group participants into three clusters or groups in which 
combinations of age, income, and education levels occur together.  Race was 
excluded from this analysis because it cannot be ranked ordinally.  Cubic clustering 
criterion determined the number of clusters (3) and an iterative process determined 
the mean of each cluster.  Then, each participant was assigned to the cluster with the 
closest mean. 
Cluster 1 is older, highly educated and high income (n=392); Cluster 2 is 
older, less educated, and middle income (n=344); and Cluster 3 is younger, highly 
educated, and high income (n=224).  Cluster 1 consists of individuals that are best 
described as 51-65 years of age, with incomes greater than $100,000, and advanced 
degrees.  Cluster 2 generally describes individuals who are also 51-65 years of age, 
but of incomes between $40,000-50,000 and with Associate’s degrees.  Cluster 3 best 
describes individuals between 36-50 years of age, with incomes exceeding $100,000 
and advanced degrees (Table 2). 
The overlap in these clusters shows that most of the sample is either older or a 
high earner with advanced education (if not both) as shown by the nearly 400 





Table 2.  Cluster analysis of demographic characteristics. 
Cluster n Descriptiona Ageb Incomeb Educationb 
1 392 Older, high income, high education 51 – 65 > $100,000 Advanced Degree 





3 224 Younger, high income, high education 36 – 50 > $100,000 Advanced Degree 
acharacterizes the cluster relative to all participants.  
brepresent the average for each cluster. 
 
4.1.2 Frequency of Supplement Use 
965 (87.6%) subjects reported using herbal dietary supplements.  The 
frequency of herbal dietary supplement use within each demographic group is 
displayed in Table 1.  Including only those subjects who reported using at least one 
HDS, each subject used an average of about 6 HDS (mean=5.70, median=6, mode=6, 
standard deviation=2.49).  When including both those who did and did not use HDS, 
an average of 5 HDS were used by each subject (mean=4.97, median=5, mode=6, 
standard deviation=3.00).    
The most commonly used supplements for non-medicinal purposes were soy, 
green tea, chamomile, ginger, and flaxseed, respectively (Figure 3).  Each of these 
was used by at least one-third of all survey subjects, while soy was used by over half 
of participants (50.3%).  Less than one-fourth of subjects reported using each of the 
remaining supplements for non-medicinal purposes, including 41 subjects (4.3%) 
who reported using black cohosh for non-medicinal purposes.  
The most commonly used supplements for medicinal purposes were flaxseed, 
green tea, ginger, and curcumin/turmeric, respectively.  At least one fourth of 




flaxseed was used by 43.8% of all participants who responded to the question 
regarding flaxseed use.  Less than one fourth of participants reported using each of 
the remaining supplements for medicinal purposes, with 191 subjects (19.8%) using 












Use of Herbal Dietary Supplements by HDS
Medicinal Purposes Other Purposes Total
 
Figure 3.  Use of HDS for medicinal and other purposes.  
Use for medicinal purposes includes only instances when an HDS is taken with the specific intent to 
treat a medical condition or symptom, or to improve health.  Use for other purposes includes uses in 
cooking and for other non-medically related reasons.  Total is the sum of medicinal and other use.   
 
It is important to note that subjects were forced to report their supplement use 
as being either for medicinal or non-medicinal purposes, and were not able to report 
using supplements for both purposes.  To determine the overall use of HDS 
irrespective of purpose, HDS use was analyzed using a chi-square goodness of fit test.  




flaxseed, green tea, curcumin, and ginger.  The least frequently used HDS were saw 












Use of HDS for Medicinal and Other Purposes as Percentage of Total Users Per HDS
Medicinal Purposes Other Purposes
 
Figure 4.  Relative use of each individual HDS for medicinal and other purposes.  
Use for medicinal purposes includes only instances when an HDS is taken with the specific intent to 
treat a medical condition or symptom, or to improve health.  Use for other purposes includes uses in 
cooking and for other non-medically related reasons. 
 
While supplements were used almost equally for medicinal and non-medicinal 
purposes overall, there were differences in how individual supplements were used.  
Most supplements were used more often for one purpose than the other.  For example, 
black cohosh, curcumin, evening primrose, flaxseed, milk thistle, red clover, St. 
John’s wort, and valerian were used significantly more for medicinal purposes as 
indicated by a chi-square test of association.  Conversely, chamomile, ginger, 




medicinal (other) purposes.  Kava kava was used about equally for medicinal and 
other purposes (Figure 4). 
The demographic clusters previously obtained were examined with HDS use 
via chi square analysis of variance to determine whether the number of HDS used 
differed between the clusters.  In fact, there is no significant difference between the 
number of HDS used and demographic cluster membership.  To determine whether 
cluster membership can predict the use of specific HDS, a logistic regression was 
estimated for each supplement where HDS use is the dependent variable and cluster 
membership is the explanatory variable.  Cluster membership appears to only the 
affect the use of milk thistle (p=0.0298) and soy (p=0.0042), where Cluster 1 is less 
likely to than Clusters 2 and 3 to use milk thistle and Cluster 3 is less likely than 
Clusters 1 and 2 to use soy.  Because Cluster 1 shares characteristics with the other 
clusters, the interpretation of the milk thistle regression is unclear.  Yet because 
Cluster 3 is younger than Clusters 1 and 2, it can be speculated that older women are 
more likely to use soy. 
Cluster analysis was also used to determine whether or not there were 
common patterns of HDS use, with certain groups of HDS frequently used together 
(Table 3).  Survey respondents clustered into 4 groups when considering the 
simultaneous use of all HDS, based on two criteria: the number of HDS used relative 
to the overall average, and the type of HDS used relative to the overall frequencies of 
use.  Thus the number of supplements used can be greater than, equal to, or less than 
average; while the kinds of supplements used can be common or rare.  Cluster 1 used 




increased use of curcumin, chamomile, ginger, ginseng and soy compared to other 
clusters.  Cluster 2 used a high number of HDS (µ=9.1), and used both common and 
rare HDS, with increased use of all HDS.  Cluster 3 used a minimal number of HDS 
(µ=2.8) and used mostly common known HDS, with the highest use of flaxseed and 
green tea.  Cluster 4 used an average number of HDS (µ=5.4), but used both common 
and rare HDS, with increased use of black cohosh, milk thistle, and evening primrose 
(rare HDS) as well as soy, chamomile, ginger, green tea and flaxseed (common HDS) 
compared to other clusters.  The clusters are roughly equal in size, while Cluster 1 
contains a plurality of survey participants. 
Table 3.  Cluster analysis of HDS use. 
Cluster n Number of HDS
a 
(µ) 
Increased Use of Common 
HDSb 
Increased Use of Rare 
HDSb 
1 305 Average (6.2) Curcumin, Chamomile, Ginger, Ginseng, Soy   
2 152 High (9.1) All All 
3 220 Minimal (2.8) Flaxseed, Green Tea   
4 191 Average (5.4) Soy, Chamomile, Ginger, Green, Tea, Flaxseed 
Black Cohosh, Milk 
Thistle, Evening Primrose 
acharacterizes HDS use as “minimal,” “average,” or “high” relative to all survey participants.  
b“Common” and “Rare” HDS are inferred from the chi square test of association used to determine 
which supplements are used most frequently.  “Increased Use” is relative to all survey participants. 
 
In addition to examining patterns of HDS use in general, our survey also 
examined HDS use prior to and after breast cancer diagnoses.  If subjects answered 
“yes” to using a particular supplement, they were then prompted to disclose whether 
they used the supplement before their diagnosis and/or after their diagnosis.  The aim 
of this analysis was to determine whether HDS use changed after cancer was 
diagnosed.  In order to assess the change, a pair-wise comparison was conducted by 
coding the responses as a positive change (began HDS use after diagnosis), a negative 
change (discontinued use after diagnosis), or no change.  On average, the change ratio 




suggesting that subjects were more likely to begin taking HDS after they were 
diagnosed with breast cancer.   
However, the changes in use varied among the different supplements.  We 
used chi-square tests of association to determine if a specific HDS was more likely to 
undergo a change in use after cancer diagnosis and whether the change was more 
likely to be positive or negative.  We found that the use of black cohosh, curcumin, 
evening primrose, flaxseed, ginseng, kava kava, milk thistle, red clover, St. John's 
wort, saw palmetto, and soy was more likely to change after cancer diagnosis than the 
use of chamomile, ginger, green tea or valerian.  Use of chamomile, curcumin, 
flaxseed, ginger, green tea and milk thistle increased after cancer diagnosis while the 
use of kava kava and St. John's wort decreased after diagnosis.  The use of black 
cohosh, evening primrose, ginseng, red clover, saw palmetto, soy, and valerian both 
increased and decreased after cancer diagnosis, indicating that approximately equal 
numbers of survey respondents either started or stopped taking these supplements 
after being diagnosed with breast cancer (Table 4). 
Table 4.  Use of HDS before and after breast cancer diagnoses.  
Mostly Increased Use After 
Diagnosesa 
Mostly Decreased Use After 
Diagnosesb 
Both Increased and Decreased 
Usec 
Chamomile Kava Kava Black Cohosh 
Curcumin St. John’s Wort Evening Primrose 
Flaxseed  Ginseng 
Ginger  Red Clover 
Green Tea  Saw Palmetto 
Milk Thistle  Soy 
  Valerian 
amost likely to have their use begin after breast cancer diagnoses. 
bmost likely to have their use end after breast cancer diagnoses.   





4.1.3 Reasons for Supplement Use 
Subjects were asked open-ended questions regarding specific reasons for why 
they used HDS.  Thirteen of the 15 supplements were reported by at least one subject 
as being used to directly treat cancer or prevent its recurrence.  The only supplements 
that were not reported as being used to treat or prevent cancer were St. John’s wort 
and valerian.  Most notably, 125 subjects reported using green tea, 112 subjects 
reported using curcumin, 100 subjects reported using flaxseed, and 25 subjects 









Use of HDS to Treat or Prevent Breast Cancer Recurrence
 
Figure 5.  Use of HDS to treat and/or prevent breast cancer recurrence.  
This chart displays the number of respondents who reported using each HDS to specifically treat 
and/or prevent the recurrence of their breast cancer as reported in open-ended questions addressing 
reasons for use.  
 
Survey respondents indicated several other reasons for using HDS, shown in 




specific type of HDS.  “Most frequent reasons” are those cited by at least 10 percent 
of respondents who answered the questions about reasons for use. 
Table 5.  Most frequent reasons for using HDS. 
HDS Total Respondents Who Cited Reasons 
Most Frequent 




















































Ginger 281 Nausea 213 75.8 % 




















Milk Thistle 150 Liver Function 113 75.3 % 





























aratio of the “Number of Respondents” over the “Total Respondents who Cited Reasons” for that 
supplement. 
 
It is important to note that questions regarding specific reasons for use were 
open-ended, which may have introduced bias according to how the questions were 
interpreted.  After the survey was administered, similar responses to open-ended 




immune support, to compare the reasons for use for a particular HDS.  The categories 
were further aggregated in order to compare reasons for use among all HDS.  A 
concise list of categories is necessary to determine whether there are actual 
differences in the reasons for using different supplements, and reasons cited by only a 
few respondents would skew the distribution.  Further, several respondents cited 
multiple reasons for using a particular HDS.  For the first round of coding, each 
reason a subject gave was individually counted, but the second round of coding 
eliminated this “double-counting” by assigning a new variable denoting that a 
particular subject gave multiple reasons for taking an HDS. 
The reasons for using HDS were ultimately condensed from the original 30+ 
categories into 8 broad categories (Table 6).  Each of these broad categories includes 





Table 6.  Reasons for using HDS. 
Broad Categorya Specific Reasons for Use 
Heart (HRT)  
 Heart health 
 Cholesterol 
 Blood Pressure 










 Hot Flashes 
Cancer Treatment (CAN)  
 Cancer treatment 
 Prevention of recurrence 
Diet (DIET)  
 Diet 
 Omega fatty acids 
 Antioxidants 
 Fiber 
General Health (HLTH)  
 General health and well-being 
 Immune support 
Misc. bodily functions (BODY)  
 Digestion 
 Liver function 
 Bone/skeletal 
 Pain/inflammation 
Chemotherapeutic Symptoms (CHEMO)  
 Nausea 
 Fatigue 
 Weight control 
 Cell damage 
 Hair damage 
 Acne 
 Eye problems 
aEach broad category includes specific reasons for use. 
 
In order to further analyze which supplements were used for which reasons, 
we used a correspondence analysis.  Figure 6 shows the supplements and the reasons 
for use arranged in four distinct clusters.  Correlations between a supplement and its 
use can be inferred by the clusters of plots.  For example, the triangle cluster indicates 




psychological reasons, such as anxiety and insomnia.  Black cohosh, soy, red clover, 
and evening primrose were used mostly for estrogen related reasons, such as 
symptoms of menopause (rectangle cluster).  As seen in the square cluster, ginger and 
ginseng were used mostly to treat common side effects of chemotherapy.  Flaxseed, 
saw palmetto, curcumin, green tea, and milk thistle were all used for a combination of 
reasons, including heart health, cancer treatment, improved diet, general health, body 
functions, and multiple/other reasons (oval cluster, Figure 6). 
 
Figure 6.  Correlation of HDS and reasons for use.  
Correspondence analysis was used to determine correlations between groups of HDS and broad 
categories of reasons for use.  Abbreviations for reasons: CAN, cancer; EST, estrogen related reasons; 
PSYCH, psychological reasons; CHEMO, side effects of conventional therapies; HRT, heart health; 
HLTH, general health; DIET, dietary reasons; BODY, digestive, liver, and bone health as well as 
pain/inflammation; MULTI, multiple reasons; OTH, other reasons.  Abbreviations for supplements: 
BC, black cohosh; EP, evening primrose; SP, saw palmetto; RC, red clover; Flax, flaxseed; Cur, 





4.1.4 HDS to Treat Side Effects of Conventional Treatments 
After being asked the general reasons for using supplements, subjects were 
asked whether or not they used HDS to treat side effects of conventional cancer 
therapy.  A chi-square goodness of fit test showed that ginger was by far the most 
commonly used supplement to treat side effects of conventional cancer treatments, 
and was the only HDS used more than 50% of the time for this purpose.  Other 
commonly used HDS to treat side effects of conventional therapies were chamomile, 
black cohosh, green tea, flaxseed, and milk thistle.  HDS used least often to treat side 
effects of conventional cancer therapies were saw palmetto, kava kava, red clover, St. 
John's wort, and soy.  
Those who reported using a supplement to treat side effects of conventional 
therapies were then asked which specific side effects of conventional cancer 
treatments they had hoped to treat with each supplement.  Table 7 shows how many 
survey participants cited side effects they hoped to treat with each supplement and of 
those side effects, the most frequently cited. 
These results should be interpreted with caution, however, as it appears that 
the survey questions addressing reasons for using HDS, and the symptoms or side 
effects of conventional cancer treatments that subjects hoped to treat with HDS, may 
have been misunderstood.  Many respondents who answered both of these open-
ended questions provided the same response.  For example, a respondent would 
indicate “inflammation” as both a reason for using curcumin as well as the side effect 
of conventional therapy she hoped to alleviate by taking the supplement.  In addition, 




conventional cancer therapy, further suggesting that some of the survey questions 
were ambiguous.  Nevertheless, the number of respondents who answered the 
question regarding symptoms of conventional treatments was about half the number 
who answered the question about reasons for using HDS.  This is consistent with the 
notion that the number of subjects who used HDS to treat side effects of conventional 
cancer therapies would be a smaller subset of those who used HDS for any medical 
purposes. 
Table 7.  Most frequent side effects treated by HDS. 






Black Cohosh 63 Hot Flashes 56 88.9% 
Chamomile 63 Anxiety 31 49.2% 





Evening Primrose 45 Hot Flashes 35 77.8% 





Ginger 173 Nausea 156 90.2% 
Ginseng 43 Cognitive Function 11 25.6% 










Milk Thistle 30 Liver Function 46 76.7% 
Red Clover 14 Hot Flashes 6 42.9% 
Soy 31 Hot Flashes 22 71.0% 
Saw Palmetto 4       
St. John’s Wort 21 Depression/Mood 18 85.7% 





aratio of “Number of Respondents” over “Total Respondents Who Cited Side Effects” for that 
supplement. 
 
4.1.5 Perceived Efficacy of HDS 
 Our survey also asked how effective subjects considered each HDS, and 
repeated this question for each supplement.  Overall, the supplements included in our 




questions regarding effectiveness, the forced-choice responses of “not effective,” 
“somewhat effective,” “very effective,” and “don’t know” are distributed equally.  
For statistical analysis, however, “don’t know” responses were excluded because we 
cannot interpret their meaning and because they skew the results.  Some supplements 
were rated “don’t know” more than other supplements.  For example, 62.9% of 
responses for milk thistle effectiveness were “don’t know,” versus 1.6% of responses 
for chamomile effectiveness.  Each possible response was calculated as a ratio of the 
total number of responses per supplement.  The average ratios across supplements 
were 18.0% “not effective,” 47.2% “somewhat effective,” and 34.8% “very 
effective.” 
A chi-square test of association indicated that there were significant 
differences of perceived effectiveness among individual HDS.  Ginger, green tea, 
milk thistle, and curcumin were considered very effective.  Ginseng, valerian, 
flaxseed, red clover, and chamomile were considered somewhat effective.  Black 
cohosh, soy, St. John’s wort, and evening primrose were considered not effective.  
Saw palmetto and kava kava were excluded from this analysis because they received 















Perceived Efficacy of Individual HDS
Not Effective Somewhat Effective Very Effective
 
Figure 7.  Perceived efficacy of individual HDS.  
This chart shows the relative percentage of respondents that reported each supplement as “not 
effective,” “somewhat effective,” and “very effective.”  Saw palmetto and Kava kava were excluded 
due to low reported use.  “Don’t know” responses were also excluded.  
 
4.1.6 Sources of Information 
Survey participants were asked to rate how often they consulted various 
sources of information, and were provided with the following choices: websites found 
through search engines, government websites, companies, non-profit organizations, 
cancer related health organizations, popular magazines and newspapers, academic 
journals, friends, family, health care providers, and complementary and alternative 
medicine practitioners.  Survey participants could indicate that they consulted the 
source never, rarely, sometimes, often, or indicate that they were unsure or did not 




Most (n=986) respondents reported having sought information on herbal 
dietary supplements.  Subjects were also more likely to consult some sources of 
information more than others.  A chi-square goodness of fit test determined that 
subjects were more likely to consult websites found through search engines, non-
profit organizations and support groups, and health care practitioners.  They were less 













Frequency of Consultation of Sources
Never Rarely Sometimes Often
 
Figure 8.  Frequency of use of HDS sources of information.  
The frequency that each source of information was consulted by survey participants.  Websites 
includes any websites found through databases and search engines, such as Yahoo and Google.  
GovtWeb includes only government sponsored websites, such as the NIH website.  Companies 
includes any information obtained from for profit companies, such as GNC.  NonProfit includes any 
information from non-profit organizations, such as Susan G. Komen.  CRHOs includes information 
obtained from cancer related health organizations, such as the American Cancer Society.  MagsNews 
includes popular magazines or newspapers, such as Time or the Washington Post.  Journals includes 
academic journals, such as The Journal of the American Medical Association. HCP includes any 
regular health care provider, such as nurses, oncologists, and general physicians.  Practitioner includes 






4.1.7 Reliability of Information Sources 
Subjects were also asked to rate how reliable or trustworthy they consider 
each of the aforementioned sources of information regarding HDS.  Here, the 
response choices were “not reliable,” “somewhat reliable,” and “very reliable,” along 
with “I don’t know what this is” and “don’t know/not sure” options.  In general, 
survey participants felt that their sources of information about HDS were either 
somewhat or very reliable.  A chi-square goodness of fit test indicated that cancer-
related health organizations, health care practitioners, academic journals, non-profit 
organizations, government websites, and HDS practitioners were considered more 
reliable than for-profit companies, family, friends, or magazines/newspapers.  The 
most frequently used source of information—websites found through search 
engines—was generally viewed favorably, as 708 respondents indicated this source 
was “somewhat reliable,” 120 indicated “very reliable,” and 95 reported “not 















Perceived Reliability of Sources
Not Reliable Somewhat Reliable Very Reliable
 
Figure 9.  Perceived reliability of HDS sources of information. 
The perceived reliability of each source of information that was consulted by survey participants.  
Websites includes any websites found through databases and search engines, such as Yahoo and 
Google.  GovtWeb includes only government sponsored websites, such as the NIH website.  
Companies includes any information obtained from for profit companies, such as GNC.  NonProfit 
includes any information from non-profit organizations, such as Susan G. Komen.  CRHOs includes 
information obtained from cancer related health organizations, such as the American Cancer Society.  
MagsNews includes popular magazines or newspapers, such as Time or the Washington Post.  Journals 
includes academic journals, such as The Journal of the American Medical Association. HCP includes 
any regular health care provider, such as nurses, oncologists, and general physicians.  Practitioner 
includes only practitioners that specialize in CAM.  Don’t know and unsure answers are not included 
in the chart.   
 
4.1.8 Decision Influences 
In order to determine correlations between sources of information used and 
the decision to use or not use HDS, a multi-way ANOVA test was used.  Respondents 
who answered I don’t know or unsure for at least one information source were 
excluded from this analysis.  We found that journals (p=0.0369), websites found 




practitioners (p<0.0001) were correlated with the number of HDS used.  Journals, 
websites, and CAM practitioners were associated with increased HDS use while 
government websites was associated with decreased HDS use. 
A further analysis using chi-square tests of assocation was performed to 
determine whether correlations existed between sources of information and the use of 
specific HDS.  With respect to black cohosh, people who consulted health care 
providers or CAM practitioners were more likely to use black cohosh than people 
who did not consult health care providers or CAM practitioners (p=0.0405 and 
p=0.0493 respectively). 
Table 8 shows the correspondence of sources of information with specific 
HDS use.  For each of the following sources of information, increased or decreased 
use of the HDS listed was correlated with the source.  It is interesting to note that 
milk thistle and curcumin, which were both considered “very effective” in terms of 
efficacy, followed the same use pattern.  Also, academic journals and CAM 
practitioners were associated with increased use of several supplements.  Only 
government websites, cancer related health organizations, healthcare providers, and 





Table 8.  Perceived reliability of HDS sources of information. 
Source Consulted More Likely to Usea Less Likely to Usea 
Websites     
Red Clover (p=0.0287) 
Kava Kava (p=0.0305) Government Websites Ginger (p=0.0214) 
Saw Palmetto (p=0.0057) 
For-profit Companies Ginseng (0.0009)   
Non-profit Organizations Green Tea (p=0.0033)   
Red Clover (p=0.0180) Cancer Related Health 
Organizations   Valerian (p=0.0052) 
Magazines and Newspapers Flaxseed (p=0.0278)   
Red clover (p=0.0348) 
Curcumin (p=0.0003) 
Flaxseed (p=0.0236) 




Green Tea (p=0.0140) 
  
Friends Soy (p=0.0119)   
Family Ginseng (p=0.0138) Red Clover (p=0.0269) 
Curcumin (p=0.0034) 
Healthcare Providers Chamomile (p=0.0282) 
Milk Thistle (p=0.0041) 




Milk Thistle (p<0.0001) 
Ginger (p=0.0008) 
Evening Primrose (p<0.0001) 
Ginseng (p<0.0001) 
Kava Kava (p=0.0005) 




aFor each of the information sources listed, use of the source was correlated with increased (“more 
likely to use”) or decreased (“less likely to use”) use of the HDS. 
 
Survey participants were asked to rate the amount of influence that their 
family, friends, physician, and religion had on their decision to use an herbal dietary 




but physicians received the greatest number of responses (n=334) as being very 












Family Friends Physician Religion
Influences on Decision to Use HDS
Not Influential Somewhat Influential Very Influential
 
Figure 10.  Influence of various factors on decision to use or not use HDS.  
The extent to which survey participants felt that family, friends, physicians, and religion influenced 
their decision to use or not use HDS. Responses of Don’t Know/Unsure are not included. 
 
4.1.9 Safety Issues: Labeling and Testing 
Survey respondents were generally concerned about the issue of proper 
labeling and safety testing of herbal dietary supplements.  Close to half reported being 
“very concerned” and half reported being “somewhat concerned” about each of these 
issues.  Only a small percentage of respondents reported not being concerned about 















Safety Testing Proper Labeling
Concern Regarding HDS
Very Concerned Somewhat Concerned Not Concerned
 
Figure 11.  Concern regarding safety and labeling of HDS.  
Participants were asked to rank their level of concern regarding adequate safety testing of HDS and 
proper  labeling of HDS.  Proper labeling includes insuring that the label indicates the correct 





4.2 Effects of SERMs and Actein on Breast Cancer Cells  
4.2.1 Individual Effects of Actein and SERMs on MCF-7 Cell Proliferation 
Tamoxifen and raloxifene are both selective estrogen receptor modulators 
(SERMs) commonly prescribed to reduce the risk of developing breast cancer, to help 
treat existing breast cancer, and to help reduce the risk of breast cancer recurrence.  
Although the effects of tamoxifen and raloxifene on breast cancer cell proliferation 
are established, we measured the proliferation of MCF-7 human breast cancer cells 
treated with tamoxifen or raloxifene alone to establish a baseline for our combination 
studies (Coezy, Borgna, & Rochefort, 1982; Levenson, et al., 2002).  Tamoxifen 
significantly inhibited MCF-7 cell proliferation at 5.0 µM, and raloxifene 
significantly inhibited MCF-7 cell proliferation at 0.1 µM (Figure 12).   
Actein significantly inhibited MCF-7 cell proliferation at a concentration of 
5.0 µM (3.3 µg/mL).  According to the NCI’s Developmental Therapeutics Program 
database, the half maximal inhibitory concentrations (IC50) for tamoxifen and 
raloxifene in MCF-7 cells are 1.6 µM and 0.1 µM, respectively (Collins).  These 
values were smaller than the concentrations we observed, which were between 5 and 
10 µM for raloxifene, about 10 µM for tamoxifen, and slightly above 10 µM for 
actein.  The difference is likely due to differences in culture conditions or length and 





Figure 12.  Actein, tamoxifen, and raloxifene inhibit MCF-7 cell proliferation.   
Actein and tamoxifen significantly inhibit the proliferation of MCF-7 cells at 5.0 µM; raloxifene 
significantly inhibits proliferation at 0.1 µM.  Cells were maintained in medium with FBS and treated 
for 72 hours with actein, tamoxifen, or raloxifene in medium at the indicated concentrations.  Relative 
number of viable cells, shown as mean ± SEM and normalized by DMSO control, was determined by 
SRB assay.   
 
4.2.2 Individual Effects of Actein and SERMs on Estrogen-Induced  MCF-7 Cell 
Proliferation 
Actein significantly inhibited estradiol-induced cell proliferation at 10.0 µM 
and thus may have an anti-estrogenic effect (Figure 13).  Before this experiment, 
MCF-7 cells were maintained in phenol red-free media with CSS to remove 
exogenous estrogens.  Additionally, unlike cells cultured in media with FBS, actein 
alone did not significantly inhibit proliferation of cells cultured with phenol red-free 
media with CSS.  Cells were also treated with tamoxifen or raloxifene with and 
without estradiol to observe their anti-estrogenic effects.  Tamoxifen inhibited 




13).  For tamoxifen and raloxifene, the observed IC50 was between 1 and 10 µM.  For 
actein, the observed IC50 was greater than 10 µM. 
 
Figure 13.  Actein, tamoxifen, and raloxifene inhibit estradiol-induced proliferation of MCF-7 
cells. 
Actein and tamoxifen significantly inhibit estradiol-induced proliferation of MCF-7 cells at 10.0 µM; 
raloxifene significantly inhibits estradiol-induced proliferation at 1.0 µM.  Cells were maintained in 
medium with CSS and treated for 72 hours with actein, tamoxifen, or raloxifene at the indicated 
concentrations and 1.0 nM E2 in medium.  Relative number of viable cells, shown as mean ± SEM and 
normalized by the DMSO control, was determined by SRB assay.  
 
4.2.5 Combined Effect of SERMs and Actein on MCF-7 Cell Proliferation 
Since most breast cancer survivors who use HDS use them in addition to their 
prescribed drug regimen, we were interested in how treating cells with a combination 
of actein and the commonly prescribed SERM drugs tamoxifen and raloxifene would 
affect cell proliferation.  Using the combination index method of Chou and Talalay, 
Einbond’s group had determined that combinations of the anthracycline doxorubicin 




actein (0.3 µM, 1.5 µM, or 3 µM, respectively) exhibited synergistic inhibition of 
MDA-MB-453 breast cancer cell proliferation (Chou & Talalay, 1984).   
We were particularly interested in whether a synergistic effect would be 
observed in combination with SERMs, as they act by binding to estrogen receptors in 
breast cells in a way that prevents the stimulation of the cell proliferation pathway by 
estrogen in some tissues.  Although black cohosh extracts and the isolated triterpene 
glycosides have been shown to not interact with estrogen receptors, their  
(anti-)estrogenic properties are still unclear (Burdette, et al., 2003; Jiang, et al., 2008; 
Liu, et al., 2001; Mahady, 2003).  
Having confirmed the growth inhibitory and anti-estrogenic effects of actein, 
tamoxifen, and raloxifene alone, we began our study of the combined effects of actein 
and each of the SERMs.  For these experiments, we used concentrations of the 
SERMs near their IC50 as reported by NCI’s Developmental Therapeutics Program 
database.  This concentration was also close to the lowest concentration at which 
significant inhibition was observed in our experiments. Initially, cells were treated for 
72 hours as in the previous cell proliferation experiments.  No significant differences 
were observed between the SERMs alone with estradiol and the combination of the 
SERMs and actein with estradiol.  Thus, treatments were extended to 120 hours and a 





Figure 14.  Actein does not interact with tamoxifen or raloxifene in inhibition of MCF-7 cell 
proliferation. 
Actein does not significantly affect the inhibition of MCF-7 cell proliferation by tamoxifen or 
raloxifene.  Cells were maintained in medium with CSS and treated for 120 hours with actein at the 
indicated concentrations, 1.0 µM tamoxifen or 0.1 µM raloxifene, and 1.0 nM E2 in medium.  Relative 
number of viable cells, shown as mean ± SEM, was determined by SRB assay.   
 
No synergistic growth inhibitory effect was observed when cells were treated 
with a combination of a SERM and actein in the presence or absence of estradiol 
(Figure 14-15).  Since synergism was not indicated, we did not perform follow-up 
experiments with a complete range of concentrations of both the drugs and actein in 
order to determine the combination index for each drug and actein.  Additionally, in 
contradiction to our previous results, actein significantly stimulated cell proliferation 
in both 120 hours experiments, suggesting that the length of the treatment affected 
whether a proliferative (and antagonistic, when combined with the SERMs) or anti-





Figure 15.  Actein does not interact with tamoxifen or raloxifene in inhibition of estradiol-
induced proliferation of MCF-7 cells. 
Actein does not significantly affect the inhibition of MCF-7 cell proliferation by tamoxifen or 
raloxifene.  Cells were maintained in medium with CSS and treated for 120 hours with actein at the 
indicated concentrations, 1.0 µM tamoxifen or 0.1 µM raloxifene, and 1.0 nM E2 in medium.  Relative 
number of viable cells, shown as mean ± SEM, was determined by SRB assay.   
 
4.2.6 Effect of Actein on Gene Expression in MCF-7 Cells 
Cell proliferation experiments provide only rudimentary information about the 
physiological effects of a compound.  In order to gain insight into the mechanism of 
action of actein, we used RT-PCR to measure the expression of four genes of interest 
in MCF-7 cells treated with a range of 0-25 µM actein with and without 1 nM 
estradiol.  First, we quantified CDKN1A expression (Figure 16).  CDKN1A encodes 
cyclin-dependent kinase inhibitor 1A (p21, Cip1), a protein that arrests the cell cycle 
by inhibiting the activity of cyclin-dependent kinase 2 or 4 complexes.  CDKN1A is 
typically induced in response to stress stimuli such as DNA damage (Bokoch, 2003).  




actein in both the presence and absence of estradiol, at a 1.9 and 2.2-fold change 
relative to the housekeeping gene GAPDH, respectively. 
 
Figure 16.  Actein induces CDKN1A expression at high concentration. 
CDKN1A, which encodes a protein that arrests the cell cycle in response to DNA damage, is 
significantly induced in MCF-7 cells by treatment with 25 µM actein. Cells were maintained in 
medium with CSS and treated for 48 hours with actein at the indicated concentrations and 1.0 nM E2 in 
medium, RNA was isolated, cDNA was synthesized, and relative level of CDKN1A transcription, 
shown as mean ± SEM, was determined by RT-PCR with appropriate primer and probe.   
 
 To further investigate the controversial (anti-)estrogenic effects of actein, the 
expression of TFF1, an oncogenic gene that is classically induced by estradiol, was 
measured (Perry, Kannan, Grandison, Mitchell, & Lobie, 2008).  As expected, TFF1 
was induced (4.8-fold) in the presence of estradiol.  Actein was able to block the 
induction of TFF1 by estradiol with an IC50 between 1 and 10 µM, confirming the 
anti-estrogenic effect observed in the cell proliferation studies (Figure 17).  This is the 
first report of actein’s anti-estrogenic effect at the level of transcription.  Actein alone 





Figure 17.  Actein inhibits the induction of TFF1 by estradiol.  
The induction of TFF1, a classically estradiol-induced gene, by estradiol treatment, is significantly 
repressed by treatment with 10 µM actein. Cells were maintained in medium with CSS and treated for 
48 hours with actein at the indicated concentrations and 1.0 nM E2 in medium, RNA was isolated, 
cDNA was synthesized, and relative level of TFF1 transcription, shown as mean ± SEM, was 
determined by RT-PCR with appropriate primer and probe. 
 
Because breast cancer survivors frequently combine dietary herbal 
supplements with their drug regimen, we were interested in how actein affects the 
expression of xenobiotic metabolizing enzymes.  These enzymes metabolize foreign 
chemicals that are not normally produced or found in the organism.  CYP1A1 encodes 
one such enzyme, a cytochrome P450 isozyme also known as aryl hydrocarbon 
hydroxylase, that oxidizes drugs and other foreign compounds.  Gaube reported an 
induction of CYP1A1 of about 20-fold in MCF-7 cells treated with 15 µg/mL black 
cohosh extract, and a slight induction in cells treated with 20 µM actein (Gaube, et 
al., 2007).  We suspected that culture conditions would greatly influence the 
expression of CYP1A1, so we conducted the experiment with two different types of 




CDS.  Actein significantly induced CYP1A1 under both culture conditions at 1.0 µM, 
but to a much greater extent in FBS-supplemented media than in CDS-supplemented 
media (Figure 18).  Interestingly, the combination of actein treatment with estradiol 
blocked the induction of CYP1A1 by actein.  In the presence of estradiol, CYP1A1 
was only significantly induced by the highest concentration actein treatment. 
 
Figure 18.  Actein induces CYP1A1 expression 
CYP1A1, which encodes a protein that is involved in the oxidation of xenobiotics, steroids, and lipids, 
is significantly induced in MCF-7 cells by treatment with 1.0 µM actein -E2 and with 25 µM actein 
+E2.  Cells were maintained in medium with A (CSS) or B (FBS) and treated for 48 hours with actein 
at the indicated concentrations and 1.0 nM E2 in medium, RNA was isolated, cDNA was synthesized, 
and relative level of CYP1A1 transcription, shown as mean ± SEM, was determined by RT-PCR with 
appropriate primer and probe.   
 
Gaube measured 4-fold induction of VEGFA when MCF-7 cells were treated 
with 15 µg/mL black cohosh extract and slightly less induction when they were 
treated with 20 µM actein (Gaube, et al., 2007).  VEGFA encodes a vascular 
endothelial growth factor, which promotes angiogenesis, vasculogenesis, and 
endothelial cell growth, processes that are essential to tumor development.  VEGFA 




find it to be estradiol-sensitive in the MCF-7 cells (Mueller, et al., 2000).  VEGFA 
was significantly induced in both culture media at the highest concentration actein 
treatment and the level of induction was similar in the presence and absence of 
estradiol (Figure 19). 
 
Figure 19.  Actein induces VEGFA expression. 
VEGFA, which encodes a protein that promotes angiogenesis, vasculogenesis and endothelial cell 
growth, is significantly induced in MCF-7 cells by treatment with 25 µM actein. Cells were maintained 
in medium with A (CSS) or B (FBS) and treated for 48 hours with actein at the indicated 
concentrations and 1.0 nM E2 in medium, RNA was isolated, cDNA was synthesized, and relative level 
of VEGFA transcription, shown as mean ± SEM, was determined by RT-PCR with appropriate primer 
and probe.   
 
4.3 Hepatotoxicity of SERMs and Actein on Liver Cells 
4.3.1 Hepatotoxicity of Actein Alone, Tamoxifen Alone, and Raloxifene Alone on 
Liver Cells  
In general, actein was not found to be toxic to the HepG2/C3A liver cells, and 




only at relatively high concentrations.  The individual results for the various endpoint 
assays used to test for different modes of hepatotoxicity are summarized in Table 9. 
Table 9.  Individual effects of actein, tamoxifen, and raloxifene on hepatotoxicity indicators.  
Hepatotoxicity 
Indicator Actein Tamoxifen Raloxifene 
Cell Viability 0 ++ ++ 
Reactive Oxygen 
Species 0 ++ ++ 
CYP1A1 Activity ++ ++ ++ 
Neutral Lipid Content 0 ++ ++ 
Phospholipid Content 0 0 +/++ 




0 0 ++ 
Albumin 0 ++ + 
0 indicates no change compared to control at any concentrations tests, + indicates an effect compared 
to control at moderate concentrations, and ++ indicates an effect compared to control at high 
concentrations, as determined by Fisher LSD tests in SAS 9.1. 
 
4.3.1.1 Effect of Actein on Oxidative Stress  
We found a significant decrease in the amount of oxidative stress between the 
control group and the HepG2/C3A liver cells treated with 0.76 µM actein as shown in 
Figure 20.  This was somewhat expected as one study showed that black cohosh 
extracts were able to scavenge ROS to protect cells from DNA damage in S80 breast 
cancer cells treated with quinines (Burdette, et al., 2002).  However, our results are 
not pharmacologically relevant as there was only a slight decrease at 0.76 M that did 





Figure 20.  Actein decreases the amount of ROS at 0.76 µM. 
Actein significantly decreases the amount of ROS in HepG2/C3A liver cells at 0.76 µM.  Confluent 
cells were treated with 0, 0.76, 1.55, 3.1, 6.25, 12.5, 25, 50, and 100 µM actein for 48 hours, and ROS 
was measured with the DCFDA assay. Data were normalized as a percentage of the mean value of the 
0 µM control, and expressed as mean ± SEM; *p<0.05 Fisher LSD Test. 
 
4.3.1.2 Effect of Actein on CYP1A1 Activity 
We found that actein caused a significant increase in the amount CYP1A1 
activity compared to the control groups when the HepG2/C3A liver cells were treated 
with 6.25 and 100 µM, but a significant decrease at 0.76 µM, as shown in Figure 21.  
The increases in CYP1A1 activity were not entirely expected, as the literature 
generally indicates that black cohosh extracts inhibits CYP450 activity (Tsukamoto, 





Figure 21.  Actein increased CYP1A1 activity. 
Levels of CYP1A1 activity changed at varying concentrations of actein in HepG2/C3A liver cells.  
Confluent cells were treated with 0, 0.76, 1.55, 3.1, 6.25, 12.5, 25, 50, and 100 µM actein for 48 hours, 
and CYP1A1 activity was measured with the EROD assay. Data were normalized as a percentage of 
the mean value of the 0 µM control, and expressed as mean ± SEM; *p<0.05, ***p<0.001 Fisher LSD 
Test. 
 
4.3.1.3 Effect of Actein on Neutral Lipid and Phospholipid Retention 
There were no significant differences in the amount of neutral lipid or 
phospholipid accumulation between the control groups and the HepG2/C3A liver 
cells treated with any of the concentrations of actein, as shown in Figure 22 and 
Figure 23, respectively.  This contradicted the results reported in Lude, et al., of 
observed steatosis in the livers of rats treated with black cohosh extract (Lude, et al., 
2007).  However, this contradiction may suggest that compounds other than actein in 






Figure 22.  Actein does not affect intracellular neutral lipid accumulation.  
Confluent HepG2/C3A liver cells were treated with 0, 0.76, 1.55, 3.1, 6.25, 12.5, 25, 50, and 100 µM 
actein for 48 hours, and lipid accumulation was measured with the Nile Red assay.  Data were 
normalized as a percentage of the mean value of the 0 µM control, and expressed as mean ± SEM. 
 
 
Figure 23.  Actein does not affect membrane phospholipid accumulation. 
Confluent HepG2/C3A liver cells were treated with 0, 0.76, 1.55, 3.1, 6.25, 12.5, 25, 50, and 100 µM 
actein for 48 hours, and lipid accumulation was measured with the Nile Red assay.  Data were 





4.3.1.4 Effect of Actein on Mitochondrial Membrane Depolarization and 
p-Glycoprotein Activity 
We found no significant differences in the extent to which mitochondrial 
membrane depolarization occurred between the control group and the HepG2/C3A 
cells treated with different concentrations of actein, and actein was not shown to 
affect p-glycoprotein activity, as shown in Figure 24.  Our results did not confirm the 
results found by Lude’s group that black cohosh decreases the mitochondrial 
membrane potential, but our results for p-glycoprotein activity agreed with the results 
of Gurley, et al. (2007; 2006).   
 
Figure 24.  Actein does not affect mitochondrial membrane potential or p-glycoprotein 
activity. 
Actein does not affect the mitochondrial membrane potential or p-glycoprotein activity in HepG2/C3A 
cells.  Mitochondrial membrane potential and p-glycoprotein activity at 0, 0.76, 1.55, 3.1, 6.25, 12.5, 
25, 50, and 100 µM actein were measured with the R123 assay.  Data were normalized as a percentage 
of the mean value of the 0 µM control, and expressed as mean ± SEM. 
4.3.1.5 Effect of Actein on Cell Viability 




between the control groups and the HepG2/C3A liver cells treated with actein at any 
of the concentrations tested, as shown in Figure 25.    
 
Figure 25.  Actein does not affect cell viability. 
Actein does not affect HepG2/C3A cell viability. Confluent cells were treated with 0, 0.76, 1.55, 3.1, 
6.25, 12.5, 25, 50, and 100 µM actein for 48 hours, and cell viability was measured with the DNA 
assay.   Data were normalized as a percentage of the mean value of the 0 µM control, and expressed as 
mean ± SEM. 
 
4.3.1.6 Effect of Actein on Albumin Production 
The albumin assay on the HepG2/C3A liver cells treated with varying 
concentrations of actein displayed a decrease in albumin levels starting at 25 µM.  
However, there were no statistically significant differences in albumin production at 
any of the concentrations of actein tested, as shown in Figure 26.  The lack of a 





Figure 26.  Actein does not affect albumin production.  
Actein does not affect albumin production by HepG2/C3A cells.  Confluent cells were treated with 0, 
0.76, 1.55, 3.1, 6.25, 12.5, 25, 50, and 100 µM actein for 48 hours, and 50 uL of media were taken 
from each well to use in the albumin ELISA.  Data were normalized as a percentage of the mean value 
of the 0 µM control, and expressed as mean ± SEM. 
 
4.3.2 Hepatotoxicity of Tamoxifen  
4.3.2.1 Effect of Tamoxifen on Oxidative Stress 
When determining the toxic concentrations of tamoxifen on the HepG2/C3A 
liver cells used, we found a significant increase in the amount of oxidative stress 
between the control group and the HepG2/C3A liver cells treated with 12.5 and 100 





Figure 27.  Tamoxifen increases the amount of ROS. 
Reactive oxygen species increase in HepG2/C3A cells treated with 12.5 and 100 µM tamoxifen.  
Confluent cells were treated with 0, 0.76, 1.55, 3.1, 6.25, 12.5, 25, 50, and 100 µM tamoxifen for 48 
hours, and ROS was measured with the DCFDA assay. Data were normalized as a percentage of the 
mean value of the 0 µM control, and expressed as mean ± SEM; ***p<0.001 Fisher LSD Test. 
 
4.3.2.2 Effect of Tamoxifen on CYP1A1 Activity 
We found that tamoxifen caused significant increases in the amount of 
CYP1A1 activity compared to the control groups in HepG2/C3A cells starting at 50 





Figure 28.  Tamoxifen increases CYP1A1 activity. 
Levels of CYP1A1 activity increased at high concentrations of tamoxifen in HepG2/C3A liver cells.  
Confluent cells were treated with 0, 0.76, 1.55, 3.1, 6.25, 12.5, 25, 50, and 100 µM tamoxifen for 48 
hours, and CYP1A1 activity was measured with the EROD assay. Data were normalized as a 
percentage of the mean value of the 0 µM control, and expressed as mean ± SEM; *p<0.05, **p<0.01 
Fisher LSD Test. 
 
4.3.2.3 Effect of Tamoxifen on Neutral Lipid and Phospholipid 
Retention 
There was a significant increase in the amount of neutral lipid accumulation in 
the membranes of HepG2/C3A cells when treated with 50 and 100 µM tamoxifen, as 
shown in Figure 29.  We found no significant differences in the amount of 
phospholipids retained in the cell membrane between the control group and any of the 





Figure 29.  Tamoxifen increases intracellular neutral lipid acculumation. 
Tamoxifen significantly increases neutral lipid accumulation in HepG2/C3A cells starting at 50 µM.   
Confluent cells were treated with 0, 0.76, 1.55, 3.1, 6.25, 12.5, 25, 50, and 100 µM tamoxifen for 48 
hours, and lipid accumulation was measured with the Nile Red assay.  Data were normalized as a 
percentage of the mean value of the 0 µM control, and expressed as mean ± SEM; *p<0.05, 
***p<0.001 Fisher LSD Test. 
 
4.3.2.4 Effect of Tamoxifen on Mitochondrial Membrane 
Depolarization and p-Glycoprotein Activity 
The significant increase in R123 retention in the HepG2/C3A cells at 0.76 and 
1.55 µM tamoxifen indicated that p-glycoprotein activity was inhibited at these low 
concentrations, as shown in Figure 30.  Mitochondrial membrane depolarization was 





Figure 30.  Tamoxifen decreases p-glycoprotein activity at low concentrations. 
Tamoxifen decreases p-glycoprotein activity at 0.76 and 1.55 µM in HepG2/C3A cells.  Mitochondrial 
membrane potential and p-glycoprotein activity at 0, 0.76, 1.55, 3.1, 6.25, 12.5, 25, 50, and 100 µM 
tamoxifen were measured with the R123 assay.  Data were normalized as a percentage of the mean 
value of the 0 µM control, and expressed as mean ± SEM; ***p<0.001 Fisher LSD Test. 
 
4.3.2.5 Effect of Tamoxifen on Cell Viability 
A significant decrease in the number of cells with double-stranded DNA was 
seen when HepG2/C3A cells were treated with 100 µM tamoxifen, as shown in 
Figure 31.  Fortunately, 100 µM tamoxifen is beyond the concentration of tamoxifen 
that would normally be in the body, so this is not a problem for patients using 





Figure 31.  100 µM Tamoxifen decreases cell viability. 
Tamoxifen decreases HepG2/C3A cell viability at 100 µM. Confluent cells were treated with 0, 0.76, 
1.55, 3.1, 6.25, 12.5, 25, 50, and 100 µM tamoxifen for 48 hours, and cell viability was measured with 
the DNA assay.  Data were normalized as a percentage of the mean value of the 0 µM control, and 
expressed as mean ± SEM; ***p<0.001 Fisher LSD Test. 
 
4.3.2.6 Effect of Tamoxifen on Albumin Production 
We additionally found a significant decrease in the amount of albumin 





Figure 32.  100 µM Tamoxifen decreases albumin production.  
Tamoxifen decreases albumin production by HepG2/C3A cells.  Confluent cells were treated with 0, 
0.76, 1.55, 3.1, 6.25, 12.5, 25, 50, and 100 µM tamoxifen for 48 hours, and 50 uL of media were taken 
from the inner 60 wells of 96-well plates to use in the albumin ELISA.  Data were normalized as a 
percentage of the mean value of the 0 µM control, and expressed as mean ± SEM; **p<0.01 Fisher 
LSD Test.  
 
4.3.3 Hepatotoxicity of Raloxifene  
4.3.3.1 Effect of Raloxifene on Oxidative Stress 
We found a significant decrease in the amount of reactive oxygen species 
present when the HepG2/C3A liver cells were treated with 6.25, 25 and 50 µM 





Figure 33.  Raloxifene decreases the amount of ROS. 
ROS decrease in HepG2/C3A cells treated with 6.25, 50 and 100 µM raloxifene.  Confluent cells were 
treated with 0, 0.76, 1.55, 3.1, 6.25, 12.5, 25, 50, and 100 µM raloxifene for 48 hours, and ROS was 
measured with the DCFDA assay. Data were normalized as a percentage of the mean value of the 0 
µM control, and expressed as mean ± SEM; *p<0.05, **p<0.01 Fisher LSD Test. 
 
4.3.3.2 Effect of Raloxifene on CYP1A1 Activity 
We found that raloxifene caused a significant increase in the amount CYP1A1 
activity compared to the control groups when the HepG2/C3A liver cells were treated 





Figure 34.  Raloxifene increases CYP1A1 activity. 
Levels of CYP1A1 activity increased at several concentrations of raloxifene in HepG2/C3A liver cells.  
Confluent cells were treated with 0, 0.76, 1.55, 3.1, 6.25, 12.5, 25, 50, and 100 µM raloxifene for 48 
hours, and CYP1A1 activity was measured with the EROD assay. Data were normalized as a 
percentage of the mean value of the 0 µM control, and expressed as mean ± SEM; **p<0.01, 
***p<0.001 Fisher LSD Test. 
 
4.3.3.3 Effect of Raloxifene on Neutral Lipid and Phospholipid 
Retention 
There were significant increases in neutral lipid accumulation between the 
control group and the HepG2/C3A cells starting at 25 µM raloxifene, as shown in 
Figure 35.  The trend for phospholipid retention by HepG2/C3A cells treated with 
varying concentrations of raloxifene was less clear.  We found significant increases in 
the amount of phospholipids retained in the cell membrane at 1.55, 3.1, 12.50, 25.00, 





Figure 25.  Raloxifene increases intracellular neutral lipid accumulation. 
Raloxifene significantly increases neutral lipid accumulation in HepG2/C3A cells starting at 25 µM.   
Confluent cells were treated with 0, 0.76, 1.55, 3.1, 6.25, 12.5, 25, 50, and 100 µM raloxifene for 48 
hours, and lipid accumulation was measured with the Nile Red assay.  Data were normalized as a 
percentage of the mean value of the 0 µM control, and expressed as mean ± SEM; *p<0.05, 
***p<0.001 Fisher LSD Test. 
 
 
Figure 36.  Raloxifene increases membrane phospholipid accumulation. 
Raloxifene increases phospholipid accumulation in HepG2/C3A cells at various concentrations ranging 
from 1.55 to 100 µM.   Confluent cells were treated with 0, 0.76, 1.55, 3.1, 6.25, 12.5, 25, 50, and 100 
µM raloxifene for 48 hours, and phospholipid accumulation was measured with the Nile Red assay.  
Data were normalized as a percentage of the mean value of the 0 µM control, and expressed as mean ± 




4.3.3.4 Effect of Raloxifene on Mitochondrial Membrane 
Depolarization and p-Glycoprotein Activity 
We found that less R123 was retained in HepG2/C3A cells treated with 100 
µM raloxifene compared to the control, as shown in Figure 37.  This indicates either 
that mitochondrial membrane depolarization and/or an increase in p-glycoprotein 
activity occurred at 100 µM, a high dose. 
 
Figure 37.  100 µM Raloxifene increases p-glycoprotein activity. 
Raloxifene increases p-glycoprotein activity at 100 µM in HepG2/C3A cells.  Mitochondrial 
membrane potential and p-glycoprotein activity at 0, 0.76, 1.55, 3.1, 6.25, 12.5, 25, 50, and 100 µM 
raloxifene were measured with the R123 assay.  Data were normalized as a percentage of the mean 
value of the 0 µM control, and expressed as mean ± SEM; ***p<0.001 Fisher LSD Test. 
 
4.3.3.5 Effect of Raloxifene on Cell Viability 
Significant decreases in the amount of double-stranded DNA in HepG2/C3A 
cells treated with raloxifene were seen at 50 and 100 µM raloxifene, as shown in 




µM, though the decrease in cell viability was not pharmacologically significant.  
 
Figure 38.  Raloxifene decreases cell viability. 
Raloxifene decreases HepG2/C3A cell viability starting at 50 µM.  Confluent cells were treated with 0, 
0.76, 1.55, 3.1, 6.25, 12.5, 25, 50, and 100 µM raloxifene for 48 hours, and cell viability was measured 
with the DNA assay.   Data were normalized as a percentage of the mean value of the 0 µM control, 
and expressed as mean ± SEM; **p<0.01, ***p<0.001 Fisher LSD Test. 
 
4.3.3.6 Effect of Raloxifene on Albumin Production 
The HepG2/C3A cells seemed to increase their albumin production when 





Figure 39.  Raloxifene increases albumin production. 
Raloxifene increases albumin production by HepG2/C3A cells at 1.55 and 3.1 µM.  Confluent cells 
were treated with 0, 0.76, 1.55, 3.1, 6.25, 12.5, 25, 50, and 100 µM raloxifene for 48 hours, and 50 µL 
of media were taken from the inner 60 wells of 96-well plates to use in the albumin ELISA.  Data were 
normalized as a percentage of the mean value of the 0 µM control, and expressed as mean ± SEM; 
*p<0.05 Fisher LSD Test.  
 
4.3.4 Interactions Between Actein and Tamoxifen 
After investigating the effects that actein, tamoxifen, and raloxifene alone had 
on the HepG2/C3A cells, we investigated the effects of actein with tamoxifen on 
these cells.  This was an important aspect of our study, because breast cancer patients 
who use or may consider using black cohosh to treat their cancer may also be taking a 
SERM like tamoxifen concurrently.  While actein alone generally did not exhibit 
toxic effects on the HepG2/C3A cells, we were interested in whether or not actein and 
tamoxifen would interact to magnify or even minimize some of the toxic effects seen 
in the HepG2/C3A cells treated with tamoxifen alone.  A two-way ANOVA in SAS 




with 30 µM actein plus increasing concentrations of tamoxifen and from confluent 
cells treated with 90 µM tamoxifen plus increasing concentrations of actein.  Table 5 
summarizes which modes of hepatotoxicity were affected by an interaction between 
actein and tamoxifen. 
Table 10.  Combination effects of actein and tamoxifen on hepatotoxicity indicators. 
Mode of 
Hepatotoxicity 
Interaction Type p-valueg Corresponding 
Figure 
Oxidative Stressa Absent N/A 0.2930 47 
CYP1A1 Activityb Present Indeterminable < 0.0001 40 
Neutral lipid 
Steatosisc 
Absent N/A 0.8319 48 
Phospholipid 
Steatosisc 




Absent N/A 0.5617 49 
p-Glycoprotein 
Activityd 
Absent N/A 0.5617 49 
Cell Viabilitye Present Synergistic <0.0001 42 
Albumin 
Productionf 
Indeterminableh N/A N/A 50 
ameasured with DCFDA assay, bmeasured with EROD assay, cmeasured with Nile Red assay, 
dmeasured with R123 assay, emeasured with DNA assay, fmeasured with ELISA.   
gp-values were obtained from two-way ANOVA run in SAS 9.1. 
halbumin ELISA was incomplete. 
 
4.3.4.1 Effect of Tamoxifen with Actein on Oxidative Stress   
When we tested for oxidative stress in HepG2/C3A cells treated with both 
actein and tamoxifen, we did not find any interaction effect between actein and 
tamoxifen after running a two-way ANOVA on the raw data.  Figure 47 in Appendix 
B demonstrates the absence of an interaction using data from the HepG2/C3A cells 
treated with tamoxifen alone and the HepG2/C3A cells treated with 30 µM actein 




4.3.4.2 Effect of Tamoxifen with Actein on CYP1A1 Activity 
The two-way ANOVA indicated that tamoxifen and actein interacted to affect 
CYP1A1 activity in HepG2/C3A cells.  The data from the HepG2/C3A cells treated 
with tamoxifen alone and from the HepG2/C3A cells treated with 30 µM actein plus 
varying concentrations of tamoxifen were used to depict this interaction, as shown in 
Figure 44.  Whether or not the interaction was synergistic or antagonistic could not be 
definitively concluded, as there was no clear shift in the dose-response curve (Figure 
40). 
























Tamoxifen Alone Tamoxifen + 30 _M Actein
 
Figure 40.  Actein and tamoxifen interact to affect CYP1A1 activity. 
Confluent HepG2/C3A cells were treated with the indicated concentrations of actein and tamoxifen for 
48 hours, and CYP1A1 activity was measured with the EROD assay.  Data were normalized as a 
percentage of the mean value of the 0 µM control, and expressed as mean ± SEM. 
 
4.3.4.3 Effect of Tamoxifen with Actein on Neutral Lipid and 
Phospholipid Retention 




both actein and tamoxifen, we did not find any interaction effects after running a two-
way ANOVA on the raw data.  Figure 48 in Appendix B demonstrates the absence of 
an interaction using data from the HepG2/C3A cells treated with tamoxifen alone and 
the HepG2/C3A cells treated with 30 µM actein plus varying concentrations of 
tamoxifen.  However, there did seem to be a synergistic effect between actein and 
tamoxifen on phospholipid accumulation in the HepG2/C3A cells starting at 30 µM 
actein and approximately 30 µM tamoxifen, as shown in Figure 41. 



































Tamoxifen Alone Tamoxifen + 30 _M Actein
 
Figure 41.  Actein and tamoxifen have a synergistic effect on membrane phospholipid 
accumulation at high concentration. 
Confluent HepG2/C3A cells were treated with the indicated concentrations of actein and tamoxifen for 
48 hours, and lipid accumulation was measured with the Nile Red assay.  Data were normalized as a 
percentage of the mean value of the 0 µM control, and expressed as mean ± SEM. 
 
4.3.4.4 Effect of Tamoxifen with Actein on Mitochondrial 
Membrane Depolarization and p-Glycoprotein Activity 
When we tested for R123 retention in HepG2/C3A cells treated with both 




tamoxifen after running a two-way ANOVA on the raw data, indicating that there 
were no combined effects of these two compounds on mitochondrial membrane 
depolarization or p-glycoprotein activity.  Figure 49 in Appendix B demonstrates the 
absence of an interaction using data from the HepG2/C3A cells treated with 
tamoxifen alone and the HepG2/C3A cells treated with 30 µM actein plus varying 
concentrations of tamoxifen.   
 
4.3.4.5 Effect of Tamoxifen with Actein on Cell Viability  
The two-way ANOVA indicated that tamoxifen and actein interacted to affect 
HepG2/C3A cell viability.  The data from the HepG2/C3A cells treated with 
tamoxifen alone and from the HepG2/C3A cells treated with 30 µM actein plus 
varying concentrations of tamoxifen were used to depict this interaction, as shown in 
Figure 42.  This interaction appeared to be synergistic as the dose-response curve for 
tamoxifen with 30 µM actein shifted to the left compared to the curve for tamoxifen 
with 0 µM actein (Figure 42).  These findings are particularly interesting because 

































Tamoxifen Alone Tamoxifen + 30 _M Actein
 
Figure 42.  Actein and tamoxifen have a synergistic effect on cell viability at high 
concentration. 
Confluent HepG2/C3A cells were treated with the indicated concentrations of actein and tamoxifen for 
48 hours, and cell viability was determined with the DNA assay.  Data were normalized as a 
percentage of the mean value of the 0 µM control, and expressed as mean ± SEM. 
 
4.3.4.6 Effect of Tamoxifen with Actein on Albumin Production 
This assay was not able to be completed as the plates containing sample media 
assay from the HepG2/C3A liver cells treated with 90 µM tamoxifen and increasing 
concentrations of actein were not well-labeled.  Thus, any interaction effects between 
actein and tamoxifen could not be determined by the two-way ANOVA in SAS 9.1.  
Figure 50 in Appendix B shows albumin production by HepG2/C3A cells treated with 
0 and 30 µM actein at increasing concentrations of tamoxifen based solely on data 





4.3.5 Interactions between Actein and Raloxifene 
After looking for potential interaction effects between actein and tamoxifen on 
the various indications of hepatotoxicity using the HepG2/C3A cells, we did the same 
for actein and raloxifene.  A two-way ANOVA in SAS 9.1 was run for each of the 
endpoint assays using data from confluent cells treated with 30 µM actein plus 
increasing concentrations of raloxifene and from confluent cells treated with 50 µM 
raloxifene plus increasing concentrations of actein.  Table 11 summarizes which 
modes of hepatotoxicity were affected by an interaction between actein and 
raloxifene. 
Table 11.  Combination effects of actein and raloxifene on hepatotoxicity indicators. 
Mode of 
Hepatotoxicity Interaction Type p-value
g Corresponding 
Figure 
Oxidative Stressa Absent N/A 0.2119 51 
CYP1A1 Activityb Absent N/A 0.1175 52 
Neutral lipid 
Steatosisc 
Absent N/A 0.0787 53 
Phospholipid 
Steatosisc 




Absent N/A 0.9153 54 
p-Glycoprotein 
Activityd 
Absent N/A 0.9153 54 
Cell Viabilitye Present Indeterminable 0.0483 44 
Albumin 
Productionf 
Absent N/A 0.1231 55 
ameasured with DCFDA assay, bmeasured with EROD assay, cmeasured with Nile Red assay, 
dmeasured with R123 assay, emeasured with DNA assay, fmeasured with ELISA.   
gp-values were obtained from two-way ANOVA run in SAS 9.1. 
 
4.3.5.1 Effect of Raloxifene with Actein on Oxidative Stress 
When we tested for oxidative stress in HepG2/C3A cells treated with both 
actein and raloxifene, we did not find any interaction effect after running a two-way 




interaction using data from the HepG2/C3A cells treated with raloxifene alone and 
the HepG2/C3A cells treated with 30 µM actein plus varying concentrations of 
raloxifene. 
 
4.3.5.2 Effect of Raloxifene with Actein on CYP1A1 Activity 
When we tested for CYP1A1 activity in HepG2/C3A cells treated with both 
actein and raloxifene, we did not find any interaction effect after running a two-way 
ANOVA on the raw data.  Figure 52 (Appendix B) demonstrates the absence of an 
interaction using data from the HepG2/C3A cells treated with raloxifene alone and 
the HepG2/C3A cells treated with 30 µM actein plus varying concentrations of 
raloxifene. 
 
4.3.5.3 Effect of Raloxifene with Actein on Neutral Lipid and 
Phospholipid Retention 
When we tested for neutral lipid steatosis in HepG2/C3A cells treated with 
both actein and raloxifene, we did not find any interaction effects after running a two-
way ANOVA on the raw data.  Figure 53 in Appendix B demonstrates the absence of 
an interaction using data from the HepG2/C3A cells treated with raloxifene alone and 
the HepG2/C3A cells treated with 30 µM actein plus varying concentrations of 
raloxifene.  However, there did seem to be an interaction between actein and 






































Raloxifene Alone Raloxifene + 30_M Actein
 
Figure 43.  Actein and raloxifene affect membrane phospholipids accumulation.  
Confluent HepG2/C3A cells were treated with the indicated concentrations of actein and raloxifene for 
48 hours, and phospholipid accumulation was measured with the Nile Red assay.  Data were 
normalized as a percentage of the mean value of the 0 µM control, and expressed as mean ± SEM. 
 
4.3.5.4 Effect of Raloxifene with Actein on Mitochondrial 
Membrane Depolarization and p-Glycoprotein Activity 
When we tested for R123 retention in HepG2/C3A cells treated with both 
actein and raloxifene, we did not find any interaction effects after running a two-way 
ANOVA on the raw data, indicating that there were no combined effects of these two 
compounds on mitochondrial membrane depolarization or p-glycoprotein activity.  
Figure 54 in Appendix B demonstrates the absence of an interaction using data from 
the HepG2/C3A cells treated with raloxifene alone and the HepG2/C3A cells treated 




4.3.5.5 Effect of Raloxifene with Actein on Cell Viability 
The two-way ANOVA indicated that raloxifene and actein interacted to affect 
HepG2/C3A cell viability.  The data from the HepG2/C3A cells treated with 
raloxifene alone and from the HepG2/C3A cells treated with 30 µM actein plus 
varying concentrations of raloxifene was used to depict this interaction, as shown in 
Figure 44.  However, as there was no clear dose-response shift, the type of interaction 
could not be determined. 
Amount of Double-Stranded DNA in HepG2/C3A Cells Treated with Varying 
















Raloxifene Alone Raloxifene + 30_M Actein
 
Figure 44.  Actein and raloxifene interact to affect cell viability. 
Confluent HepG2/C3A cells were treated with the indicated concentrations of actein and raloxifene for 
48 hours, and cell viability was determined with the DNA assay.  Data were normalized as a 
percentage of the mean value of the 0 µM control, and expressed as mean ± SEM. 
 
4.3.5.6 Effect of Raloxifene with Actein on Albumin Production 
When we tested for albumin production in HepG2/C3A cells treated with both 
actein and raloxifene, we did not find any interaction effect after running a two-way 




interaction using data from the HepG2/C3A cells treated with raloxifene alone and 






5.1 HDS Uses and Perceptions 
5.1.1 Patterns of HDS Use Among Breast Cancer Survivors 
5.1.1.1 Most Common Supplements Used Are Soy, Green Tea, 
Flaxseed, Ginger and Curcumin 
Among supplements used for non-medicinal purposes, soy was used the most, 
followed by green tea, chamomile, ginger, and flaxseed.  A reason that such 
supplements may be used so frequently is that they are found in many common 
household products such as food, drinks, and soaps.  
Among supplements used for medicinal purposes, the five most often used 
were flaxseed, green tea, ginger, curcumin, and evening primrose.  As shown in our 
literature review, empirical studies have suggested that flaxseed, green tea, and 
curcumin may have an inhibitory effect on cancer cell proliferation (Aggarwal & 
Shishodia, 2006).  Ginger and evening primrose, although not linked to inhibition of 
cancer cell growth, have been shown to affect digestion and PMS symptoms, 
respectively (Geller, et al., 2005; Srivastava & Gupta, 2007). 
 
5.1.1.2 Patients Consult Internet More Often Than Healthcare 
Practitioners 
Survey participants were asked to rate the sources of information about HDS 




about HDS were internet websites, followed by non-profit organizations, and finally 
healthcare practitioners.  Although physicians were consulted less often than websites 
and the literature from non-profit organizations, our results suggest that the survey 
participants were consulting their physicians at least sometimes.   
It is possible that physicians may not be a major source of information about 
HDS because of the recognized lack of communication between patients and 
physicians regarding HDS.  Physicians often advise patients to cease taking all HDS 
when beginning a regimen of conventional medicine in order to avoid possible side 
effects or dangerous interactions (Cassidy, 2003).  Our finding that many survey 
respondents prefer using websites rather than consulting healthcare providers for 
information about HDS is consistent with previous findings that indicated a level of 
discomfort among patients about discussing HDS with their physicians (ICR, 2007).  
It is also possible that our survey results may have been different if the 
question about sources of information had been stated differently.  Our study asked 
how often the subjects consulted sources of information.  It is possible that websites 
found through search engines were consulted most often simply because of their ease 
of access.  Therefore, these results may indicate that breast cancer survivors have 
greater access to the internet than to their health care providers, rather than an actual 
preference to consult one source more than the other. 
Survey participants were asked to rate the reliability of sources of information 
about HDS as “very reliable,” “somewhat reliable,” or “not reliable.”  Although many 
subjects reported consulting the internet, a large majority of respondents rated internet 




about HDS were healthcare practitioners, peer-reviewed journals, and non-profit 
organizations.  This would seem to indicate that although survey respondents were 
consulting internet sources more often, they recognized the limitations of some 
websites and realized that the content may not always be reputable.  This is also 
consistent with a previous report in the literature, which found that patients put more 
trust in professional opinion, even though they may consult other informational 
sources more frequently (Adams & Jewell, 2007). 
 
5.1.1.3 Family, Friends, Doctors, and Religion Not Influential in 
HDS Use 
Survey participants were asked to rate the influence of their religion and 
various people in their lives, including physicians, friends, and family members, on 
their decision either to use or not use HDS.  Survey respondents overwhelmingly 
rated all four categories as mostly being “not influential.”  The category receiving the 
most “very influential” responses was physicians.  Religion was almost never an 
influence on the decision to use HDS, with 990 respondents (95.6%) indicating that 
religion was “not influential” compared to only 13 respondents who reported it was 
“very influential.”  
Our survey results suggest that outside entities such as family, friends, 
doctors, and/or religion have relatively little influence on breast cancer survivors’ 
decisions to use HDS.  This result is interesting, since one of this study’s 
hypothesized reasons for taking HDS was the influence of one’s social network and 




supporting the hypothesis that the decision to use HDS is mainly influenced by 
cultural beliefs, contrary to a previous report (Adams & Jewell, 2007).  However, 
since our survey contained only one proxy (i.e., religion) for cultural beliefs, it is 
possible that other cultural beliefs not captured by our survey may have influenced 
the decision to use HDS.  
Also contrary to previous reports in the literature, our results did not indicate 
that friends and family were more influential than physicians in the decision to use 
HDS (ICR, 2007).  It may be difficult to compare our findings to those of other 
studies, however, since the participants in our study reported having an unusually 
high education level.  Nearly 40% of the sample subjects reported attaining a post-
graduate degree, which is a much higher educational level than that of the general 
U.S. population.  Moreover, the role of physicians in influencing their patients is 
unclear, as other authors have reported on the lack of communication between 
patients and doctors concerning HDS.  Therefore, we can hypothesize that physicians 
may be more influential in the decision to use HDS only when patients feel 
comfortable talking about HDS and if they believe such lines of communication are 
open to them (Kemper, et al., 2006; Roberts, et al., 2005; Wahner-Roedler, et al., 
2006). 
 
5.1.1.4 Demographic Limitations of Sample  
The main demographic captured by the survey was that of upper middle class, 
late middle-aged, highly educated Caucasian, Christian females.  All other 




possible to make meaningful comparisons.  Therefore we were not able to fully 
analyze our results for relationships based on gender, age, race, and income.  
Considering that the average survey respondent reported taking multiple HDS 
modalities, the results seem to agree with previous findings that educated women are 
more likely to use HDS than less educated people of either gender (Boon, et al., 
2000).  While we analyzed HDS use among three clusters of participants based on 
age, income, and education; the only meaningful inference we could make is that 
older, female breast cancer survivors may be more likely to use soy. 
The skewed demographic of our sample could have occurred because 
participants were self-selected and no attempt was made to recruit a random sample.  
It is possible that people with higher education and income levels would be more 
likely to seek information online about their health concerns or about a particular 
from which they are suffering.  In response to seeing the advertisement for our study, 
participants seeking information about breast cancer were able to click on a link to 
access the internet-based survey.  The types of people who choose to take internet-
based surveys could be representative of the participants in our study.  
We did not adjust our data or provide a weighted analysis to reflect the current 
national population of breast cancer survivors.  In the U.S., female breast cancer 
patients are comprised of 82.2% Caucasian women, 8.6% African American women, 
5.4% Hispanic/Latina women, 3.5% Asian American/Pacific Islander women, and 
0.3% American Indian/Alaska Native women (Smigal, Jemal, Ward, Cokkinides, 
Smith, Howe, and Thun, 2006).  A weighted analysis of the findings may be useful to 




5.1.1.5 Black Cohosh Was Used For Menopausal Symptoms 
The HDS black cohosh has been postulated to have anti-proliferative effects 
on cancer cells (Einbond, et al., 2004).  The lab portion of this study supported this 
claim, demonstrating an anti-proliferative effect of the active ingredient actein on 
breast cancer cells in vitro.  Since a purpose of the survey was to gather information 
about the use and perceptions of black cohosh among breast cancer patients, it was 
disappointing that the majority of respondents did not use black cohosh.  Of survey 
respondents, 232 reported using black cohosh for medicinal or other purposes while 
732 respondents did not use it at all.  Black cohosh was mainly used to treat hot 
flashes, PMS symptoms, and menopausal symptoms.  Most respondents who reported 
using black cohosh also reported that it was somewhat effective at treating their 
symptoms. 
As our primary research motive was to investigate how a HDS user’s 
perceptions about a particular supplement compared to the empirical knowledge 
available for that HDS, this information directly relates to a major purpose of our 
study.  There appear to be contradictions between the published reports existing in the 
literature, what our laboratory studies found, and what breast cancer survivors report 
using.  Thus, despite several recently published reports and our own study indicating 
that black cohosh extracts and certain bioactive compounds may have an anti-
proliferative effect, black cohosh was used to treat or prevent cancer by only 2 
respondents in our sample.  Instead, all the respondents who used black cohosh 




5.1.1.6 Hypothesis About Survivor HDS Use Confirmed 
The results from our survey analysis were consistent with existing literature 
and our hypotheses.  The majority of the women surveyed reported taking HDS, 
which was expected since female breast cancer patients are among the groups most 
likely to take HDS.  We found that breast cancer survivors answering our survey were 
most likely to take black cohosh to treat hot flashes and menopausal symptoms.  This 
and other female conditions have been the traditional use of black cohosh for 
centuries in American Indian medicine.  The most frequently used supplements in our 
study, curcumin and green tea, are also some of the most well-studied and widely 
reported supplements appearing in the scientific and popular literature.  
Survey respondents reported using websites as their most frequently consulted 
source of information regarding HDS.  This also agreed with our hypothesis, given 
published studies showing that patients are unlikely to go to their primary physician 
with questions related to HDS and CAM.  Important areas for future study, therefore, 
are to explore why patients are less likely to consult healthcare providers than other 
information sources, and to gain further insight about communication barriers that 






5.1.2 Perspectives on HDS 
5.1.2.1 Reported Reasons for Using HDS 
HDS are used to treat and alleviate a wide variety of symptoms and 
conditions.  The summary below lists the five supplements most commonly used for 
medicinal purposes by our survey participants, and the three most often cited reasons 
for using each of them (listed in order of percentage of respondents):  
Flaxseed:  Flaxseed was used primarily for treating cancer, then for general 
health, and finally for lowering cholesterol and obtaining omega-3 fatty acids.  
Green Tea:  Green tea was used as an antioxidant, to treat cancer, and to 
promote general health.  
Ginger:  Respondents used ginger to treat nausea, to aid in digestive problems, 
and for reducing inflammation.  
Curcumin:  Curcumin was used to assist in treating cancer, to reduce 
inflammation, and as an antioxidant.  
Evening Primrose: Respondents stated that they used evening primrose to 
treat hot flashes, to assist with symptoms of menopause (other than hot 
flashes), and to reduce the effects of PMS.  
 
Clearly, many survey respondents took or have taken an HDS to directly treat 
their cancer (i.e., affect tumor growth and/or size).  Many others reported taking 
dietary supplements to treat side-effects of cancer treatments and just to enhance their 
basic health.  Many of the reasons for taking a particular supplement, other than to 




supplement.  For example, most people are aware of the time-honored remedy of 
using ginger ale for an upset stomach; unsurprisingly, ginger was used primarily to 
treat nausea. 
 
5.1.2.2 Beginning or Ending HDS Use 
Survey participants were asked to state whether they used a certain HDS 
before their diagnosis with breast cancer and if they used it after their diagnosis.  A 
statistical analysis of the responses showed that breast cancer survivors were likely to 
begin taking an HDS after their diagnosis with breast cancer, and that this supplement 
was one not previously reported being taken.  This suggests that being diagnosed with 
breast cancer played a vital role in a person’s decision to take HDS.  
Our data indicate that breast cancer survivors’ use of HDS before or after their 
cancer diagnoses varied with different supplements.  Particularly intriguing are the 
results we found for black cohosh and evening primrose, as these supplements 
showed an approximately equal number of positive and negative change responses.  
That is, subjects were as likely to start using them as they were to stop using them 
after their diagnosis.  At least for these supplements, breast cancer survivors may be 
exposed to conflicting information or messages about how the supplements may 
interact with their cancer treatments.  Or, there may exist an alternative explanation of 
why similar individuals (i.e, breast cancer survivors) make opposite choices when 
deciding whether to use HDS.  In any case, further study is warranted regarding the 





5.1.3 Survey Limited To Online Respondents and Fixed Questions 
There are two main limitations to the survey portion of our study:  the sources 
of respondents and the types of responses given.  We used a convenience sample, as 
all of the 1106 usable surveys submitted came from members of two online breast 
cancer patient and survivor communities—BreastCancer.net and the Love/Avon 
Army of Women.  From those two sites, over 1000 surveys were collected.  However, 
the vast majority of respondents were upper middle class, late middle-aged Caucasian 
women, and only 64 people of other ethnicities and/other income brackets 
participated.  This factor limits the applicability of the data, and we cannot 
extrapolate our data to other population groups. 
In the survey, respondents were asked to identify “other” complementary or 
alternative medicines besides those specifically spoken of already.  This question 
provided a myriad of possibilities for further research; but given that 528 participants 
answered with many different types of supplements, no significant conclusions can be 
drawn from those responses.  In other words, nearly half of our survey sample used 
other supplements not already listed in our survey for medicinal purposes.  The major 
conclusion we can draw from this finding is that breast cancer survivors use many 
different HDS for many different reasons.  At the very least, this underscores the need 
for further research into HDS and breast cancer.  A logical next step would be to 
further investigate the motivations in the decision to use HDS, and to examine 





5.1.4 Contributions to Existing Literature 
Despite the limitations, one of the strengths of our study was the large sample 
size.  Because we had more than 1,000 subjects, our survey results contribute to the 
literature by providing information about the use of certain types of integrative 
medicine in upper middle class, late-middle aged Caucasian women.  In general, our 
data are consistent with the conclusions of many previous studies cited in the 
literature review. 
Although websites were listed as the source of information most often 
consulted, physicians were also considered to be influential in the decision to use 
HDS.  This suggests that patients view physicians favorably, and that ways of 
improving doctor-patient communication about HDS use should be a priority for 
future research.  Considering the large variation in the quality of information 
available on the internet, it is plausible that many individuals may be exposed to 
information that is not reputable.  Therefore, it would be in the best interests of 
physicians to become knowledgeable about HDS to the extent that they are able to 
address this issue with their patients.  Moreover, although our survey respondents 
reported that they consulted websites most often to obtain information about HDS, 
they also indicated that they trusted the information they received from doctors, 
journals, and non-profit organizations the most.  
An important finding from our survey that may warrant further study is the 
indication that survey respondents were likely to being using an HDS after being 




with breast cancer caused these respondents to being taking an HDS, it may have 
contributed at least in part to the decision to take HDS.  
Nearly half of respondents indicated they took black cohosh before their 
diagnosis, but not after, while the other half indicated that they did not take black 
cohosh before diagnosis, but did take it after.  Survey respondents also reported that 
they began taking or continued taking other HDS, such as green tea and curcumin. 
Decisions about beginning, continuing, or ending the use of certain dietary 
supplements may have been influenced by information regarding safety and efficacy 
about these supplements that was available to the respondents.  In the case of black 
cohosh, the available information may have been contradictory: some studies suggest 
that black cohosh has inhibitory effects on breast cancer cells, others report that black 
cohosh showed signs of estrogenic effects, and at least one study indicated that black 
cohosh showed signs of toxicity to liver cells. 
 
5.1.5 Other Survey Limitations 
5.1.5.1 Ambiguity with Medical Purposes vs. Other Reasons 
The survey participants were asked about their reasons for using the HDS 
which they reported using.  They were also asked to specify whether it was for 
medicinal purposes or for other purposes.  It is possible that this question may have 
seemed ambiguous and that some survey respondents may have misunderstood what 
was meant by “medicinal purposes.”  The problem of ambiguity may have arisen 
because the survey was originally intended to be administered in the form of a person 




pilot tested in an interview format with breast cancer patients.  We anticipated that if 
any question lacked clarity or was not properly interpreted by the respondent, the 
meaning of the question could be readily explained.  Although the original intent of 
the “reason for use” question was to eliminate responses that pertained to using HDS 
primarily for non-medical (cooking for example) purposes, we recognize that this 
question may have caused confusion among some subjects. 
 
5.1.5.2 Advertising Bias 
The survey respondent providers, BreastCancer.net and Love/Avon Army of 
Women are web-based, and both websites included advertisements for different 
commercially available dietary supplements.  It is possible that these advertisements 
may have influenced the survey participants as the survey sample was gathered from 
both of these websites.  Some usage trends found in our results may have been 
influenced by the advertisements appearing on these websites.  However, 
BreastCancer.net and Love/Avon Army of Women represent a small portion of the 
total amount of information available to breast cancer survivors, and we assume that 
the advertisements our subjects may have been exposed to would have minimal 
impact on the results we obtained.  
 
5.1.5.3 Problems with Open-ended Questions 
The questions about the participants’ reasons for using their particular HDS 




different responses were given.  It was necessary to group and condense these 
responses into a smaller number of categories in order to manage the data.  However, 
this process may have resulted in a source of bias introduced by the coders.  It also 
appears that some respondents were confused about the meaning of the term 
“conventional treatment side effects” versus general reasons for using a supplement.  
Thus, the responses to some of the open-ended questions lacked clarity and needed to 
be interpreted, which also could have been a source of bias and may have affected the 
results.  
5.1.5.4 Source of Sample Population 
The Love/Avon Army of Women organization provided the majority of the 
survey respondents, who were recruited through a mass email “blast.”  A relatively 
small number of responses were obtained from BreastCancer.net.  The members of 
Love/Avon Army of Women appear to be highly motivated, actively engaged, and 
involved in seeking information about breast cancer and in participating in 
fundraising for breast cancer research.  They also may be more likely to seek out 
solutions and support in dealing with their cancer diagnosis.  It is impossible to tell 
what the effects of this involvement bias might be; however, it is possible that 
respondents may have been more likely to use HDS because they were actively 
searching for newer treatment options and were more open to ideas through their 





5.1.5.5 Increased Access to the Internet 
The fact that the survey participants were recruited through internet sources 
may have influenced the results.  Since the survey was administered over the internet, 
people who took this survey needed to have internet access to begin with and 
therefore they may have been biased towards using internet informational sources.  It 
is possible that some subjects may have been frequent or habitual internet users.   
 
5.2 Effects of Actein on Breast Cancer Cell Proliferation 
5.2.1 SERMs and Actein Inhibit MCF-7 Cell Proliferation  
In our cell proliferation experiments, we confirmed that actein has a growth 
inhibitory effect on MCF-7 human breast cancer cells and furthermore, inhibits 
estradiol-stimulated MCF-7 cell proliferation.  These effects were statistically 
significant at 5.0 µM and 10.0 µM, respectively.  These concentrations are on the 
order of the published 3.6 µM peak serum level of actein measured in Sprague-
Dawley rats (Einbond et al., 2009).  However, the concentrations at which their 
effects were pharmacologically relevant were generally slightly or significantly 
higher than the concentrations at which the effects were statistically significant.   
The SERM drugs tamoxifen and raloxifene, both of which act by inhibiting 
estradiol-induced proliferation of ER+ breast cancer cells, statistically significantly 
inhibited estradiol-stimulated MCF-7 cell proliferation at low concentrations.  In this 
respect, treatment with tamoxifen and raloxifene alone acted as a positive control.  




reveal a synergistic effect on growth inhibition or on the inhibition of E2-stimulated 
proliferation, even when treatment was extended for 120 hours.  These results 
differed from the potentiation of tamoxifen’s effect reported by Al-Akoum, but that 
study involved powdered black cohosh root rather than pure compound, and the 
synergism reported was not determined by the accepted combination index method 
(Al-Akoum, et al., 2007). 
The results underscored the importance of culture conditions and the length of 
treatment.  Large differences were observed in the actein-treated cell proliferation 
experiments when 72 hour treatments were conducted versus 120 hour treatments. 
Significant differences were also observed in gene expression and cell proliferation 
when cells were cultured in RPMI-1640 media supplemented with FBS versus phenol 
red-free RPMI-1640 media supplemented with CDS.  The effect of culture media was 
likely due to the presence of hormonal compounds in RPMI-1640 with FBS that are 
absent in phenol red-free media with CDS, especially phenol red itself, which has a 
known estrogenic effect (Berthois, Katzenellenbogen, & Katzenellenbogen, 1986).  
The origin of the time-related variation was less clear and necessitates further study. 
Based on this in vitro model, actein, a bioactive compound in black cohosh, 
has anti-estrogenic and anti-proliferative effects that warrant additional research of 
actein as a potential chemopreventative or chemotherapeutic agent.  However, the 
proliferative effect of actein observed when treatments were conducted for 120 hours 
rather than 72 hours may be cause for concern. This effect may be related to the 





5.2.2 Actein Alters the Expression of Breast Cancer- and Drug Metabolism-
Related Genes 
By using RT-PCR to measure the expression of CDKN1A, CYP1A1, TFF1, 
and VEGFA in MCF-7 cells treated with a range of actein concentrations, we found 
that CDKN1A and CYP1A1 were significantly induced only at the highest 
concentration of actein with or without estradiol.  CDKN1A and VEGFA are both 
involved in hypoxia-response, one of the pathways in the integrated stress response 
pathway to which Einbond’s group attributed the anti-proliferative and gene 
expression effects of actein and black cohosh in breast cancer cells and rats (Einbond, 
et al., 2009; Einbond, Su, Wu, Friedman, Wang, Ramirez, et al., 2007).  CYP1A1, a 
gene encoding a drug-metabolizing enzyme, was more significantly induced in media 
containing phenol red and FBS than in media with CSS and without phenol red.  This 
effect was not due to the presence of exogenous estrogens, as estradiol treatment 
actually blocked the induction of CYP1A1 by actein, showing that estrogen and actein 
have opposing effects on the regulation of CYP1A1 expression in this case.  The 
difference in induction between the two types of media may be related to the presence 
of other exogenous compounds in the FBS-containing media.  
Interestingly, actein alone had no effect on the expression of TFF1, and actein 
was able to block estradiol-stimulated induction of TFF1.  To our knowledge, this is 
the first direct evidence of actein’s anti-estrogenic activity at the transcriptional level.  
Overall, our study provided additional evidence that actein is anti-estrogenic in ER+ 
breast cancer cells, as shown by its inhibition of estradiol-stimulated MCF-7 cell 




concentrations.  Our results are consistent with those of other researchers who have 
found actein to be anti-estrogenic (Einbond, Su, Wu, Friedman, Wang, Jiang, et al., 
2007; Zierau, Bodinet, Kolba, Wulf, & Vollmer, 2002). 
Based on the gene expression data obtained in this study, we propose the 
mechanism of action shown in Figure 59 for actein to explain its anti-proliferative 
and anti-estrogenic effects.  Actein activates the detoxification pathway by increasing 
expression of CYP1A1 while deactivating the progression of estrogen-responsive 
breast cancer by blocking the induction of estrogen responsive genes like TFF1 by 
estradiol.  However, at high concentrations that are unlikely to be achieved 
physiologically, actein also induces VEGFA, which promotes angiogenesis and 
metastasis. 
 
Figure 45.  Proposed mechanism of action for actein in MCF-7 cells. 
Actein activates the expression of CYP1A1 which aids in the detoxification of carcinogens, blocks the 
induction of TFF1 by E2 thereby slowing cancer progression, and induces VEGFA only at high 
concentrations as part of the hypoxia response. 
 
5.3 Hepatotoxicity of Actein in Liver Cells 
5.3.1 Hepatotoxicity of Actein Is Concentration Dependent in HepG2/C3A Cells 
Previous literature indicates that actein is toxic at high concentrations, 




HepG2/C3A cells (Lude, et al., 2007).  For instance, even the highest concentration of 
actein did not have a significant effect on neutral lipid or phospholipid retention, 
mitochondrial membrane activity and p-glycoprotein activity, cell viability, or 
albumin production.  While we did find actein to affect ROS levels in HepG2/C3A 
cells, this was at a low (0.76 µM) concentration and the effect was actually inhibitory.  
This finding suggests that actein may be able to reduce elevated levels of ROS and 
therefore warrants further study.   
One incidence of potential hepatotoxicity we found involved CYP1A1 activity 
levels.  At 100 µM and 6.25 µM actein, the activity of CYP1A1 was significantly 
increased; however, at a lower concentration of 0.76 µM actein, CYP1A1 activity was 
significantly reduced.  The literature available suggested that actein may have an 
inhibitory effect on cytochrome P450 activity; however, these studies were performed 
on CYP34A instead of CYP1A1 (Tsukamoto, et al., 2005).  Therefore, the variability 
in these results stresses the need for further investigation.   
 
5.3.2  Interactions Between Actein and SERMs Are Weak and Few  
Our initial investigation of the effects of actein alone on HepG2/C3A cells 
demonstrated a lack of hepatotoxicity of actein; however, further studies were 
required to examine the effects of interactions between actein and the SERMs 
tamoxifen and raloxifene.  When actein and tamoxifen were combined, we found a 
synergistic effect with phospholipid accumulation and cell viability.  However, we 
did not find any interaction with mitochondrial membrane depolarization and p-




an interaction between actein and tamoxifen with CYP4501A1 activity, the nature of 
this interaction was unclear due to the ambiguity of the dose response curve.  Our 
two-way ANOVA indicated an interaction between actein and tamoxifen with two 
intersecting curves representing tamoxifen alone and the other tamoxifen with 30uM 
actein.  After the intersection of the two curves, the nature of the interaction could be 
identified by the shifting of the respective curves, however our graph did not show 
the curves to have any significant shifts.  Therefore, it was difficult to definitively 
conclude the nature of the apparent interaction.  In hindsight, we conclude that this 
and other dose response curve ambiguities were the result of poor experimental 
design.  Upon consulting with a statistician after our assays were performed, we 
found that in order to produce more telling, accurate results, we would have had to 
use the same set of concentrations for tamoxifen and raloxifene at 0 and 30 µM 
actein.  From this we learned the importance of an early statistician consultation, and 
we suggest a proper reinvestigation at a future time.   
When actein and raloxifene were combined, we found an interaction with 
phospholipid accumulation and cell viability.  The dose response shift was weak and 
ambiguous, respectively, resulting in an unclear interaction.  We did not find an 
interaction between actein and raloxifene with ROS activity, CYP4501A1 activity, 
neutral lipid steatosis, mitochondrial membrane depolarization and p-glycoprotein 
activity, or albumin production.  While the interactions discovered between actein 
and tamoxifen, and actein and raloxifene were few, the only identifiable interactions 








In order to address the lack of reliable information regarding the use, safety, 
and efficacy of HDS, Team IMAC applied a mixed methods approach.  A survey was 
used to investigate current patterns of, perceptions regarding, sources of information 
about, and communication related to HDS use.  The survey instrument was 
developed, pilot tested, and then administered online to members of BreastCancer.net 
and Love/Avon Army of Women.  To add to the amount of reliable safety and 
efficacy information available regarding HDS and breast cancer, a specific 
supplement, black cohosh, was selected for further study due to the presence of 
conflicting published findings. 
Our survey found that most breast cancer survivors who responded use HDS, 
generally in conjunction with conventional therapies.  Of the supplements that our 
respondents reported using specifically to treat breast cancer, curcumin, flaxseed, and 
green tea were the most common.  Interestingly, these supplements are also some of 
the best characterized in scientific literature.  As expected, of the women who 
reported using black cohosh, nearly all said that they used the supplement to 
ameliorate hot flashes and other symptoms of menopause.  The most commonly 
consulted source of information about HDS was internet websites, although 




practitioners, government websites, academic journals, breast cancer support groups, 
and cancer related health organizations. 
In our in vitro studies of actein, a bioactive component of black cohosh,  
MCF-7 cells were employed as a model for ER+ breast cancer and HepG2/C3A cells 
were used to model the human liver.  This allowed us to examine actein’s effects on 
both the breast, the target tissue for chemopreventive and chemotherapeutic breast 
cancer drugs, and the liver, which processes xenobiotics.  Based on cell proliferation 
and gene expression experiments with the MCF-7 cells, actein inhibited cell 
proliferation, was anti-estrogenic, and did not change the effect of the SERMs 
tamoxifen and raloxifene.  We also observed significant variations in results based on 
culture conditions and the time course of treatments, which, in addition to the use of 
various black cohosh preparations and model systems in experiments, could be the 
source of existing contradictory results in the scientific literature.  In the liver cell 
assays used to determine whether actein may be hepatotoxic, toxicity was only 
indicated at very high concentrations (>25 µM).  In combination with the SERMs, 
actein actually lowered some of the effects indicative of liver toxicity as compared to 
treatment with the SERMs alone.  
We conclude that HDS use among women who have been diagnosed with 
breast cancer continues to be widespread.  There is a need for further research in 
order to increase the quantity, quality, and availability of information regarding the 
safety and efficacy of HDS.  Based on our finding that websites are commonly 
consulted, the Internet may be a good platform through which to provide this 




regarding any HDS use.  Furthermore, we conclude that actein, a bioactive 
component of black cohosh, is anti-proliferative and anti-estrogenic under the 
conditions of our experiment, and that experimental conditions including culture 
media and length of treatment may have led to conflicting published results.  Clearly, 
continued research is needed in both areas of our project, in 1) the biological study of 
supplement effects alone and in combination with commonly used conventional 
medicine, and in 2) the sociological and psychological study of supplement use and 
how to ensure that cancer survivors use supplements in a safe and potentially 
beneficial way. 
 
5.5 Future Studies 
Our study had a few important limitations that could be reduced in future 
studies.  Our survey was administered online to subscribers of BreastCancer.net and 
Love/Avon Army of Women, which meant that we were unable to draw conclusions 
about the larger population of women affected by breast cancer.  This also meant that 
our sample population was not demographically representative of breast cancer 
survivors at-large.  Since demographic factors may be related to women’s perceptions 
about HDS, this could have skewed our results.  To obtain a more representative, 
random sample, the survey instrument could be administered at one or several large 
cancer hospitals.  Future studies could also add questions about supplements that 
women used which were not listed on our survey instrument, such as mushroom 
extracts, melatonin, dong quai, fish oils, and ocean plant extracts.  In order to obtain 




perceptions of those supplements, a more in-depth, qualitative study could be 
conducted using focus groups or interviews. 
One of the main limitations of our in vitro studies was that the cell lines used 
as model systems for human ER+ breast cancer tissue and liver tissue do not 
necessarily respond in the same way that the human body would respond.  
Additionally, our results were obtained with only one chemical component of black 
cohosh, therefore our results cannot entirely explain effects that may be had with the 
intact herbal supplement.  Now that we have shown actein to be anti-estrogenic, anti-
proliferative, and non-hepatotoxic at low concentrations, the use of an animal model 
could provide additional insight into whether this effect might also be observed in 
humans.  Our laboratory results also suggest future studies into the mechanism by 
which the observed effects occurred, such as how actein is able to block the induction 
of TFF1 by estradiol.  Because interactions between HDS, conventional therapies, 
and differences between individual people can cause enormous variance in how safe 
or effective a given supplement is, more work is needed within the scientific 
community in developing a coherent, consistent methodology for measuring 







































































































































 Appendix B.  Lack of Hepatotoxicity of Tamoxifen and Lack of Interactions 
Between Actein and SERMs 



































Figure 46.  Tamoxifen does not affect membrane phospholipid accumulation.  
Tamoxifen does not affect phospholipid accumulation in HepG2/C3A cells.   Confluent cells were 
treated with 0, 0.76, 1.55, 3.1, 6.25, 12.5, 25, 50, and 100 µM tamoxifen for 48 hours, and 
phospholipid accumulation was measured with the Nile Red assay.  Data were normalized as a 
percentage of the mean value of the 0 µM control, and expressed as mean ± SEM. 
 
Effect of Tamoxifen with 30 µM Actein on the Amount of Reactive Oxygen 







































Tamoxifen Alone Tamoxifen + 30 _M Actein
 
Figure 47.  Actein and tamoxifen do not have an interaction effect on oxidative stress. 
Actein and tamoxifen do not have an interaction effect on oxidative stress in HepG2/C3A cells.  
Confluent cells were treated with the indicated concentrations of actein and tamoxifen for 48 hours, 
and ROS was measured with the DCFDA assay.  Data were normalized as a percentage of the mean 






Figure 48.  Actein and tamoxifen do not have an interaction effect on intracellular neutral lipid 
accumulation.  
Actein and tamoxifen do not have an interaction effect on neutral lipid accumulation in HepG2/C3A 
cells.  Confluent cells were treated with the indicated concentrations of actein and tamoxifen for 48 
hours, and lipid accumulation was measured with the Nile Red assay.  Data were normalized as a 
percentage of the mean value of the 0 µM control, and expressed as mean ± SEM. 
 






























Tamoxifen Alone Tamoxifen + 30 _M Actein
 
Figure 49.  Actein and tamoxifen do not have an interaction effect on R123 retention. 
Actein and tamoxifen do not have an interaction effect on R123 retention in HepG2/C3A cells.  
Confluent cells were treated with the indicated concentrations of actein and tamoxifen for 48 hours, 
and R123 accumulation was measured with the R123 assay.  Data were normalized as a percentage of 
the mean value of the 0 µM control, and expressed as mean ± SEM. 
 
 



































































Tamoxifen Alone Tamoxifen + 30 _M Actein
 
Figure 50.  Actein and tamoxifen do not have an interaction effect on albumin production. 
Actein and tamoxifen do not have an interaction effect on albumin production by HepG2/C3A cells.  
Confluent cells were treated with the indicated concentrations of actein and tamoxifen for 48 hours, 
and albumin production was measured with an albumin ELISA.  Data were normalized as a percentage 
of the mean value of the 0 µM control, and expressed as mean ± SEM. 
 
Effect of Raloxifene with 30 µM Actein on the Amount of Reactive Oxygen 







































Raloxifene Alone Raloxifene + 30_M Actein
 
Figure 51.  Actein and raloxifene do not have an interaction effect on oxidative stress.   
Actein and raloxifene do not have an interaction effect on oxidative stress in HepG2/C3A cells.  
Confluent cells were treated with the indicated concentrations of actein and raloxifene for 48 hours, 
and ROS was measured with the DCFDA assay.  Data were normalized as a percentage of the mean 





























Raloxifene Alone Raloxifene + 30_M Actein
 
Figure 52.  Actein and raloxifene do not have an interaction effect CYP1A1 activity. 
Actein and raloxifene do not have an interaction effect on CYP1A1 activity in HepG2/C3A cells.  
Confluent cells were treated with the indicated concentrations of actein and tamoxifen for 48 hours, 
and CYP1A1 activity was measured with the EROD assay.  Data were normalized as a percentage of 
the mean value of the 0 µM control, and expressed as mean ± SEM. 
 


































Raloxifene Alone Raloxifene + 30_M Actein
 
Figure 53.  Actein and raloxifene do not have an interaction effect on intracellular neutral lipid 
accumulation. 
Actein and raloxifene do not have an interaction effect on neutral lipid accumulation in HepG2/C3A 
cells.  Confluent cells were treated with the indicated concentrations of actein and raloxifene for 48 
hours, and lipid accumulation was measured with the Nile Red assay.  Data were normalized as a 



































Raloxifene Alone Raloxifene + 30_M Actein
 
Figure 54.  Actein and raloxifene do not have an interaction effect on R123 retention. 
Actein and raloxifene do not have an interaction effect on R123 retention in HepG2/C3A cells.  
Confluent cells were treated with the indicated concentrations of actein and raloxifene for 48 hours, 
and R123 accumulation was measured with the R123 assay.  Data were normalized as a percentage of 
the mean value of the 0 µM control, and expressed as mean ± SEM. 
 






























Raloxifene Alone Raloxifene + 30_M Actein
 
Figure 55.  Actein and raloxifene do not have an interaction effect on albumin production. 
Actein and raloxifene do not have an interaction effect on albumin production by HepG2/C3A cells.  
Confluent cells were treated with the indicated concentrations of actein and raloxifene for 48 hours, 
and albumin production was measured with an albumin ELISA.  Data were normalized as a percentage 
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Abstract 
Conventional cancer treatments are often associated with unpleasant side 
effects, leading many patients to integrate complementary and alternative medicine 
(CAM) modalities with their standard therapies.  One commonly used and relatively 
inexpensive CAM is herbal dietary supplements (HDS).  However, little information 
is available regarding the types of HDS used by breast cancer survivors, the perceived 
effectiveness of HDS, and adverse reactions associated with its use, such as 
interactions between HDS and prescribed drugs.  Using a mixed-methods approach in 
both a clinical and laboratory setting, we will investigate two aspects of HDS and 
breast cancer:  (1) A survey instrument that we developed and pilot tested will be 
administered to ~ 200 breast cancer survivors undergoing treatment at the Lombardi 
Cancer Center (Washington, D.C.) to study their use and perceptions of HDS; (2) The 
in-vitro effects of a commonly used HDS, black cohosh (Actaea racemosa), alone and 
in combination with the chemohormonal drugs raloxifene and tamoxifen, will be 
studied using human breast cancer (MCF-7) and liver (HepG2-C3A) cell lines.  We 
expect our investigation to provide a deeper understanding of perceptions, use, and 
potential effectiveness of HDS in general, and black cohosh in particular, as part of an 
integrative approach to treating breast cancer. 
 
Rationale 
Our research goal is to qualitatively compare local breast cancer survivor use 
and perceptions of herbal dietary supplements to their proven effects and safety 
profiles in literature and in our own in vitro study of black cohosh.  In 2007, an 
estimated 2.5 million people were diagnosed with cancer in the United States, 
including 178,480 new cases of breast cancer 1, 2.  Conventional chemotherapy agents 
treat cancer by targeting rapidly dividing cells, including healthy cells in the lining of 
the mouth and intestines, bone marrow, and hair follicles, causing side effects such as 
hair loss, nausea, vomiting, fever, immune system vulnerability, and fatigue3. In 
addition to the side effects associated with general chemotherapy and radiation 
therapy, breast cancer patients frequently experience amenorrhea, premature 
menopause, and menopausal symptoms such as hot flashes and changes in the 
urogenital epithelium due to the endocrine-targeted therapies and the action of 
chemotherapy on the ovary4. Hormone replacement therapy (HRT) with estrogen 
alone or in combination with progestin has been found to be effective in relieving 
menopausal symptoms5.  However, estrogen may also stimulate the growth and 
development of some types of breast cancer, and there is evidence suggesting that 
HRT is related to breast cancer recurrence and mortality6. 
The side effects of conventional treatments lead many cancer survivors to 
seek alternatives to alleviate these side effects, increase immune function, augment 
overall health, or even replace conventional treatment. A study conducted in 2004 




complementary and alternative medicine (CAM) modalities following cancer 
diagnosis7. A 2006 study of over 2000 women diagnosed with breast cancer during 
1998-2003 showed that 62% used some form of CAM, with 19% of the women 
reporting that they used herbs8.  In a study comparing 2005 survey data to data from 
1998, breast cancer survivors reported using a variety of CAM modalities, most 
commonly herbal or high-dosage vitamin supplements. A significant increase in the 
use of these therapies was observed between 1998 and 20059. Because herbal dietary 
supplements (HDS) are widely available, relatively inexpensive, and a commonly 
used CAM modality, we will focus our study on HDS, particularly those that have 
been cited as frequently used by breast cancer survivors: black cohosh or Remifemin, 
curcumin, echninacea, flaxseed, garlic, ginger, ginkgo, ginseng, kava kava, saw 
palmetto, soy or soy-derivative (isoflavones, genistein), St. John’s wort, valerian, 
dong quai, and red clover.  To determine the specific HDS that local breast cancer 
survivors are using and their reasons for using these therapies, we will conduct a 
survey of survivors at the Lombardi Cancer Center of Georgetown University 
Medical Center (GUMC).   
Concerns regarding HDS use by breast cancer survivors involve a lack of 
evidence regarding the safety and efficacy of some herbals, lack of communication 
about HDS use with health care professionals, and potentially harmful herb-drug 
interactions.  In 2005, a survey of over 300 breast and prostate cancer survivors found 
that 61% reported not discussing CAM use with their physician, while 63% of 
oncologists said that they bring up the topic of CAM at least some of the time10.  This 
can be dangerous as some botanicals are known to affect drug metabolism, increase 
bleeding risk during surgery, or have estrogenic properties that may stimulate the 
growth and proliferation of breast cancer cells.  Because the Food and Drug 
Administration does not require pre-market testing or approval of HDS,  the safety 
and efficacy of commercially available botanicals is controversial or largely unknown 
11, 12.  Our survey will address such attitudinal and behavioral issues as where breast 
cancer survivors obtain information about HDS and whether they discuss it with their 
health care providers. 
One dietary supplement frequently used by breast cancer patients is black 
cohosh (Actaea racemosa or Cimicifuga racemosa), which is controversial with 
respect to its safety and efficacy.  For example, reports in the literature suggest that 
black cohosh may have estrogenic properties, which would be dangerous to breast 
cancer patients with estrogen-sensitive cancer13-17.  Additionally, there have been 
several reported cases of hepatotoxicity in individuals using black cohosh18. Because 
existing literature has come to mixed conclusions about the safety and efficacy of 
black cohosh, we hope to build on the existing knowledge base through further in 
vitro studies.  We will investigate the effects of black cohosh  alone and in 
combination with the selective estrogen receptor modulators tamoxifen and raloxifene 
– drugs frequently prescribed to breast cancer patients – on breast cancer cell 
proliferation and on hepatic processes.  
 
Methods 
 Survey research.  Breast cancer survivors’ use and perceptions of HDS will be 




has been validated by expert reviewers and will be further validated by pilot testing 
with cognitive interviewing in mock interviews among our peers, residents of 
Spelman House Advanced Care Center, and with other volunteers.  The survey and 
study design and protocol have already been approved by the University of Maryland 
Institutional Review Board (IRB) and will soon be submitted to the GUMC IRB.  
Subjects for the study will be recruited and interviewed on site as part of the 
Lombardi Cancer Center’s ongoing recruitment for the Breast Cancer Biomarker and 
Clinical Outcomes Research Database.  We will use a convenience sample of subjects 
from a sampling frame of all female breast cancer survivors > 18 years of age  who 
visit the Lombardi Comprehensive Cancer Center at GUMC over the course of a 
defined 12-month period.  The interviewer will read each question from the 
questionnaire to the subject, using response cards as aids for some questions, and 
record the responses with a predetermined coding scheme.  
 Laboratory research.  The effects of black cohosh will be tested in vitro using 
the putative active compounds actein, 23-epi-26-deoxyactein, and cimicifugoside.  
Cell proliferation of estrogen receptor-positive human breast cancer MCF-7 cells 
treated with the black cohosh compounds alone and in combination with tamoxifen 
and raloxifene will be tested by plating cells in 24-well plates with 25,000 cells/well, 
incubating for 24 hours at 37 ºC, and then replacing medium with or without test 
compounds at physiological concentrations, including appropriate controls.  
Treatment medium will be replaced twice after 24-hour incubations. 96 hours after 
the initial treatment, the number of cells in each well will be assessed by fixing, 
staining with sulforhodamine B, and measuring the absorbance with UV-vis 
spectrophotometry at a wavelength of 490 nm.  The extent that these active 
compounds have an estrogenic effect will also be examined using the same 
methodology, but modifying the treatment to include 17β-estradiol. 
 Potential hepatotoxicity of the black cohosh compounds will be examined in 
vitro using HepG2/C3A human liver cells grown in a hormonal cocktail to provide a 
better model of female liver cells.  Cells will be plated and treated with the black 
cohosh compounds as described above.  Following treatment, cell death will be 
measured by determining the amount of double-stranded DNA present in each well.  
Oxidative stress will be measured by adding dihydrodichlorofluorescein diacetate to 
the cells, which will be oxidized by reactive oxygen species to dichlorofluorescein, a 
fluorescent product.  The intensity of the fluorescence can be measured and used to 
determine the concentration of reactive oxygen species.  The activity of cytochrome 
P4501A1, cytochrome P2B, and cytochrome P3A, enzymes involved in xenobiotic 
metabolism, will be measured by adding substrates that form fluorescent products 
upon enzyme-catalyzed hydrolysis and then measuring the intensity of the 
fluorescence.  Other endpoint assays may be used to further investigate hepatic 
effects of the black cohosh compounds. 
 
Analysis of Results 
 Using descriptive statistics, we will describe the attitudes and behaviors of the 
breast cancer survivors in our sample with respect to HDS.  We will use a statistical 
analysis program (such as SPSS or SAS) to perform multiple regression analyses to 




individual dietary supplement.  Additionally, we will examine relationships between 
various information sources and HDS use.  
 To analyze differences in cell proliferation, amount of double stranded DNA, 
amount of reactive oxygen species, and CYP1A1, CYP2B, and CYP3A activity under 
the different treatment conditions (black cohosh compounds alone and in combination 
with either tamoxifen or raloxifene), results will first be expressed as a percent of the 
appropriate control.  Next, an analysis of variance (ANOVA) will be performed to 
test for differences between treatment condition means.  If the existence of significant 
differences in the means is established, Dunnet’s test for multiple comparisons will be 
used to determine whether each treatment condition/concentration in a group is 
significantly different from a shared control.  Additionally, the IC50 (concentration 
causing 50% inhibition of cell proliferation) of each of the black cohosh test 
compounds will be determined. 
 Finally, the breast cancer survivors’ perceptions of HDS will qualitatively be 
compared to evidence of safety and efficacy that exists in the published literature.  If 
appropriate, comparisons will also be made to our in-vitro black cohosh studies.  The 
PubMed database will be searched for English articles published in peer-reviewed 
journals related to breast cancer and each of the specific dietary supplements used by 
our subjects.  Clinical studies, reviews, and primary in vitro and in vivo studies 
published between 2004-2009 will be included.  The reported use and perceptions of 
HDS in our study will be qualitatively evaluated in the context of existing literature 
and our black cohosh study, with particular consideration given to the safety and 
efficacy of each supplement. 
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Item Unit Unit Price Quantity Total 
Filtration units 12/case $142.00 3 $426.00 
24-well plates 100/case $242.00 1 $242.00 
T-175 flasks 32/case $184.68 3 $554.04 
RPMI-1640 media 500 mL $15.75 20 $315.00 
Fetal bovine serum 500 mL $250.00 1 $250.00 
Charcoal dextran-treated 
serum 500 mL $603.00 1 $603.00 
25 mL pipettes 200/case $188.99 2 $377.98 
10 mL pipettes 50/case $29.30 4 $117.20 




(ChromaDex), 10 mg 
of each $782.50 2 $1,565.00 
23-epi-26-deoxyactein included in kit     $0.00 
Cimicifugoside included in kit     $0.00 
Raloxifene 500 mg $295.00 1 $295.00 
Tamoxifen 1 g $157.00 1 $157.00 
Transportation to USDA 
12 mile/round trip at 
$0.38/mile $4.56 250 $1,140.00 
Transportation to 
Georgetown 
round trip metro to 
Georgetown $6.85 250 $1,712.50 
Transportation to FDA 
16 mile/round trip at 
$0.38/mile $6.08 150 $912.00 
Office supplies/photocopying       $100.00 
Postage for correspondence 
with Georgetown patients       $100.00 
Survey data management and 
storage       $500.00 
Graduate student for 
statistical consultation       $200.00 
Conference to present results       $750.00 






Fitration units, 24-well plates, T-175 flasks, RPMI-1640 media, fetal bovine 
serum, charcoal dextran-treated serum, and pipettes are essential materials for the cell 
culture portion of our project.  Actein, 23-epi-26-deoxyactein, and cimicifugoside are 
the compounds from black cohosh that we will be testing.  Raloxifene and tamoxifen 
are selective estrogen receptor modulators commonly used in breast cancer treatment 
that will be used to investigate herb-drug interactions with black cohosh.  
Transportation costs are a necessary part of our project, as we must be able to 
transport our team members to Lombardi Cancer Center to interview survey 
participants, to the toxicology lab at the Food and Drug Administration’s Center for 
Food Safety and Applied Nutrition, and to the Diet, Genomics, and Immunology lab 
at the U.S. Department of Agriculture’s Agricultural Research Service facility.  
Office supplies and postage are for the reproduction of questionnaires and participant 
consent forms.  The fee for survey data management and storage allows us to use 
Georgetown University Medical Center’s data storage facility, protecting subject 
confidentiality by ensuring that access to personal information is limited and that 
personal information is properly separated from questionnaire responses.  The 
statistical consultation will teach our team how to use appropriate statistics software 
to analyze our data and obtain meaningful results.  Financial support for the 
conference will allow two or three of our team members to travel to a conference 
such as that held by the American Institute for Cancer Research and present our 
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Vulnerable Populations: The proposed research will involve the following (Check all that apply): 
pregnant women   ,                        human fetuses   ,     neonates    ,    minors/children    ,    
prisoners    ,     students    ,    individuals with mental disabilities    ,       individuals with 
physical disabilities   Exempt or Nonexempt (Optional): You may recommend your research for exemption or 
nonexemption by completing the appropriate box below.  For exempt recommendation, list the 
numbers for the exempt category(s) that apply.  Refer to pages 5-6 of this document.    Exempt----List Exemption Category 
Numbers  
      Or           Non-Exempt 
If exempt, briefly describe the reason(s) for exemption.  Your notation is a suggestion to the IRB 
Manager and IRB Co-Chairs. 
 
 
     Our study involves survey administration only, which falls under exemption category #2. 
       
Date Signature of Principal Investigator or Faculty Advisor  (PLEASE NOTE: 
Person signing above accepts responsibility for the research even when data 
collection is performed by other investigators)        
Date Signature of Co-Principal Investigator  
       
Date Signature of Student Investigator  
       
Date 
 
REQUIRED Departmental Signature  
Name _______________________________________, 
Title_______________________________ 






(PLEASE NOTE: The Departmental signature block should not be signed by the investigator or the 
student  investigator’s advisor.) 
 




Instructions for Completing the Application 
The Departmental Signature block should be signed by the IRB Liaison or Alternate 
IRB Liaison unless there is a conflict of interest.  If the Department or Unit does not 
have an IRB Liaison, the Department Head, Unit Head or Designee should sign the 
application. 
 
 Please provide the following information in a way that will be intelligible to non-
specialists in your specific subject area. 
1.  Abstract:  Provide an abstract (no more than 200 words) that describes the 
purpose of this research and summarizes the strategies used to protect human 
subjects. 
 
Due to the negative side effects of conventional cancer treatments, many 
patients are turning to less-understood complementary and alternative medicine 
(CAM) therapies.  One commonly available and frequently inexpensive form of 
CAM is herbal dietary supplements.  We will investigate breast cancer patients’ 
use and perception of herbal dietary supplements in the Washington, D.C. 
metropolitan area.  We will also determine the metabolic effects of commonly 
used supplements on cancer cells in vitro. Participants will be entered to win one 
of two fifty dollar visa gift cards.  Each subject who volunteers to participate will 
be asked to complete the survey form.  Data for participants will be stored in a 
locked filing cabinet located at Georgetown.  An electronic copy of the survey 
responses data in which participants are identified only with a study number will 
be compiled by Georgetown employees and given to team IMAC so that no 
names or other identifying information will be associated with the results.  If 
quotes of participant responses are used to illustrate key results, no identifying 
information will be included.  Ultimately, we plan to publicize our results either 








2.  Subject selection: 
 a. Who will be the subjects? How will you recruit them? If you plan to advertise 
for subjects, please include a copy of the advertisement. 
 
Subjects will be female breast cancer survivors over the age of 18 that are 
currently being treated at Georgetown University Medical Center.  Following 
their regular appointment, their physician will refer them to our desk and give 
them general information about our project.  They will be given a brochure 
explaining the purposes of our research and a general description of what we 
are studying.  (attached)  If they are interested, they will approach the desk 
and will be asked to participate in our survey.     
 
 b. Will the subjects be selected for any specific characteristics (e.g., age, sex, 
race, ethnic origin, religion, or any social or economic qualifications)? 
 
The subjects will be female breast cancer survivors over the age of 18.  The 
will not be selected for according to race, ethnic origin, religion, or social or 
economic qualifications. 
 
 c. State why the selection will be made on the basis or bases given in 2(b). 
 
Participants will be female because breast cancer most commonly occurs 
among females. Participants must be over the age of 18 so that they may 
legally sign the consent form.   
 
 d. How many subjects will you recruit? 
 
We hope to recruit approximately 200 subjects over the course of about 1 
year. 
 
3. Procedures:   
What precisely will be done to the subjects?  Describe in detail your methods and 
procedures in terms of what will be done to subjects.   
 
Following their regular appointment at Georgetown University Medical Center, 
the subject’s physician will briefly explain our project and refer them to our desk 
if they are interested.  Brochures will also be handed to the patients by the clinic 
staff when they register for their appointment. Upon approaching our desk, 
subjects will be given a consent form explaining the purposes of our research as 
well as the benefits and risks associated.  If the subjects agree to participate, they 




one of two fifty dollar visa gift cards as an incentive.  Subjects will be 
interviewed by a member of the Gemstone team for approximately 20 minutes.  
The interview will be a closed, fixed response interview consisting of 15 
questions about their use of herbal dietary supplements during cancer treatment. 
(See attachment).  The questions on the interview come from both the Gemstone 
team and researchers at Georgetown University.  The researchers at Georgetown 
have already received IRB approval for their interview questions.  Each subject 
will only be interviewed once.  They will only be contacted by team IMAC again 
if they are chosen in the raffle for one of the fifty dollar visa gift cards.   
 
How many subjects are being recruited?   
 
Approximately 200 subjects are being recruited.  
 
What is the total investment of time of the subjects?   
 
The total investment time is approximately 20 minutes.   
 
4. Risks and Benefits:  Are there any risks to the subjects? If so, what are these 
risks including physical, psychological, social, legal and financial risks? Please do 
not describe the risk(s) as minimal.  If there are known risks, please list them.  
 
There are no known physical, social, legal, or financial risks involved in 
completing the questionnaire.  There are both psychological and emotional risks 
that could result from participation in the interview.  Since cancer is a very 
sensitive topic for those who have been personally affected by it, patients may 
undergo emotional discomfort and psychological distress as they recall their 
experiences.  In some cases completing the questionnaire may cause past feelings 
of depression, hopelessness, and fear to reoccur.  They also may feel 
uncomfortable discussing their experiences with the interviewer.    
 
What are the benefits?  If there are known risks associated with the subject’s 
participation in the research, what potential benefits will accrue to justify taking 
these risks?   
 
Although this research is unlikely to benefit subjects with respect to mitigating 
their disease or improving their long term prognosis, there may be some possible 
benefits associated with participation in our study.  Cancer patients will have a 
vested interest in furthering research that may improve cancer treatments.  
Patients may feel a sense of satisfaction and gratification in knowing that their 
survey contributions could ultimately lead to recommendations for relieving side 
effects associated with chemotherapy, and therefore help others who are 
struggling with a similar disease.  The process of recalling their experiences may 
help them discover new ways of coping with their illness.  It may also prompt 
them to search for treatments that are better suited to their needs, and to 





5.  Confidentiality:  Adequate provisions must be made to protect the privacy of subjects 
and to maintain the confidentiality of identifiable information. Explain how your 
procedures accomplish this objective, including such information as the means of data 
storage, data location and duration, description of persons with access to the data, and 
the method of destroying the data when completed.  
 
Subjects’ names and telephone number will be recorded on raffle form. The completed 
survey instruments and other written documents containing information about the 
subjects and associated with this research project will be stored in a locked file cabinet 
at Georgetown University Medical Center.  Employees at Georgetown will transfer the 
data to an electronic system at which point they will give each participant a number.  
This electronic data will be given to team IMAC.  The names of the participant will no 
longer be linked with their survey, thus maintaining confidentiality.  However, team 
IMAC will have a list of the participants’ names and phone numbers for purposes of the 
raffling off the incentive.  The subject (s) that is chosen in the raffle drawing will be 
contacted by team IMAC.  At UMCP, only the 12 members of the Gemstone team, the 
Gemstone mentor Dr. Mark Kantor, and a statistician will have access to the electronic 
data.  Team IMAC will store the data in an electronic database using SQL that will be 
password protected.    Following graduation of the Gemstone team and successful 
defense of the team’s thesis, the database will be first sent back to the Georgetown 
University investigators (e.g. so they can acquire any enhanced features such as 
summary scores and other created variables, to merge with their data) and then 
destroyed at UMCP by deleting the electronic files no later than December 2010.  
 
 If the research involves audio taping, videotaping or digital recordings, state who will 
have access to the tapes or recordings, where the tapes or recordings will be kept, and 
state the final disposition of the tapes or recordings (i.e. Will the tapes or recordings be 
destroyed?  If so, when will the tapes or recordings be destroyed?). 
 
The research does not involve audio or videotaping. 
 
 
6. Information and Consent Forms:  State specifically what information will be 
provided to the subjects about the investigation.   
 
The subjects will be told that the purpose of the research is to study the attitudes, 
beliefs, and perceptions of herbal dietary supplements among women who are breast 
cancer survivors.  Other specific information, including a description of the research 
and its purpose is provided on the consent form that the subjects will receive.   
 
Is any of this information deceptive?   
All information provided to the subjects will be straightforward and not at all deceptive. 
 
 




consent in a language other than English?   
 
Informed consent will be obtained with a written consent form and will only be 
obtained in English.  All participants will be fluent English speakers.  
 
As per federal guidelines, consent forms are to be kept for at least 3 years after the 
completion of the study. 
 
7. Conflict of Interest:  Describe the potential conflict of interest, including how such a 
conflict would affect the level of risk to the study participants. Please consult the 
University of Maryland policy on conflict of interest as defined by the University of 
Maryland Policies and Procedures III-1.11and II-3.10. These may be viewed at:  
http://www.usmh.usmd.edu/Leadership/BoardOfRegents/Bylaws/SectionIII/III111.html  
 
There is no known conflict of interest. 
 
8. HIPAA Compliance:  State whether you are using HIPAA protected health 
information or “PHI”.   
Currently, researchers employed by the University of Maryland Center or who are 
working within or under the auspices of the University Health Center are subject to 
specific HIPAA requirements regarding the creation, use, disclosure, or access of  PHI. 
Please consult the University of Maryland’s Summary of HIPAA’s Impact on 
University Research. 
 
HIPAA protected health information or PHI is not being used. The staff at Georgetown 
University are required to obtain signed HIPAA releases from every participant, under 









Research Outside of the United States:  Provide responses to the following 
questions.  Separate responses are required for each country where the research 
will be conducted. If you are not conducting research outside the U.S., please 
state “Not Applicable” 
 
Not applicable. 
       
10. Research Involving Prisoners:  Provide responses to the following additional 
IRB criteria for research involving prisoners. If you are not conducting research 












































Each copy of the application should include the IRB application cover form, the 
information required in items 1-10 above, and all relevant supporting documents 
including: consent forms, letters sent to recruit participants, questionnaires 
completed by participants, the ORAA Internal Routing Form for Proposals (if 
any), and any other material germane to human subjects review.  Please also 
include a mailing label for the IRB to send the approval notification.   
 
NUMBER OF COPIES 
 
Please send 1 original application with signatures and 1 copy of the signed, 
original application unless your research requires full Board Review.  Please 
submit 1 signed original application and seventeen (17) copies of any application 
which will require the review of the full IRB.  Full Board reviews are required for 
initial applications involving greater than minimal risk to the subjects (i.e. more risk 
than subjects would generally encounter in their routine daily activities).  
  
IRB Campus Mailing Address:  2100 Lee Building, Zip -5125. 
IRB MEETING DATES AND APPLICATION SUBMISSION DEADLINES 
 
To view the dates for upcoming meetings and the final date for submission of 
applications to be considered for each meeting, please check the following URL:   
http://www.umresearch.umd.edu/IRB/IRBdates.html. 
  






Page 1 of 2 
Initials ________ Date ______ 
CONSENT FORM  
 
Project Title Herbal Dietary Supplement Use Among Breast Cancer Survivors 
Why is this 
research being 
done? 
This is a research project being conducted by Gemstone Team 
Integrative Medicine and Cancer (IMAC) at the University of 
Maryland, College Park.  We are inviting you to participate in this 
research project because you are a female breast cancer survivor over 
the age of 18.  The purpose of this research project is to investigate the 
uses and perceptions of herbal dietary supplements among a group of 
female breast cancer survivors and test the effects and safety of the 
most commonly used herbal dietary supplements in a laboratory 
setting. 
What will I be 




The procedures involve completing a short interview with one of our 
team members.  The interview will be completed while at Georgetown 
University Medical Center, will take approximately 20 minutes to 
complete, and will only be completed once.  The questions will relate 
to the use of herbal dietary supplements during and after cancer 
treatment.  They will include reasons for use, sources of information 
about the reliability of herbal dietary supplements, duration of use, 
perceived efficacy, and perceived safety. We also will ask you some 
basic demographic questions, such as your race and education level, 
so that we can describe the group of participants when we report the 
results of this study.  Your participation in this interview will place you 
in a drawing to win one of two fifty dollar visa gift cards, unless you 
decide not to participate in the raffle. Please check one of the choices 
below: 
[ ] I wish to be entered into the drawing 













We will do our best to keep your personal information confidential.  To 
help protect your confidentiality, your surveys will be  kept in a locked 
filing cabinet at Georgetown University Medical Center.  Employees at 
Georgetown will assign your survey form an identification number, 
and they will never give out other information that may personally 
identify you.  The answers on your survey form will be given to team 
IMAC where it will be stored in an electronic database.  The database 
will be password protected and will only be accessible to members of 
the Gemstone team, the team mentor Dr. Mark Kantor, and a 
professional statistician.  If you decided to participate in the drawing, 
we will keep your name and telephone number in a separate list so that 
we may contact you if you are selected to receive a prize in the the 
raffle drawing.  After the drawng is over that list will be destroyed. If 
we write a report or article about this research project, your identity 




summarized along with all of the study participants’ responses. Your 
information may be shared with representatives of the University of 
Maryland, College Park or governmental authorities if you or someone 





  Page 2 of 2 
                  Initials _______ Date ______ 
Project Title Herbal Dietary Supplement Use Among Breast Cancer Survivors 
What are the 
risks of this 
research? 
 
There may be some risks from participating in this research study.  
There are both psychological and emotional risks that could result from 
participation in the questionnaire.  Since cancer is a very sensitive 
topic for those who have been personally affected by it, patients may 
undergo emotional discomfort and psychological distress as they recall 
their experiences.  In some cases completing the questionnaire may 
cause past feelings of depression, hopelessness, and fear to reoccur.   
What are the 
benefits of this 
research?  
This research is not designed to help you personally, but the results 
may help the investigators learn more about dietary supplements that 
help relieve some of the side effects of chemotherapy. The benefits to 
you may include feeling a sense of satisfaction and gratification in 
knowing that your contribution may help others in the same situation.  
We hope that, in the future, other people might benefit from this study 
through improved understanding of the benefits and safety of herbal 
dietary supplement use during cancer treatment.  
 
Do I have to be 
in this 
research? 
May I stop 
participating at 
any time?   
Your participation in this research is completely voluntary.  You may 
choose not to take part at all.  If you decide to participate in this 
research, you may stop participating at any time.  If you decide not to 
participate in this study or if you stop participating at any time, you will 
not be penalized or lose any benefits to which you otherwise qualify.  
Is any medical 
treatment 
available if I am 
injured? 
 
The University of Maryland does not provide any medical, 
hospitalization or other insurance for participants in this research 
study, nor will the University of Maryland provide any medical 
treatment or compensation for any injury sustained as a result of 
participation in this research study, except as required by law. 





This research is being conducted by Dr. Mark Kantor at the Gemstone 
Program at the University of Maryland, College Park.  
 If you have any questions about the research study itself, please 
contact Dr. Mark Kantor at: The University of Maryland, Dept. of 
Nutrition and Food Science, 0112 Skinner Building, College Park, MD 
20742-7640, 301-405-1018, mkantor@umd.edu  
If you have questions about your rights as a research subject or wish to 
report a research-related injury, please contact: Institutional Review 
Board Office, University of Maryland, College Park, Maryland, 
20742;             
(e-mail) irb@deans.umd.edu;  (telephone) 301-405-0678  
This research has been reviewed according to the University of 
Maryland, College Park IRB procedures for research involving human 
subjects. 
Statement of 
Age of Subject 
and Consent 
 
Your signature indicates that: 
   you are at least 18 years of age;,  
   the research has been explained to you; 




  you freely and voluntarily choose to participate in this research 
project. 
NAME OF SUBJECT  
 












Appendix E.  IRB Addendum 
To whom it may concern: 
 
 We plan to modify the protocol for the project titled “Herbal Dietary Supplement Use 
Among Breast Cancer Survivors”. We will no longer use the survey supplement titled: 
“Appendix B Survey Supplement Page” and these questions have been incorporated into the 
survey instrument originally titled “Appendix A Survey Instrument” as noted below. 
 Question 4 is now formatted as a chart, rather than a series of questions.  The 
questions numbered 5-10 originally included in Appendix B are now included in the chart for 
Question 4.  Using a chart format will simplify survey administration by facilitating the 
interviewer’s recording of responses, so the interview will run more smoothly. 
 For question 4, we now ask whether the supplements are used specifically for 
medicinal purposes, used for other reasons, or not used rather than asking whether or not they 
are used.  Since we are interested in supplement use for medicinal purposes and many of the 
supplements are used for other reasons, it is necessary to clarify whether the subjects’ reason 
for use is in fact medicinal purposes. 
 The supplements that we ask about in question 4 are also changed.  Red clover, 
chamomile, milk thistle, evening primrose are included in place of blue cohosh, echinacea, 
garlic, and gingko.  After further reviewing the most recent literature, we have decided that 
these supplements are more pertinent to our research since they are used more often or more 
specifically by breast cancer patients.   
   For questions 11a-11d, 15, and 16 the answer choice “don’t know/no response” is 
changed to two separate answer choices “don’t know” and “no response”.  For questions 13 
and 14a-14j, the answer choice “don’t know/no response” is changed to three separate answer 
choices “don’t know”, “I don’t know what this is”, and “no response”.  This allows us to 
clarify the reason that the subject does not provide an answer for statistical and coding 
purposes.   
 The procedure for survey administration has not changed.  The survey will still be 
administered in interview format, so that the subjects do not see the survey itself.  Since the 
majority of the changes are formatting changes and the subjects will not see the survey, these 
changes do not affect the risk to the subjects.  The changes in the supplements of interest do 
not change the risk to the subjects, as these are all common supplements similar to the 





Dr. Mark Kantor 
Mentor, Gemstone Team IMAC 
Dept. Nutrition & Food Science 
0112 Skinner Building 







Appendix F. IRB Renewal 
 
           UNIVERSITY OF MARYLAND COLLEGE PARK 
      Institutional Review Board 




June 9, 2009 
Protocol Number 08-0330 
Protocol Title Herbal Dietary Supplement Use Among Breast Cancer 
Survivors 
Risk Classification 
(check one)       







The Principal Investigator, Co-Investigator, and Student Investigator, in signing this 
renewal application, certify that they have conducted research in accordance with the 
IRB-approved protocol and that any consent forms used in connection with the 
project have been retained by the Principal Investigator unless otherwise indicated in 
this renewal application.  
 
 












Dr. Mark Kantor, Dept. 
Nutrition & Food 
Science, 0112 Skinner 
Building, Univ. 








Jessica Stevens (and 
Gemstone Team: IMAC) 
 
 








           Principal Investigator or Faculty Advisor   Date 
 
           
           _________________________________________ ___________________ 
           Co-Investigator (if applicable)                  Date 
 
            
            _________________________________________ ___________________ 




University of Maryland College Park 




1) Participant Enrollment to Date 
 
- This is required to ensure equitable subject selection according to the populations 
identified in the approved IRB protocol.  If race was not collected as a demographic, 
please include recruitment numbers in the All Races Included Row.  If gender was 
not collected, please include recruitment numbers under the Total Column.  If race 
and gender were not collected, please include recruitment numbers in the All Races 
Included/Total cell. 
 
No participants have been interviewed to date.  
 
Population (If known) Adults Children/Adolescents Total 
 Male Female Male Female   
All Races Included 0 0 0 0 0 
White/Caucasian 0 0 0 0 0 
African American 0 0 0 0 0 
Hispanic 0 0 0 0 0 
Native American 0 0 0 0 0 
Asian/ Pacific Islander 0 0 0 0 0 
Other 0 0 0 0 0 
TOTAL 0 0 0 0 0 
 
 
2) Data and Safety Monitoring  
- Required for protocols presenting greater than minimal risk.  State if project was 
monitored during the previous approval period and provide a summary of the reviews 









3) Open to Enrollment 
 
 
- State if protocol will remain open to participant enrollment.  If not, please state 
why. Also state the number of participant withdrawals, if any, and the reason for 









4) Project Summary 
- Provide a summary of the study progress to date.  This should include any interim 
findings (positive/negative), problems encountered, goals for upcoming approval 









5) Problem History 
- Provide a summary of any adverse events and/or unanticipated problems involving 
risks to participants or others.  This should also include any participant complaints.  






6) Additional Information 
- Provide a summary of any relevant literature, additional risks to participation that 







- Indicate whether there were deviations to the currently IRB Approved protocol and 
why these occurred. A deviation is any difference in study conduct from the criteria 
or activities prescribed in the IRB Approved protocol, which may or may not affect 




The protocol will remain open to participant enrollment because no participants have been 
interviewed to date.  This is due to complications with gaining access to our subjects at 
Georgetown, and not due to participant withdrawals. 
There has been no progress to date with data collection.  Due to complications with gaining 
access to subjects at Georgetown, we have decided to use alternative subjects (see section 
8).  During the upcoming approval period, we hope to collect at least 50 surveys and plan 
to complete the project by December 2009.   
No deviations have occurred because there have been no subject interviews yet.   
No other risks have been identified.   
There have been no adverse events or unanticipated problems involving risks to 




8) Request for Approval of New Changes 
- The IRB Office does not recommend submitting Addendum requests during the 
Continuing Review process as this will increase the turnaround time for these 
applications.  However, if the requested modifications are minor (for example: 
editorial or research staff changes) please make the changes to the appropriate section 



































9) Conflict of Interest 
- Indicate if any conflict of interest (COI) issues exist that were not previously 
reported to the IRB Office.  If there is a new COI issue, describe the potential COI, 
including a plan to mitigate the conflict and how the conflict may affect the level of 







There are no changes in the COI.   
New Online Survey Protocol: 
Due to the difficulty in obtaining an adequate number of subjects from the 
Georgetown clinic to complete our survey, we need to find a different source of 
subjects.  Therefore, we have decided to administer our survey (Appendix A) to a 
different population.  Subjects will be female breast cancer survivors over the age of 18 
that currently subscribe to the website BreastCancer.net.  An advertisement for our 
research and survey will appear on the website’s home page (See Appendix E).  Website 
users can click on the advertisement and will be brought to our website, where they will 
complete the survey and consent form.  Patients will not be able to complete the survey 
until they have completed the consent form.   
The survey (Appendix A) will be modified slightly because questions 13 and 14 
will be changed to the past tense.  We feel that this makes more sense when reading the 
survey online, since many subjects are no longer receiving treatments for their cancer.  
We have also removed any interviewer instructions previously included, since the 
format will not be an interview.  Minor changes have been made to the consent form 
(See Appendix C) to better explain the current project.  Subjects will select a check box 
after reading the consent form prior to beginning the survey.   
There will be no additional risks to participants, since the survey questions have 
not changed.  The risks may even be less, since the participants will be able to answer 
the questionnaire from their own home and will not experience any discomfort or 
emotional stress that may occur during a physical interview.  The consent form will only 
contain a check box not a signature box.  No personal identifying information will be 
collected on either the consent form or the survey.  Each survey and consent form will 
contain an assigned number for identification purposes.  Patients will still be able to 
enter the raffle previously described by completing a short information form after the 
survey (See Appendix F).  This form contains personally identifying information, but 
the information will in no way be linked to their survey or consent form.  The raffle will 
be for a $50 cash prize, not a $50 gift card as indicated in our previous IRB submission. 
Completed surveys will be stored in a secure file on a password protected 






10) Funding Sources/Research Support 
- Provide the names of any organization, including Federal agencies, providing 








11) Protocol/Consent Forms  
- If changes have been made during this Renewal Application a copy of the update 
documents (protocol, surveys, advertisements, etc.) must be included with the 
application.  A copy of the consent form must be submitted as well. The consent 
should be the version the IRB will stamp when the project is ready for approval.  If 
more than one consent form (Parent Consent, Assent, Group A, Group B, etc.) will be 
used for this protocol please list them below: 
 
Please note that missing information and documents will result in a delay of IRB 
review.  Please DO NOT include a copy of your IRB Approval Letter or stamped 














New Online Survey: 
 -The original survey (Appendix A) will be used with minimal modifications 
explained above.  Questions from Appendix B were added to Appendix A.  Appendix B is 
no longer used.  We received approval for this change in January 27th, 2009.   
 -The original consent form (Appendix C) will be used with minimal modifications 
explained above. 
 -A new advertisement (Appendix E) will be used. 
 -A raffle form (Appendix F) will be used for the drawing. 
-Appendix D will no longer be used.   
  
The Howard Hughes Medical Institute Undergraduate Research Program has provided a 
grant for $5220 to support our research.  The University of Maryland Gemstone Program 






actein:  a triterpene glycoside that is a bioactive component of the HDS black 
cohosh; the ingredient chosen for the focus of our lab studies 
 
albumin:  protein that carries many compounds, such as some hormones and certain 
drugs, through the blood; made in the liver - low albumin levels suggest liver 
problems 
 
ANalysis Of VAriance (ANOVA):  a basic statistical test that tests for significant 
differences between means 
 
angiogenesis:  the growth of new blood vessels from pre-existing ones; increased 
angiogenesis provides the blood supply to tumors 
 
anti-estrogenic:  having properties that block, inhibit, or decrease the effect of 
estrogen 
 
black cohosh:  common name for Actaea racemosa; a plant native to eastern North 
America, traditionally used as a Native American medicine; an HDS, often in tablet 
form, commonly used to alleviate hot flashes and menopausal symptoms; the chosen 
HDS for our mixed methods study 
 
Bonferroni post-test: post hoc test used to determine the significant differences 
between group means in an analysis of variance setting 
 
CDKN1A:  a gene that encodes a potent cyclin-dependent kinase inhibitor, which 
regulates cell cycle progression at stage G1; plays an important role in the cell's 
response to DNA damage 
 
cell proliferation:  an increase in the number cells as a result of cell growth and cell 
division 
 
chamomile:  the common name for several daisy-like plants which are often made 
into a tea that helps with sleep; an HDS traditionally used to treat many ailments such 
as skin inflammation, common cold, and gastrointestinal conditions; used by survey 
participants for its calming effects to alleviate insomnia and anxiety 
 
chemotherapy:  a common treatment for cancer using cytotoxic chemicals/drugs that 
target and kill rapidly dividing cells 
 
complementary and alternative medicine (CAM):  the group of diverse medical 
and healthcare systems, practices, and products that are not generally considered part 






confluence:  in cell culture, refers to the extent of coverage of a surface (in a dish or 
flask) by cells; 100% confluence indicates that the surface is completely covered by 
cells and there is no room for cells to grow and divide 
curcumin:  the principal curcuminoid and bioactive component of the Indian spice 
turmeric of the ginger family; an HDS that has been suggested to have therapeutic or 
preventive properties for many ailments; used by many survey participants to directly 
treat their cancer 
 
CYP1A1:  a gene that encodes a member of the cytochrome P450 superfamily of 
enzymes, which catalyze many reactions involved in drug metabolism; mutations to 
this gene have been associatd with cancer risk 
 
CYP1A1:  an enzyme of the cytochrome P450 superfamily of enzymes, encoded by 
the gene CYP1A1 (see CYP1A1) 
 
DCFDA assay: a test that measures levels of reactive oxygen species with 
fluorescence. 
 
double-stranded DNA assay: a test that measures the levels of viable DNA in cells 
 
Dunnett’s test: statistical test that compares all group means to the mean of the 
control. 
 
endothelial cell growth:  growth of the cells that line blood vessels 
 
EROD assay:  test that measures cytochromeP4501A1 activity in cells 
 
estradiol:  natural estrogen receptor agonist (activator); this molecule binds to the 
estrogen receptor on cells to regulate the menstrual cycle, help develop secondary sex 
characteristics in females, and stimulate a variety of pathways (see estrogen) 
 
estrogen receptor negative (ER-): cells lacking estrogen receptors, which thus do 
not rely on estrogen for growth (see estrogen) 
 
estrogen receptor positive (ER+): cells with estrogen receptors, which thus do rely 
on estrogen for growth (see estrogen) 
 
estrogen:  a group of steroid compounds that function as the primary female sex 
hormone; estrogen-dependent breast cancer is dependent on estrogen for growth (see 
estradiol) 
 






evening primrose:  common name for Oenothera; a genus of herbaceous flowering 
plants native to North and South America; used to heal asthmatic coughs, whooping 
cough, gastrointestinal disorders, and as a sedative pain-killer; used by survey 
participants to alleviate hot flashes and other symptoms of menopause 
 
ex vivo:  in scientific research, refers to experimentation done in or on tissue in an 
artificial environment outside the organism, as close to natural conditions as possible 
 
Fisher LSD Test: statistical test that finds significant differences between all group 
means. 
 
flaxseed:  a common name for Linum usitatissimum, also known as common flax  
 
ginger:  the rhizome of the plant Zingiber officinale; a tuber originally cultivated in 
Asia that is consumed as a medicine or spice; an HDS used by many survey 
participants to treat digestive problems and nausea 
 
ginseng:  also known as Ginnsuu; any one of 11 species of slow growing plants with 
fleshy roots; a member of the Panax genus and the family Araliaceae; native to north 
eastern Asia; thought to possibly have antioxidant and anticarcinogenic properties; 
used by survey participants to improve cognition and treat fatigue 
 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH):  a gene that encodes an 
enzyme in glycolysis; used as a normalizing gene in observing gene expression 
because it is universally expressed in cells 
 
green tea:  a type of tea, originated from China, made with the leaves of Camellia 
sinensis that have undergone minimal oxidation during processing; an HDS with 
limited evidence of lowering risks of heart disease, weight loss management, and 
prevention against cancer; used by many survey participants to directly treat their 
cancer and for its antioxidant properties 
 
hepatotoxicity:  a general term for liver damage that is caused by chemicals or drugs 
 
HepG2/C3A: a clonal derivative of the HepG2 human hepatoma cell line that is 
commonly used in liver studies 
 
herbal dietary supplement (HDS): An herb or herbal blend taken to maintain or 
improve overall wellness. 
 
in vitro:  in scientific research, refers to experimentation done in a controlled 
environment outside of the organism, such as a test tube or Petri dish 
 
in vivo:  in scientific research, refers to experimentation done in a whole, living 






integrative medicine (IM): any healing practice that is not considered conventional 
medicine. 
 
kava kava:  common name for Piper methysticum; an ancient plant from the western 
Pacific; an HDS commonly used to relax and as a nausea remedy 
 
linseed:  a plant native to the region from the eastern Mediterranean to India; an HDS 
with a high fiber content that may possess anti-cancer properties; used by many 
survey participants to directly treat cancer, to help lower cholesterol, and to alleviate 
digestive problems 
 
lipid:  an organic molecule that is not soluble in water; there are many types of lipids 
in the body, including steroid hormones such as estrogen and estradiol 
 
MCF-7:  a breast cancer cell line isolated in 1970 from a 69-year-old Caucasian 
woman that has been the source of much current knowledge about breast cancer; an 
acronym of Michigan Cancer Foundation-7, the institute where the cell line was 
established in 1973 
 
menopausal symptoms: symptoms that occur during the permanent cessation of 
reproductive fertility in women around the age of 50, most commonly hot flashes, 
night sweats, irregular periods, loss of libido, and vaginal dryness 
 
milk thistle:  a flowering plant in the daisy family that has thistles; native to Europe, 
northern Africa, and the Middle East; the seeds are often used to treat liver disease 
and to protect against liver toxins; an HDS used by survey participants to improve 
liver function 
 
mitochondrial membrane depolarization: when the charge inside the cell 
membrane of the mitochondria becomes positive compared to the area outside of the 
cell 
 
mixed methods:  multimethodology; an approach to professional research that 
combines the collection and analysis of quantitative and qualitative data 
 
Nile Red assay: a test that measures accumulation of phospholipids and neutral lipids 
in cells 
 
oncogenic:  cancer-causing 
 
oxidative stress: a term used to describe the effect of oxidation, in which an 





p-Glycoprotein: a 170-KDa transmembrane glycoprotein that serves as an ATP-
dependent efflux pump for a variety of chemicals; overexpression of these 
glycoproteins is associated with multidrug resistance 
 
phospholipid:  type of lipid with a polar head and a nonpolar tail that is a major part 
of the cell’s membrane 
 
polymerase chain reaction (PCR):  technique to amplify exponentially a single or 
few copies of a sequence of DNA, using thermal cycling and enzymatic replication of 
DNA 
 
premenstrual syndrome (PMS):  wide range of physical or emotional symptoms 
that occur about 5 to 11 days before a woman starts her monthly menstrual cycle, 
such as mood swings, cramps, swelling, bloating, food cravings, constipation, 
anxiety, depression, and more 
 
R123 assay: test that measures mitochondrial membrane depolarization in cells 
 
raloxifene: sold under the trade name Evista®; a second generation SERM that acts 
as an antagonist in breast cancer, taken orally, and has been found to be just as 
effective as tamoxifen in reducing breast cancer incidences 
 
reactive oxygen species (ROS): highly reactive molecules containing an oxygen 
atom, which may function in cell signaling processes at lower levels and at higher 
levels, are capable of damage to cell structures 
 
real-time polymerase chain reaction (RT-PCR): a technique based on PCR, where 
amplification of DNA and quantification of a targeted DNA molecule occurs 
simultaneously (see polymerase chain reaction) 
 
red clover:  the common name for Trifolium pratense; a species of clover native to 
Europe, western Asia, and northwest Africa; an HDS used to treat symptoms of 
menopause and to treat many other ailments; used by some survey participants to 
alleviate hot flashes 
 
rhodamine: a group of synthetic dyes ranging in color from red to pink, obtained by 
condensation of phthalic anhydride with an amino derivative of phenol 
 
saw palmetto:  common name for Serenoa repens; also known as Sabal serrulatum; a 
small fruit bearing palm native to the southeastern United States; an HDS used to 
treat unrinary tract infections; used by very few survey participants 
 
selective estrogen receptor modulator (SERM):   class of compounds that act on 
the estrogen receptor and have different effects in different tissues, enabling selective 






soy:  common name for Glycine max; a member of the legume family native to East 
Asia; a common crop used in many foods; an HDS commonly used as a source of 
protein and omega-3 fatty acids; used by many survey participants to treat symptoms 
of menopause, especially hot flashes 
 
St. John's Wort:  common name for Hypericum perforatum, also known as Tipton's 
Weed or Klamath weed; an HDS commonly used to treat depression; native to 
temperate and subtropical regions of North America, Europe, Asia Minor, Russia, 
India, and China; used by many survey participants to improve mood and to alleviate 
anxiety 
 
steatosis: the collection of excessive amounts of fats such as triglycerides inside liver 
cells 
 
sulforhodamine B (SRB) assay:  a technique using the red fluorescent dye 
sulforhodamine B to quantify cellular proteins of cultured cells 
 
synergistic effect:  the cooperative effect of two or more drugs, which is more than 
the additive effect 
 
tamoxifen:  sold under the trade name Nolvadex®; a SERM that has been used to 
treat breast cancer for over 30 years, by acting as an antagonist of estrogen in breast 
tissue 
 
trefoil factor 1 (TFF1):  a gene that encodes secretory proteins expressed in the 
gastrointestinal mucosa and in human tumors 
 
Tukey post-test: statistical post-test that compares all pairs of columns following an 
ANOVA analysis   
 
two-way ANOVA:  statistical test that measures the effects of two factors in an 
experiment, simultaneously  
 
valerian:  common name for Valeriana officinali; a perennial flowering plant with 
pink or white flowers; native to Europe and parts of Asia; an HDS prepared from the 
roots of the plant used to treat insomnia and sleep disorders; used by many survey 
participants to treat insomnia and anxiety 
 
vascular endothelial growth factor A (VEGFA):  protein that specifically acts on 
endothelial cells to increase vascular permeability, induce angiogenesis and 
vasculogenesis, promote cell migration and endothelial cell growth, and inhibit 
apoptosis  
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